

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003483

International filing date: 27 January 2005 (27.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/539,837
Filing date: 28 January 2004 (28.01.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1300910

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/539,837

FILING DATE: *January 28, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/03483



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



16805 U.S.PTO

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV385630135US

60/533983
2251 S PTO**INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Lori	Friedman	San Carlos, California

Additional inventors are being named on the 1 separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)**MIGFRS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE**

Direct all correspondence to: CORRESPONDENCE ADDRESS

 Customer Number: 23500

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
Address			
City	State	Zip	
Country	Telephone	Fax	

ENCLOSED APPLICATION PARTS (check all that apply)

Specification Number of Pages 80

Drawing(s) Number of Sheets _____

Application Date Sheet. See 37 CFR 1.76

CD(s), Number _____

Other (specify) return postcard

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

Applicant claims small entity status. See 37 CFR 1.27.

A check or money order is enclosed to cover the filing fees.

The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 50-1108

Payment by credit card. Form PTO-2038 is attached.

FILING FEE
Amount (\$)

160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

 No. Yes, the name of the U.S. Government agency and the Government contract number are: _____

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Laleh Shayesteh

Date January 28, 2004

REGISTRATION NO. 47,937
(if appropriate)
Docket Number: EX04-007P

TELEPHONE 650.837.8223

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number EX04-007P

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Helen	Francis-Lang	San Francisco, California
Annette	Parks	Daly City, California
Kenneth	Shaw	
HaiGuang	Zhang	El Sobrante, California
Lynn Margaret	Bjerke	San Francisco, California
Monique	Nicoll	Pacific, California
Joanne I.	Adamkewicz	San Francisco, California

[Page 2 of 2]

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

MIGFRS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE**BACKGROUND OF THE INVENTION**

Somatic mutations in the PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) gene are known to cause tumors in a variety of human tissues. In addition, germline mutations in PTEN are the cause of human diseases (Cowden disease and Bannayan-Zonana syndrome) associated with increased risk of breast and thyroid cancer (Nelen MR et al. (1997) Hum Mol Genet, 8:1383-1387; Liaw D et al. (1997) Nat Genet, 1:64-67; Marsh DJ et al. (1998) Hum Mol Genet, 3:507-515). PTEN is thought to act as a tumor suppressor by regulating several signaling pathways through the second messenger phosphatidylinositol 3,4,5 triphosphate (PIP3). PTEN dephosphorylates the D3 position of PIP3 and downregulates signaling events dependent on PIP3 levels (Maehama T and Dixon JE (1998) J Biol Chem, 22, 13375-8). In particular, pro-survival pathways downstream of the insulin-like growth factor (IGF) pathway are regulated by PTEN activity. Stimulation of the IGF pathway, or loss of PTEN function, elevates PIP3 levels and activates pro-survival pathways associated with tumorigenesis (Stambolic V et al. (1998) Cell, 95:29-39). Consistent with this model, elevated levels of insulin-like growth factors I and II correlate with increased risk of cancer (Yu H et al (1999) J Natl Cancer Inst 91:151-156) and poor prognosis (Takanami I et al, 1996, J Surg Oncol 61(3):205-8). In addition, increased levels or activity of positive effectors of the IGF pathway, such as Akt and PI(3) kinase, have been implicated in several types of human cancer (Nicholson KM and Anderson NG (2002) Cellular Signalling, 14:381-395).

In *Drosophila melanogaster*, as in vertebrates, the Insulin Growth Factor Receptor (IGFR) pathway includes the positive effectors PI(3) kinase, Akt, and PDK and the inhibitor, PTEN. These proteins have been implicated in multiple processes, including the regulation of cell growth and size as well as cell division and survival (Oldham S and Hafen E. (2003) Trends Cell Biol. 13:79-85; Garafolo RS. (2002) Trends Endocr. Metab. 13:156-162; Backman SA et al. (2002) Curr. Op. Neurobio. 12:1-7; Tapon N et al. (2001) Curr Op. Cell Biol. 13:731-737). Activation of the pathway in *Drosophila* can result in increases in cell size, cell number and organ size (Oldham S et al. (2002) Dev. 129:4103-

4109; Prober DA and Edgar BA. (2002) Genes&Dev. 16:2286-2299; Potter CJ et al. (2001) Cell 105:357-368; Verdu J et al. (1999) Cell Biol. 1:500-506).

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a “genetic entry point”) that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a “modifier” involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as IGFR, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the IGFR pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as Modifier of IGFR (MIGFR). The invention provides methods for utilizing these IGFR modifier genes

and polypeptides to identify MIGFR-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired IGFR function and/or MIGFR function. Preferred MIGFR-modulating agents specifically bind to MIGFR polypeptides and restore IGFR function. Other preferred MIGFR-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MIGFR gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

MIGFR modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with an MIGFR polypeptide or nucleic acid. In one embodiment, candidate MIGFR modulating agents are tested with an assay system comprising a MIGFR polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate IGFR modulating agents. The assay system may be cell-based or cell-free. MIGFR-modulating agents include MIGFR related proteins (e.g. dominant negative mutants, and biotherapeutics); MIGFR -specific antibodies; MIGFR -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MIGFR or compete with MIGFR binding partner (e.g. by binding to an MIGFR binding partner). In one specific embodiment, a small molecule modulator is identified using a binding assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate IGFR pathway modulating agents are further tested using a second assay system that detects changes in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the IGFR pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the MIGFR function and/or the IGFR pathway in a mammalian cell by contacting the mammalian cell with

an agent that specifically binds a MIGFR polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

DETAILED DESCRIPTION OF THE INVENTION

A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Modifiers of the IGFR pathway and their orthologs were identified. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MIGFR genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective IGFR signaling pathway, such as cancer. Table 1 (Example II) lists the modifiers and their orthologs.

In vitro and in vivo methods of assessing MIGFR function are provided herein. Modulation of the MIGFR or their respective binding partners is useful for understanding the association of the IGFR pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for IGFR related pathologies. MIGFR-modulating agents that act by inhibiting or enhancing MIGFR expression, directly or indirectly, for example, by affecting an MIGFR function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MIGFR modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

Sequences related to MIGFR nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) or RefSeq number), shown in Table 1 and in the appended sequence listing.

The term “MIGFR polypeptide” refers to a full-length MIGFR protein or a functionally active fragment or derivative thereof. A “functionally active” MIGFR fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type MIGFR protein, such as antigenic or immunogenic activity,

enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MIGFR proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MIGFR polypeptide is a MIGFR derivative capable of rescuing defective endogenous MIGFR activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an MIGFR, such as a kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods for obtaining MIGFR polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of an MIGFR. In further preferred embodiments, the fragment comprises the entire functionally active domain.

The term "MIGFR nucleic acid" refers to a DNA or RNA molecule that encodes a MIGFR polypeptide. Preferably, the MIGFR polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MIGFR. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res

22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species.

Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term “orthologs” encompasses paralogs. As used herein, “percent (%) sequence identity” with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. “Percent (%) amino acid sequence similarity” is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and

valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, *J. of Molec.Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of an MIGFR. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of an MIGFR under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml

herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of MIGFR Nucleic Acids and Polypeptides

MIGFR nucleic acids and polypeptides are useful for identifying and testing agents that modulate MIGFR function and for other applications related to the involvement of MIGFR in the IGFR pathway. MIGFR nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of

proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of an MIGFR protein for assays used to assess MIGFR function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MIGFR is expressed in a cell line known to have defective IGFR function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding an MIGFR polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MIGFR gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the MIGFR gene product, the expression vector can comprise a promoter operably linked to an MIGFR gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MIGFR gene product based on the physical or functional properties of the MIGFR protein in *in vitro* assay systems (*e.g.* immunoassays).

The MIGFR protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, *Nature* (1984) 310:105-111).

Once a recombinant cell that expresses the MIGFR gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MIGFR proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MIGFR or other genes associated with the IGFR pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

Genetically modified animals

Animal models that have been genetically modified to alter MIGFR expression may be used in *in vivo* assays to test for activity of a candidate IGFR modulating agent, or to further assess the role of MIGFR in a IGFR pathway process such as apoptosis or cell proliferation. Preferably, the altered MIGFR expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MIGFR expression. The genetically modified animal may additionally have altered IGFR expression (*e.g.* IGFR knockout). Preferred genetically modified animals are

mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer *et al.*, Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a “knock-out” animal having a heterozygous or homozygous alteration in the sequence of an endogenous MIGFR gene that results in a decrease of MIGFR function, preferably such that MIGFR

expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MIGFR gene is used to construct a homologous recombination vector suitable for altering an endogenous MIGFR gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) *Scan J Immunol* 40:257-264; Declerck PJ *et al.*, (1995) *J Biol Chem*. 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MIGFR gene, e.g., by introduction of additional copies of MIGFR, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MIGFR gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, *PNAS* (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two

transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) *Nat Genet* 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the IGFR pathway, as animal models of disease and disorders implicating defective IGFR function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MIGFR function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MIGFR expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered MIGFR function, animal models having defective IGFR function (and otherwise normal MIGFR function), can be used in the methods of the present invention. For example, a IGFR knockout mouse can be used to assess, *in vivo*, the activity of a candidate IGFR modulating agent identified in one of the *in vitro* assays described below. Preferably, the candidate IGFR modulating agent when administered to a model system with cells defective in IGFR function, produces a detectable phenotypic change in the model system indicating that the IGFR function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of MIGFR and/or the IGFR pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the IGFR pathway, as well as in further analysis of the MIGFR protein and its contribution to the IGFR pathway. Accordingly,

the invention also provides methods for modulating the IGFR pathway comprising the step of specifically modulating MIGFR activity by administering a MIGFR-interacting or -modulating agent.

As used herein, an “MIGFR-modulating agent” is any agent that modulates MIGFR function, for example, an agent that interacts with MIGFR to inhibit or enhance MIGFR activity or otherwise affect normal MIGFR function. MIGFR function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the MIGFR - modulating agent specifically modulates the function of the MIGFR. The phrases “specific modulating agent”, “specifically modulates”, etc., are used herein to refer to modulating agents that directly bind to the MIGFR polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MIGFR. These phrases also encompass modulating agents that alter the interaction of the MIGFR with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of an MIGFR, or to a protein/binding partner complex, and altering MIGFR function). In a further preferred embodiment, the MIGFR- modulating agent is a modulator of the IGFR pathway (e.g. it restores and/or upregulates IGFR function) and thus is also a IGFR-modulating agent.

Preferred MIGFR-modulating agents include small molecule compounds; MIGFR-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in “Remington’s Pharmaceutical Sciences” Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to

1,000, and most preferably up to 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MIGFR protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MIGFR-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the IGFR pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific MIGFR-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the IGFR pathway and related disorders, as well as in validation assays for other MIGFR-modulating agents. In a preferred embodiment, MIGFR-interacting proteins affect normal MIGFR function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MIGFR-interacting proteins are useful in detecting and providing information about the function of MIGFR proteins, as is relevant to IGFR related disorders, such as cancer (e.g., for diagnostic means).

An MIGFR-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MIGFR, such as a member of the MIGFR pathway that modulates MIGFR expression, localization, and/or activity. MIGFR-modulators include dominant negative forms of MIGFR-interacting proteins and of MIGFR proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MIGFR-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

An MIGFR-interacting protein may be an exogenous protein, such as an MIGFR-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MIGFR antibodies are further discussed below.

In preferred embodiments, an MIGFR-interacting protein specifically binds an MIGFR protein. In alternative preferred embodiments, an MIGFR-modulating agent binds an MIGFR substrate, binding partner, or cofactor.

Antibodies

In another embodiment, the protein modulator is an MIGFR specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MIGFR modulators. The antibodies can also be used in dissecting the portions of the MIGFR pathway responsible for various cellular responses and in the general processing and maturation of the MIGFR.

Antibodies that specifically bind MIGFR polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MIGFR polypeptide, and more preferably, to human MIGFR. Antibodies may be polyclonal,

monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MIGFR which are particularly antigenic can be selected, for example, by routine screening of MIGFR polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of an MIGFR. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MIGFR or substantially purified fragments thereof. If MIGFR fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MIGFR protein. In a particular embodiment, MIGFR-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of MIGFR-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MIGFR polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to MIGFR polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al.,

Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

MIGFR-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be

produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Specific biotherapeutics

In a preferred embodiment, an MIGFR-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

When the MIGFR is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MIGFR, as described in the previous section, may be used as biotherapeutic agents.

When the MIGFR is a receptor, its ligand(s), antibodies to the ligand(s) or the MIGFR itself may be used as biotherapeutics to modulate the activity of MIGFR in the IGFR pathway.

Nucleic Acid Modulators

Other preferred MIGFR-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MIGFR activity. Preferred nucleic acid modulators interfere with the function of the MIGFR nucleic acid such as DNA replication, transcription, translocation of the MIGFR RNA to the site of protein translation, translation of protein from the MIGFR RNA, splicing of the MIGFR RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MIGFR RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MIGFR mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MIGFR-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281;

Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred MIGFR nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 *Nature* 391:806-811; Fire, A. *Trends Genet.* 15, 358-363 (1999); Sharp, P. A. *RNA interference* 2001. *Genes Dev.* 15, 485-490 (2001); Hammond, S. M., et al., *Nature Rev. Genet.* 2, 110-1119 (2001); Tuschl, T. *Chem. Biochem.* 2, 239-245 (2001); Hamilton, A. et al., *Science* 286, 950-952 (1999); Hammond, S. M., et al., *Nature* 404, 293-296 (2000); Zamore, P. D., et al., *Cell* 101, 25-33 (2000); Bernstein, E., et al., *Nature* 409, 363-366 (2001); Elbashir, S. M., et al., *Genes Dev.* 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 *Nature* 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, *Current Concepts in Antisense Drug Design*, *J Med Chem.* (1993) 36:1923-1937; Tonkinson JL et al., *Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents*, *Cancer Invest.* (1996) 14:54-65). Accordingly, in one aspect of the invention, an MIGFR-specific nucleic acid modulator is used in an assay to further elucidate the role of the MIGFR in the IGFR pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, an MIGFR-specific antisense oligomer is used as a therapeutic agent for treatment of IGFR-related disease states.

Assay Systems

The invention provides assay systems and screening methods for identifying specific modulators of MIGFR activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MIGFR nucleic acid or protein. In general, secondary assays further assess the activity of a MIGFR modulating agent identified by a primary assay and may confirm that the modulating agent affects MIGFR in a manner relevant to the IGFR pathway. In some cases, MIGFR modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising an MIGFR polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates MIGFR activity, and hence the IGFR pathway. The MIGFR polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or

crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of MIGFR and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MIGFR-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MIGFR protein may be assayed by various known methods such as substrate processing (*e.g.* ability of the candidate MIGFR-specific binding agents to function as negative effectors in MIGFR-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (*e.g.* ability to elicit MIGFR specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MIGFR polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MIGFR polypeptide can be full length or a fragment thereof that retains functional MIGFR activity. The MIGFR polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MIGFR polypeptide is preferably human MIGFR, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the

screening assay detects candidate agent-based modulation of MIGFR interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MIGFR –specific binding activity, and can be used to assess normal MIGFR gene function.

Suitable assay formats that may be adapted to screen for MIGFR modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, *Curr Opin Chem Biol* (1998) 2:597-603; Sundberg SA, *Curr Opin Biotechnol* 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, *Nat Struct Biol* (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, *Curr Opin Chem Biol* (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate MIGFR and IGFR pathway modulators (*e.g.* U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); U.S. Pat. No. 6,114,132 (phosphatase and protease assays), U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

Protein kinases, key signal transduction proteins that may be either membrane-associated or intracellular, catalyze the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. Radioassays, which monitor the transfer from [γ -³²P or ³³P]ATP, are frequently used to assay kinase activity. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from [γ -³³P] ATP to a biotinylated peptide substrate. The substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, *J Biomol Screen* (2000) 5:205-212). This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from

free ligand. Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA) assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133). Another example of antibody based assays for protein kinase activity is TRF (time-resolved fluorometry). This method utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

Protein phosphatases catalyze the removal of a gamma phosphate from a serine, threonine or tyrosine residue in a protein substrate. Since phosphatases act in opposition to kinases, appropriate assays measure the same parameters as kinase assays. In one example, the dephosphorylation of a fluorescently labeled peptide substrate allows trypsin cleavage of the substrate, which in turn renders the cleaved substrate significantly more fluorescent (Nishikata M *et al.*, Biochem J (1999) 343:35-391). In another example, fluorescence polarization (FP), a solution-based, homogeneous technique requiring no immobilization or separation of reaction components, is used to develop high throughput screening (HTS) assays for protein phosphatases. This assay uses direct binding of the phosphatase with the target, and increasing concentrations of target-phosphatase increase the rate of dephosphorylation, leading to a change in polarization (Parker GJ *et al.*, (2000) J Biomol Screen 5:77-88).

High-throughput assays, such as scintillation proximity assays, for synthase enzymes involved in fatty acid synthesis are known in the art (He X *et al* (2000) Anal Biochem 2000 Jun 15;282(1):107-14).

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of

fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MIGFR function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MIGFR plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by other means.

Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL *et al.*, 1998, In Vitro Cell Dev Biol Anim 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96[®] AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with MIGFR are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-GloTM, which is a luminescent homogeneous assay available from Promega.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with an MIGFR may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MIGFR function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MIGFR plays a direct role in cell proliferation or cell cycle.

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate IGFR modulating

agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MIGFR function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MIGFR plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MIGFR in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MIGFR function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MIGFR plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2 \times final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques *in situ* on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigel™ (Becton Dickinson), an extract of basement membrane proteins

containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4°C and forms a solid gel at 37°C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF-alpha. Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing an MIGFR's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are

fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing an MIGFR's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

Sprouting assay. A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 μ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 μ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MIGFR protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for

detecting MIGFR-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MIGFR gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MIGFR expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express MIGFR) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MIGFR mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, *eds.*, John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MIGFR protein or specific peptides. A variety of means including Western blotting, ELISA, or *in situ* detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MIGFR mRNA expression, may also be used to test nucleic acid modulators.

Secondary Assays

Secondary assays may be used to further assess the activity of MIGFR-modulating agent identified by any of the above methods to confirm that the modulating agent affects MIGFR in a manner relevant to the IGFR pathway. As used herein, MIGFR-modulating agents encompass candidate clinical compounds or other agents derived from previously

identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MIGFR.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express MIGFR) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MIGFR-modulating agent results in changes in the IGFR pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use “sensitized genetic backgrounds”, which, as used herein, describe cells or animals engineered for altered expression of genes in the IGFR or interacting pathways.

Cell-based assays

Cell based assays may detect endogenous IGFR pathway activity or may rely on recombinant expression of IGFR pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective IGFR pathway may be used to test candidate MIGFR modulators. Models for defective IGFR pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the IGFR pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, IGFR pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal IGFR are used to test the candidate modulator's affect on MIGFR in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at

4°C, but rapidly forms a solid gel at 37°C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MIGFR. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on MIGFR is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MIGFR endogenously are injected in the flank, 1 x 10⁵ to 1 x 10⁷ cells per mouse in a volume of 100 µL using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate

modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator.

Tumorigenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorigenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorigenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

Specific MIGFR-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation disorders.

Accordingly, the invention also provides methods for modulating the IGFR pathway in a cell, preferably a cell pre-determined to have defective or impaired IGFR function (e.g. due to overexpression, underexpression, or misexpression of IGFR, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MIGFR activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the IGFR function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored IGFR function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired IGFR function by administering a therapeutically effective amount of an MIGFR -modulating agent that modulates the IGFR pathway. The invention further provides methods for modulating MIGFR function in a cell, preferably a cell pre-determined to have defective or impaired MIGFR function, by administering an MIGFR -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MIGFR function by administering a therapeutically effective amount of an MIGFR -modulating agent.

The discovery that MIGFR is implicated in IGFR pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the IGFR pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether MIGFR expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective IGFR signaling that express an MIGFR, are identified as amenable to treatment with an MIGFR modulating agent. In a preferred application, the IGFR defective tissue overexpresses an MIGFR

relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MIGFR cDNA sequences as probes, can determine whether particular tumors express or overexpress MIGFR. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MIGFR expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the MIGFR oligonucleotides, and antibodies directed against an MIGFR, as described above for: (1) the detection of the presence of MIGFR gene mutations, or the detection of either over- or under-expression of MIGFR mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MIGFR gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MIGFR.

Kits for detecting expression of MIGFR in various samples, comprising at least one antibody specific to MIGFR, all reagents and/or devices suitable for the detection of antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MIGFR expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MIGFR expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer. The probe may be either DNA or protein, including an antibody.

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila IGFR screen

A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Activation of the pathway by overexpression of IGFR at early stages in the developing *Drosophila* eye leads to an increase in cell number which results in a larger and rougher adult eye (Potter CJ et al. (2001) Cell 105:357-368; Huang et al., 1999. Dev. 126:5365-5372). We generated a fly stock with an enlarged eye due to overexpression of IGFR and identified modifiers of this phenotype. We then identified human orthologues of these modifiers.

The screening stock carried two transgenes. The genotype is as follows:

$+; +; P\{DmIGFR-pExp-UAS\} P\{Gal4-pExp-1Xey\}/TM6B$

Screening stock females of the above genotype were crossed to males from a collection of 3 classes of piggyBac-based transposons. The resulting progeny, which contain both the transgenes and the transposon, were scored for the effect of the transposon on the eye overgrowth phenotype (either enhancement, suppression or no effect). All data was recorded and all modifiers were retested with a repeat of the original cross.

II. Analysis of Table 1

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. The columns “MIGFR symbol”, and “MIGFR name aliases” provide a symbol and the known name abbreviations for the Targets, where available, from Genbank. “MIGFR RefSeq_NA or GI_NA”, “MIGFR GI_AA”, “MIGFR NAME”, and “MIGFR Description” provide the reference DNA sequences for the MIGFRs as available from National Center for Biology Information (NCBI), MIGFR protein Genbank identifier number (GI#), MIGFR name, and MIGFR description, all available from Genbank, respectively. The length of each amino acid is in the “MIGFR Protein Length” column.

Names and Protein sequences of *Drosophila* modifiers of IGFR from screen (Example I), are represented in the “Modifier Name” and “Modifier GI_AA” column by GI#, respectively.

Table 1

EX04-007P

MIGFR symbol	MIGFR name aliases	MIGFR RefSeq_NA or GI_NA	MIGFR GI_AA	MIGFR name	MIGFR description	MIGFR protein length	Modifier name	Modifier gi_aa
NOS3	nitric oxide synthase 3 (endothelial cell) ECNOS eNOS NOS3	NM_000603	40254422	nitric oxide synthase 3 (endothelial cell)	nitric oxide synthase; electron transporter; apoptosis inhibitor	1203	Nos	24583543
PRKAG1	AMPK gamma 1 PRKAG1 Protein kinase, AMP-activated, noncatalytic, gamma-1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit	NM_002733	4506061	protein kinase, AMP-activated, gamma 1 non-catalytic subunit	protein kinase; protein serine/threonine kinase; protein binding	331	SNF4 Agamma	24648661
PRKAG2	AAKG AAKG2 H91620P H91620p H91620p protein PRKAG2 WPWS protein kinase, AMP-activated, gamma 2 non-catalytic subunit	NM_016203	33186925	protein kinase, AMP-activated, gamma 2 non-catalytic subunit	SNF1A/AMP-activated protein kinase; AMP binding	569	SNF4 Agamma	24648661
PRKAG3	AMPK gamma 3 protein kinase, AMP-activated, gamma 3 non-catalytic subunit PRKAG3	NM_017431	8394044	protein kinase, AMP-activated, gamma 3 non-catalytic subunit	nucleotide binding; protein binding; SNF1A/AMP-activated protein kinase	492	SNF4 Agamma	24648661
NOS2A	HEP-NOS INOS NO S NOS, type II NOS2 NOS2A nitric oxide synthase 2A (inducible, hepatocytes) nitric oxide synthase, macrophage	NM_000625 NM_153292	24041029	nitric oxide synthase 2A (inducible, hepatocytes)	calcium channel inhibitor; nitric oxide synthase; calmodulin binding; electron transporter; antiviral response protein	1153	Nos	24583543
ITPKA	IP3K IP3K-A IP3K-A ITPKA inositol 1,4,5-trisphosphate 3-kinase A	NM_002220	4504789	inositol 1,4,5-trisphosphate 3-kinase A	1D-myo-inositol-trisphosphate 3-kinase	461	IP3K 1	24583132

EX04-007P

	ol 1,4,5-trisphosphate 3-kinase A			e 3-kinase A				
ITPKB	IP3 3-kinase IP3K IP3 K B IP3K-B IP3KB ITPK B inositol 1,4,5-trisphosphate 3-kinase B	NM_002221	38569400	inositol 1,4,5-trisphosphate 3-kinase B	1D-myo-inositol-trisphosphate 3-kinase	946	IP3K 1	245831 32
ITPKC	IP3K C IP3K-C ITPKC inositol 1,4,5-trisphosphate 3-kinase C	NM_025194	18643383	inositol 1,4,5-trisphosphate 3-kinase C	inositol/phosphatidylinositol kinase	683	IP3K 1	245831 32
MAN2A1	Golgi alpha-mannosidase II mannosidase, alpha, class 2A, member 1 mannosidase, alpha type II MANA2 MAN2A1	NM_002372	4758698	mannosidase, alpha, class 2A, member 1	mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase	1143	alpha-Man-IIb	246472 49
MAN2A2	alpha-mannosidase IIX mannosidase, alpha, class 2A, member 2 mannosidase, alpha-, type II, isozyme X mannosidase, alpha type II-X PRO2198 MANA2X MAN2A2	NM_006122 NM_018621	3123244	mannosidase, alpha, class 2A, member 2	alpha-mannosidase	1139	alpha-Man-IIb	246472 49
NOS1	nitric oxide synthase 1 (neuronal) NOS1	NM_000620	10835173	nitric oxide synthase 1 (neuronal)	nitric oxide synthase; electron transporter	1434	Nos	245835 43
KIAA1815	FLJ23309 KIAA1815	XM_291315	37540252	KIAA1815	na	904	CG11 961	246556 10
POMT1	POMT1 RT protein-O-mannosyltransferase 1	NM_007171	21361382	protein-O-mannosyltransferase 1	mannosyltransferase	747	rt	107279 85

EX04-007P

PTPRN	IA-2 IA-2 PTP IA2 ICA 512 PTPRN R-PTP-N islet cell antigen 2 islet cell antigen 512 islet cell autoantigen 3 protein tyrosine phosphatase, receptor type, N protein tyrosine phosphatase-like N precursor	NM_002846	4506321	protein tyrosine phosphatase, receptor type, N	transmembrane receptor protein tyrosine phosphatase; transmembrane receptor protein tyrosine phosphatase	979	ia2	24580758
PTPRN2	IA-2beta IAR IAR PTPRP IAR/rec eptor-like protein-tyrosine phosphatase IC AAR KIAA038 7 PHOGrin PT PRN2 PTPRP phogrin protein tyrosine phosphatase receptor pil protein tyrosine phosphatase, receptor type, N polypeptide 2 tyrosine phosphatase IA-2 beta	NM_002847 NM_130842 NM_130843	11386149	protein tyrosine phosphatase, receptor type, N polypeptide 2	transmembrane receptor protein tyrosine phosphatase	1015	ia2	24580758
SYNJ1	INPP5G SYNJ1 inositol 5'- phosphatase (synaptosomal 1) synaptosomal 1 synaptosomal 1, polyphosphoinositide phosphatase	NM_003895	4507335	synaptosomal 1	polyphosphoinositide phosphatase; inositol-1,4,5-trisphosphate 5-phosphatase	1575	synaptosomal	18497296
SYNJ2	INPP5H SYNJ2 inositol phosphate 5'- phosphatase 2 (synaptosomal 2) synaptosomal 2	NM_003898	26190608	synaptosomal 2	protein binding; inositol/phosphatidylinositol phosphatase; inositol-1,4,5-trisphosphate 5-phosphatase	1496	synaptosomal	18497296

EX04-007P

LOC284767	na similar to dJ680N4.2 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5)) LOC 284767	XM_209367	27485630	similar to dJ680N4.2 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5))	na	147	eff	246469 06
LOC51619	ubiquitin-conjugating enzyme HBUCE1 LOC 51619	NM_015983	8393719	ubiquitin-conjugating enzyme HBUCE1	ubiquitin conjugating enzyme; enzyme	147	eff	246469 06
UBE2D2	ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) ubiquitin-conjugating enzyme E2-17 kDa 2 ubiquitin carrier protein E2(17)K B2 UBCH5B UBC4/5 PUBC1 UBC4 UBE2D2	NM_003339 NM_181838	33188456	ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast)	ubiquitin conjugating enzyme;	118	eff	246469 06
UBE2D3	ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) ubiquitin-conjugating enzyme E2-17 kDa 3 ubiquitin carrier protein E2(17)K B3 MGC43926 MGC5416 UBC H5C UBC4/5 UBE2D3	NM_003340 NM_181886 NM_181887 NM_181888 NM_181889 NM_181890 NM_181891 NM_181892 NM_181893	33149322	ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast)	ubiquitin conjugating enzyme	148	eff	246469 06
LOC378372	LOC378372 na similar to dopamine beta-hydroxylase-like	XM_353788	37539365	similar to dopamine beta-hydroxylase-like	na	451	olf41 3	285747 20
MOXD1	DKFZP564G202 MOX MOXD1 dJ248E1.1 monoxygenase, DBH-like 1	NM_015529	37183305	monoxygenase, DBH-like 1	dopamine-beta-monooxygenase; copper binding; monoxygenase	613	olf41 3	285747 20

III. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled MIGFR peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MIGFR activity.

IV. High-Throughput In Vitro Binding Assay.

^{33}P -labeled MIGFR peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate IGFR modulating agents.

V. Immunoprecipitations and Immunoblotting

For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells containing the MIGFR proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at 15,000 $\times g$ for 15 min. The cell lysate is incubated with 25 μl of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel

electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

VI. Kinase assay

A purified or partially purified MIGFR is diluted in a suitable reaction buffer, e.g., 50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and a peptide or polypeptide substrate, such as myelin basic protein or casein (1-10 µg/ml). The final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by increasing assay throughput. A 96-well microtiter plate is employed using a final volume 30-100 µl. The reaction is initiated by the addition of ^{33}P -gamma-ATP (0.5 µCi/ml) and incubated for 0.5 to 3 hours at room temperature. Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg^{2+} or Mn^{2+}) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

VII. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues are obtained from Impath, UC Davis, Clontech, Stratagene, Ardais, Genome Collaborative, and Ambion.

TaqMan® analysis is used to assess expression levels of the disclosed genes in various samples.

RNA is extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/ μ l. Single stranded cDNA is then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan® assay (Applied Biosystems, Foster City, CA) are prepared according to the TaqMan® protocols, and the following criteria: a) primer pairs are designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis is performed using a 7900HT instrument.

TaqMan® reactions are carried out following manufacturer's protocols, in 25 μ l total volume for 96-well plates and 10 μ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis is prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data are normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples are compared with matched normal tissues from the same patient. A gene is considered overexpressed in a tumor when the level of expression of the gene is 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue is not available, a universal pool of cDNA samples is used instead. In these cases, a gene is considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type is greater than 2 times the standard deviation of all normal samples (i.e., Tumor – average(all normal samples) > 2 x STDEV(all normal samples)).

A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression

of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate IGFR pathway modulating agent, said method comprising the steps of:
 - (a) providing an assay system comprising a MIGFR polypeptide or nucleic acid;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MIGFR polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective IGFR function.
4. The method of Claim 1 wherein the assay system includes a screening assay comprising a MIGFR polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a binding assay.
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising a MIGFR polypeptide and the candidate test agent is an antibody.

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a MIGFR nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

(d) administering the candidate IGFR pathway modulating agent identified in (c) to a model system comprising cells defective in IGFR function and, detecting a phenotypic change in the model system that indicates that the IGFR function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective IGFR function.

13. A method for modulating a IGFR pathway of a cell comprising contacting a cell defective in IGFR function with a candidate modulator that specifically binds to a MIGFR polypeptide, whereby IGFR function is restored.

14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in IGFR function.

15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of:

(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing MIGFR ,

(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(f) detecting an agent-biased activity of the second assay system,

wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate IGFR pathway modulating agent,

and wherein the second assay detects an agent-biased change in the IGFR pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a IGFR pathway gene.

20. A method of modulating IGFR pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a MIGFR polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the sample with a probe for MIGFR expression;

(c) comparing results from step (b) with a control;

(d) determining whether step (c) indicates a likelihood of disease.

24. The method of claim 23 wherein said disease is cancer.

ABSTRACT OF THE DISCLOSURE

Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.

Nucleic Acid and Polypeptide sequences

>gi|40254421|ref|NM_000603.2| Homo sapiens nitric oxide synthase 3
 (endothelial cell) (NOS3), mRNA

AAACTAGGGCAAGGAGACGAAGAGAACATGAAAGTTAACTTAAGATGAAGAACAAAGCTAACATAC
 TGATGCATTGGATCTTGGAGAGGATCTCAGAACTCATTGTACTTAATTACAGGCTAAACCTTAGAAG
 AGGAATTATTATATATCTACACAAGACTCCAGGGAAAGCACATGGCCTGGACTGAAGGCTGGCATCTGGA
 AGCTGTCAGGCCACCAGCACCTCTGCAGCAGGAAAAGGCCAGGGCTCTGCTGGAGCAGGCAGCAGAGTGG
 ACGCACAGTAACATGGCAACTTGAAGAGCGTGCCCCAGGAGCCTGGGCCACCCCTCGGGCTGGGCTGG
 GGCTGGCCTGGCTGTGGCAAGCAGGGCCAGCCACCCGGCCCTGAGCCCAGCCGGCCCCAGC
 ATCCCTACTCCCCACCAGCGCAGAACACAGCCCCCGAGCTCCCGCTAACCCAGCCCCAGAGGGGCC
 AAGTCCCTCGTGTGAAGAACTGGGAGGTGGGAGCATCACCTATGACACCCTCAGCGCCAGGCGAGC
 AGGATGGGCCCTGCACCCAAAGACGCTGCCCTGGCTCCCTGGTATTTCACGGAAACTACAGGGCCGGC
 CTCCCCGGCCCCCGGCCCTGAGCAGCTGCTGAGTCAGGCCGGACTTCATCAACCAGTACTACAGC
 TCCATTAAAGAGGAGCGGCTCCAGGCCACGAACAGCGGCTCAAGAGGTGGAAGGCCAGGTGGCAGCCA
 CAGGCACCTACCAAGCTTAGGGAGAGCGAGCTGGTGTGGGCTAACGCAGGCCCTGGCGAACGCTCCCCG
 CTGGCTGGCCGGATCCAGTGGGAAAGCTGCAGGTGTCAGGATGCCACCAACCGGGCACCTTCGCTCGGCCATCACAG
 ATGTTCACCTACATCTGCAACCACATCAAGTATGCCACCAACCGGGCACCTTCGCTCGGCCATCACAG
 TGTTCCCGAGCGCTGCCCTGGCGAGGAGACTTCGAATCTGGAACAGCCAGCTGGTGCCTACGCGGG
 CTACCGCAGCAGGATGGCTGTGCGGGGGACCCAGCCAACGTGGAGATCACCGAGCTTCGATTCAAG
 CACGGCTGGACCCAGGAAACGGTCGCTCGACGTGCTGCCCTGCTGTCAGGCCAGATGATCCCC
 CAGAACCTTCCCTCTGCCCGGGAGCTGGCTTGAGGTGCCCTGGAGCACCCACGCTGGAGTGGTT
 TGCAGCCCTGGGCTTGCGCTGGTACGCCCTCCCGCAGTGTCAACATGCTGCTGGAAATTGGGGGCTG
 GAGTCCCCCGAGCCCCCTTCAGTGGCTGGTACATGAGCACTGAGATGGCACGAGGAACCTGTGTGACC
 CTCACCGCTACAACATCCTGGAGGATGTGGCTGTCATGGACCTGGATACCGGACCACCTCGTCCCT
 GTGGAAAGACAAGGCAGCAGTGGAAATCAACGTGCCGTGTCACAGTTACAGCTAGCAAAGTCACC
 ATCGTGGACCACCGCCACGGCTCTTCATGAAGCAGCTGGAGATGAGCAGAACGGCCAGGGGG
 GCTGCCCTGCAGACTGGGCTGGATCGTCCCCCATCTGGCAGCCTCACTCCTGTTTCATCAGGA
 GATGGTCAACTATTCCTGTCCCCGGCCTCCGCTACCAGCCAGACCCCTGGAAGGGAGTGGCGCCAAG
 GGCACGGCATCACCAGGAAGAACCTTAAAGAAGTGGCCAACGCCGTGAAGATCTCCGCTCGTCA
 TGGGACGGTGTGGCAAGCGAGTGAAGGCAGAACCTGTATGGCTCCAGACCGCCGGGCCAGAG
 CTACGCACAGCAGCTGGGAGACTCTCCGGAAGGCTTTGATCCCCGGCTGTGTATGGATGAGTAT
 GACGTGGTGTCCCTCGAACACAGAGACGCTGGTGTGGTAACCAGCACATTGGGAATGGGATCCCC
 CGGAGAATGGAGAGGCCTTGCAAGCTGCCATGGAGATGTCGGCCCTAACACAGCTCCCTCGGCC
 GGAACAGCACAAGAGTTATAAGATCCGCTAACAGCATCTCTGCTCACGACCCACTGGTGTCCCTTTGG
 CGGCGGAAGAGGAAGGAGTCCAGTAACACAGACAGTCAGGGGCCCTGGCACCCCTAGGTTCTGTGT
 TCGGGCTGGCTCCGGCAACCCCCACTTCTGCGCTTGTGTCGTGCCGTGGACACAGGGTGGAGGA
 ACTGGGCGGGAGGGCTGCTGCAAGCTGGCCAGGGCAGAGCTGAGCTGTGCGCCAGGAGGGCTTCCGA
 GGCTGGGCCAGGGTGCCTTCAGGCCCTGTGAGACCTCTGTGTGGAGAGGATGCCAAGGCCCGCC
 CCCGAGACATCTCAGCCCCAACGGAGCTGGAAGGCCAGAGGTACGGCTGAGGCCAGGGCGAGGG
 CCTGCAGTTGCTGCCAGGTCTGATCCACGTGCACAGGCCAGGAGATGTCAGGCTACAATCCGCTCAGTG
 GAAAACCTGCAAAGCAGCAAGTCCACGAGGCCACCATCTGGTGCCTGGACACCGGAGGCCAGGAG
 GGCTGCAGTACCGCCGGGACCACATAGGTGTCTGCCGCCAACGGCCGGCTGTGGAGGCGCT
 GCTGAGCCGCGTGGAGGACCGCCGGCCACTGAGCCCGTGGCAGTAGAGCAGCTGGAGAACGGCAGC
 CCTGGTGGCCCTCCCCCGGCTGGGTGCCGGACCCCGGCTGCCCTGTCACGCTGCCAGGCTCTCA
 CCTTCTCCCTGGACATCACCTCCCCACCCAGCCCTAGCTTGCCTGCTCACGACCTGGCAGAAGA
 GCCCAGGGAAACAGCAGGAGCTGGAGGCCCTAGCCAGGATCCCCGACGCTACGAGGAGTGGAAAGTGGT
 CGCTGCCCAACGCTGCTGGAGGTGCTGGAGCAGTCCCGTGGCTGGCGCTGCCCACTGCTCCTCA
 CCCAGCTGCCCTGCTCCAGCCCCGGTACTACTCAGTCAGCTGCCACCCAGCACCCACCCAGGAGAGAT
 CCACCTCACTGTAGCTGTGGCATACAGGACTCAGGATGGCTGGGCCCTGCACTATGGAGTCTGC
 TCCACGTGGCTAACGCCAGCTAACGCCAGACCCCTGTGCCCTGCTCATCGGGGGCTCCCTCTTCC
 GGCTGCCACCCGATCCCAGCTTGCCTGCACTCTGGTGGGCCAGGACTGGCATTGCCCTTCCGGGG
 ATTCTGGCAGGAGGGCTGCATGACATGAGAGCAAAGGGCTGCAGGCCACTCCCATGACTTGGT
 GGCTGCCGATGCTCCAACTTGACCATCTACCGCAGCAGGAGTGCAGAACGCCAGCAGCGGGGT
 TTGGCCAGTCTCACCGCCTCTCCGGAAACCTGACAACCCCAAGACACTACGTGCAGGACATCCTGAG
 GACGGAGCTGGCTGCCGGAGGTGCACCGCAGTGTGCCTCGAGCGGGGCCACATGTTGTCTGGCG
 GTTACCATGGCAACCAACGCTCTGCAGACCGTGAGCGCATCTGGCGACGGAGGCCACATGGAGTGG

ACGAGGCCGGCGACGTCATGGCGTGCAGCAACGCTACCACGAAGACATTTCGGGCTCAC
 GCTGCGACCCAGGAGGTGACAAGCCGCATACGCACCCAGAGCTTTCTGCAGGAGCGTCAGTGCGG
 GGCGCAGTGCCCTGGCGTTGACCCCTCCCGGCTCAGACACCAACAGCCCCGAGAGAGCCGCTGGCTTTC
 CCTTCCAGTCCGGAGAGCGGCTGCCGACTCAGGTCCGCCGACCAGGATCAGCCCGCTCCCTCC
 CTTGAGGTGGTGCCTCTCACATCTGTCAGAGGTGCAAGGATTAGCATTATTCCCTCAGGAAGGAGC
 AAAACGCCCTTTCCCTCTAGGCCTGTTGCCCTGGGCTGGCTTAATCTGGAAGGCCCTC
 CCAGCAGCGGTACCCAGGGCTACTGCCACCCGCTCCCTGTTCTTAGTCGAATGTTAGATTCCCTTG
 CCTCTCTCAGGAGTATCTTACCTGTAAAGTCTAATCTCTAAATCAAGTATTATTGAAGATTACCA
 TAAGGGACTGTGCAGATGTTAGGAGAACTACTAAAGTGCCTACCCCAGCCAAAAAAAAAAAAAA

>gi|4506060|ref|NM_002733.1| Homo sapiens protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1), mRNA
 GCGCCCTTAAAGATGGTGGAGGGGCTCATGCTCTGAGTAGAAGGTGGTACCTCCAGGAGCGTGGGATG
 ATGAGGGCCCGGGCGCTCTGCAATGGAGACGGTCATTCTCAGATAGCTCCCAGCTGTGGAAAATG
 AGCATCCTCAAGAGACCCAGAACATCCAACAATAGCGTGTATACTTCCTCATGAAGTCTCATCGTCTA
 TGACCTGATTCCCACAAGCTCAAATTGGTTGATTTGATACTGTCCTGCAGGTGAAGAAAGCTTTTT
 GCTTGGTACTAACGGTGACGGTGAGCTGCCCTTATGGGATAGTAAGAAGCAAAGTTTGTGGGATGC
 TGACCATCACTGATTCATCAATATCTGCACCGTACTATAAAATCAGCCTGGTACAGATCTATGAGCT
 AGAAGAACACAAGATAGAAACTGGAGAGAGGTGTATCTCAGGACTCCTTAAACCGCTTGTCTGCATT
 TCTCTTAATGCCAGCTTGGTGTGATGCTGTCTCTCATTAATTGGAACAAAGATCCACAGGCTGCCAGTTA
 TTGACCCAGAACATCAGGAATACTTGTACATCCTCACCCACAAGCGCATTCTGAAGTCTCAAATTGTT
 TATCACTGAGTCCCCAAGCAGAGTTCATGTCAGTCTGGAAAGAGCTACAGATTGGCACCTATGCC
 AATATTGCTATGGTTCGCACTACCACCCCGTCTATGTCAGTCTGGGGATTGGTACAGCATCGAGTCT
 CAGCCCTGCCAGTGGTGGATGAGAAGGGCGTGTGGACATCTACTCCAAGTTGATGTTATCAATCT
 GGCAGCAGAAAAGACCTACAACAACCTAGATGTACTGTGACTAAAGCCTGCAACATCGATCACATTAC
 TTTGAGGGTGTCTCAAGTGTACCTGCATGAGACTCTGGAGACCATCATCAACAGGCTAGTGGAAAGCAG
 AGGTTCACCGACTGTAGTGGTGGATGAAATGATGTTGACAGGAAATTGATGTTACTGTCTGACATCCT
 GCAGGCCCTGGTGCACAGGTGGAGAGAACAGCCCTGAGCTGGGGAAAGGGGTATGCAGCAGCACCAGG
 GATATGCCCAACTACTGCCCTGGAGCTCTGTTGGAATCAGATGAAACTTGAGGGAAATTGTA
 GTTCCCTGTTCAAGGCTCCCTGCTATCTGGAGCTAGGGAAAGGTATGGGGAGGAAAGAGAAATGG
 ATTTATAGCTACCCCTACACATACACTGAAAAACTTCAAGGCTAGCCAGTTCTAGCCCTGT
 CCTCTTAGATATATCCCCCTTCTGGGTGAACTATAGGCTCTGTCCTCTCAGACAAATTCTGATCTA
 AGAGATCCCCAGACCTCACTGCCCTGCCTCCATCTGGCCCTGATTCAACCTAAGATAATAGCACAA
 CAAATTCTCATAAAAGATATTTCACCTGTTCTGCTATATGGAGGAGGCCAGTCCATTAGT
 GACATTCTCCATAATGTGAGTGGGAGGATTGTTG

>gi|33186924|ref|NM_016203.2| Homo sapiens protein kinase, AMP-activated, gamma 2 non-catalytic subunit (PRKAG2), mRNA
 GCGGCTCCAGTCCAGGAGCAGCGGCCGGGGAGGAAGGAGGGACCAACCCCCGAGGAGTTTCGCAGA
 ATCAACTTCTGGTTAGAGTTATGGGAAGCGCGGTTATGGACACCCAAGAAGAAAAAGATGTTCCAGCCC
 CGGCGGGAGCGGCCAGAACAAAGCAGCCAGAACAGGGCTCGCTGCGGTGACATTCCGGACCTG
 AGCTCCTCGCCATGCCGCTCTGGACGGAGACCTGGAGGGTTCCGGAAAGCATTCTCTCGAAAGGTGG
 ACAGCCCCCTCGGCCCGGGCAGCCCTCAAAGGGTTCTTCTCAGAGGCCCGAGCCCCGGCCCTCCAG
 CCCCATGTCGACCTGTGAGGCCAAGACCAGCCCCGGCTCTCCAAAACCGTGTCCCGTCTCCTAC
 CAGGAGTCCCCGCCACGCTCCCTCGACGCATGAGCTTCAGTGGATCTCCGCTCTCCTCAAAGAGT
 CTTCCCCAACTCCAACCCCTGCTACCTGCCCGGGCATCAGGTTTCTCCCGTCCAGAAAAACCTC
 CGGCCTCTCCCTCCGTCACACCCACCAAGTGCACAGCAGCACAGTTCCCTGGAATCCTAT
 AAGCAGCAGGCTGAACGGTTAGAGAATCGCATCTATGCCCTGCTTCCCCCGGACACAGGGCAGAGGT
 TCTGCCGCTTCTCCAGAGCCGACCAAGGCCACTGGCATCACCACACACTATGCTCCCTCAA
 AGCCGCCGGCTGGGGGGGGCTGGGACCCGGGAAGCCGGCATCTGGAGAAGCTGGAGTTCGAGGAC
 GAAGCAGTAGAAGACTCAGAAAGTGGTGTACATGCAGGTCACACAAGTGTATGACATCG
 TTCCAACCAGTTCAAAGCTTGTCTTGATACACTACATTACAAGTTAAAAGGCCCTTCTTGCTTGGT
 AGCCAACGGTGTCCGAGCAGGCCACTGTGGAGAGTAAAAAACAAAGTTGTAGGAATGCTAACATT
 ACAGATTCTATAAAATACATAGAATCTACACACCTATGTCAGGATTTGATTA
 ATAAAATTGAAACATGGAGGGAGCTTATTACAAGAAACATTAAAGCCTTACTGAATATCTCCAGA
 TGCAAGCCTCTCGATGCTGTACTCCTTGATCAAAAATAAAATCCACAGATTGCCGTTATTGACCC
 ATCAGTGGGAAATGCACTTATACCTACCCACAAAAGAACCTCAAGTTCCAGCTTTATGTCG

ATATGCCAAGCCTGTTCATGAAGCAGAACCTGGATGAGCTTGAATAGGAACGTACCACAACATTGC
 CTTCATACATCCAGACACTCCCATCAAAGCCTGAACATATTGTGAAAGACGAATATCAGCTCTG
 CCTGTTGTGGATGAGTCAGGAAAAGTTAGATATTATTCCAATTGTGTAATTAACTCTGCTGCTG
 AGAAAACATACAATAACCTAGATATCACGGTGACCCAGGCCCTCAGCACCGTCACAGTATTGAGG
 TGTTGTGAAGTCAATAAGCTGAAATACTGGAGACCATCGTGACAGAATAGTAAGAGCTGAGGTCAT
 CGGTTGGTGGTGGTAAATGAAGCAGATAGTATTGTGGGTATTATTCCCTGTCGGACATTCTGCAAGGCC
 TGATCCTCACACCAGCAGGTGCAAACAAAAGGAGACAGAAACGGAGTACCGCCGTGAATGTAGACGCC
 CTAGGAGGAGAACCTGAACAAAGTCTGGGTACGTTTGCTCATGAACACTGGCTGCAAGTGGTAA
 GAATGTATATCAGGGTTAACGATAGGTATTCTCCAGTGTGAAATTAAAGCTTAAAAAGAAAGA
 TTTTATGTGCTTGAAGGAAATTCAAGCTTGATTAAAAACTGTTCAAGACCTGTCAAGGATTAAAT
 GCTGTATGTCAATTAAAGTGCAGTGTGCCCTG

>gi|8394043|ref|NM_017431.1| Homo sapiens protein kinase, AMP-activated, gamma 3 non-catalytic subunit (PRKAG3), mRNA
 ACTTGGTCTGGGGCTGGCCACATGGAGGCCGGCTGGAGCACGCACTGCGCAGGACCCCTTCTGGAGCA
 GCCTTGGGGTCTGAGCATCAAGAGATGAGCTCCTAGAGCAAGAAACAGCAGCTCATGGCCATCACC
 AGCTGTGACCAGCAGTCAGAAAGAATCCGTGGAAACGGAGGGCCAAGCCTTGAGATGGACAAGGCAG
 AAGTCGGTGGAGGAAGGGGAGCCACCAGGTCAAGGGGAAGGTCCCCGGTCCAGGCCAGCTGCTGAGTCCA
 CCGGGCTGGAGGCCACATTCCCCAAGACCACACCCCTGGCTCAAGCTGATCTGCCGGGGTGGGACTCC
 ACCAACAGGTGGACTGCCCTCCCTGACTGTACAGCCTCAGCTGCAGGCTCCAGCACAGATGATGTG
 GAGCTGCCACGGAGTCCAGCCACAGAGGCCCTGGAGTGTGAGCTAGAAGGCCCTGCTGGAAGAGAGC
 CTGCCCTGTGCCCTGCCCCCAGGCCATTCCAAAGCTGGCTGGGATGACGAACTGCCGAAACCCGG
 CGCCAGATCTACATGCGCTCATCGAGGAGCACACCTGCTACGATGCCATGGCAACTAGCTCAAGCTA
 GTCATCTCGACACCAGCTGGAGATCAAGAAGGCCCTCTTGCTCTGGCCACGGTGTGCGGGCAG
 CCCCTCATGGACAGCAAGAAGCAGAGCTTGTGGGATGCTGACCATCACTGACTTCATCTGGTGC
 GCATCGCTACTACAGTCCCCCTGGTCCAGATCTAGAGATTGAAACAACATAAGATTGAGACCTGGAGG
 GAGATCTACCTGCAAGGCTGTTCAAGCCTCTGGTCTCCATCTCTTAATGATAGCCTGTTGAAGCTG
 TCTACACCCTCATCAAGAACGGATCCATGCCCTGCTTGTGACCCGGTGTCAAGCAACGTACTCCA
 CATCCTCACACACAAACGCCCTGCTCAAGTTCCCTGACATCTTGCTTCCCTGCTGCCCGGCCCTCCTC
 CTCTACCGCACTATCCAAGATTGGGCATGGCACATTGGAGACTTGCTGTGGCTGGAGACAGCAC
 CCATCCTGACTGCACTGGACATCTTGCGGCCGTGTGACTGCCCTGTGCACTGCCCTGGTCAACGAATGTG
 TCAGGTCGTGGGCCTTCTATTCCGCTTGATGTGATTCAACCTGGCTGCCAGCAAACCTACAACCACCTG
 GACATGAGTGTGGAGAAGCCTGAGGAAGAGGACACTATGCTGGAGGGAGTCCTTCTGCCAGCCCC
 ACGAGAGCTGGGGAAAGTGTGACAGGATTGCTGGAGCAGGTACACAGGCTGGTCTAGTGGACGA
 GACCCAGCATCTTGGCGTGGCTCCCTCTCCGACATCCTTCAGGCACTGGTCTCAGGCCCTGCTGG
 ATCGATCCCTCGGGCCTGAGAAGATCTGAGTCTCAATCCAAGCCACCTGCAACACCTGGAAGCCAATG
 AAAGGAACCTGGAGAACTCAGCCTCATCTCCCCACCCCCATTGCTGGTCAGCTATGATTCAAGGCTT
 CTTCAGGCCCTCCAAATTGCCCTGCCCTACCAAGAGCTCCAGAAGGCCCTCGGCATGCCAGTGCACCAT
 GGGATGATGAAATTAGGAGAACAGCTGAGTCAAGCTGGAGGTCCCTGAACCAGAGGCACTAGGATTAC
 CCCAGGCCATCTGTGCTCCATGCCGCCATCCCTTGCCCTGACTGGTCGGATGGCCCCAGTGG
 GTTAGTCAGGGCTCTGGATCCTCGGTTCTGGCTACCTATGCTTCACCTCAGCTCCTGGAGTTCC
 CAGCAACGTCGCCACTGCCCTCCTACTCTCCAGGGTTGGTCAATTCAAGGCTGCTGAAATGCTGCATT
 TCAGGGGCCACCATGGAGCAGCCGTTATTAGAAGTGCCTGTTGGAGGTGGGAGTCCTCCCTCCA
 TTCTTGCCAGAAAACCTTAGCTCTCGCAGTGAGCCATGTTCTAGTCTCCAGGGATGGATGGCCTT
 GTATATGGACCCCTGAGAATGAGCAATTGAGAAAACAAAAGGAACAAATCCATGAACCTAGATT
 ATTGGTTCACTAAAATGTCAGTCAGTCAATTGACCTGAACTGTGCAAGAGACTGTGCTTCTAAATT
 CAAAGACTAGAAGGAAATGGATAAAATCACAGTGCCCTCTTG

>gi|24041028|ref|NM_000625.3| Homo sapiens nitric oxide synthase 2A (inducible, hepatocytes) (NOS2A), transcript variant 1, mRNA
 ATAACCTTGAGCGAGTCGAAAAGTCAAGGCTCCGCCGCAGAGAAACTCAGCCTCATCCCTGCTTAAAT
 CTCTCGGCCACCTTGTGAGGGGACTGGCAGTCTAGACAGTCCCGAAGTTCTCAAGGCACAGGTCTC
 TTCCCTGGTTGACTGTCTTACCCGGGGAGGCAGTGCAGCCAGCTGCAAGCCCCACAGTGAAGAACATC
 TGAGCTCAAATCCAGATAAGTGACATAAGTGACCTGTTGTAAAGCCATAGAGATGGCCTGCTTGG
 AATTCTGTTCAAGACCAAATTCCACCAAGTATGCAATGAATGGGAAAAGACATCAACAAATGTGGA
 GAAAGCCCCCTGTGCCACCTCAGTCCAGTGACACAGGATGACCTCAGTATCACAAACCTCAGCAAGCAG
 CAGAATGAGTCCCCCAGCCCTCGTGGAGACGGAAAGAAGTCTCAGAATCTGGTCAAGCTGGATG

CAACCCCATTGTCTCCCCACGGCATGTGAGGATCAAAACTGGGGCAGCGGGATGACTTCCAAGACAC
 ACTTCACCATAAGCCAAAGGGATTTAACCTGCAGGTCAAATCTGCCTGGGTCCATTATGACTCCC
 AAAAGTTGACCAGAGGACCAGGGACAAGCCTACCCCTCAGATGAGCTCTACCTCAAGCTATCGAAT
 TTGTCAACCAATATTACGGCTCCTCAAAGAGGCAAAATAGAGGAACATCTGCCAGGGTGAAGCGGT
 AACAAAGGAGATAGAAACACAGGAACCTACCAACTGACGGAGATGAGCTCATCTCGCCACCAAGCAG
 GCCTGGCGCAATGCCCAACGCTGCATTGGAGGATCCAGTGGTCAAACCTGCAGGTCTCGATGCCGCA
 GCTGTTCACTGCCCAGGGAAATGTTGAACACATCTGCAGACACGTCGTTACTCCACCAACAATGGCAA
 CATCAGGTGGCCATCACCGTGTCCCCAGCGGAGTGATGCCAAGCAGACTCCGGGTGAGGAAATGCT
 CAGCTCATCCGCTATGCTGGTACCCAGATGCCAGATGCCAGATCAGAGGGGACCCCTGCCAACGTGGAAT
 TCACTCAGCTGTGCATCGACCTGGGCTGGAAGCCAAGTACGGCCGTTCGATGTTGCCCCCTGGTCT
 GCAGGCCAATGGCCGTGACCTGAGCTTCAAACTCCACCTGACCTTGTGCTTGAGGTGGCATGGAA
 CATCCCAAATACGAGTGGTTCGGGAACTGGAGCTAAAGTGGTACGCCCTGCCTGCAGTGGCAACATGC
 TGCTTGAGGTGGCGGCTGGAGTTCCAGGGTCCCCCTCAATGGCTGGTACATGGCACAGAGATCGG
 AGTCCGGACTCTGTGACGCCAGCGCTACAACATCCTGGAGGAAGTGGCAGGAGAATGGCCTGGAA
 ACGCACAAGCTGGCCTCGCTGGAAAGACCAGGTGTCGTTGAGATCAACATTGCTGTGCTCATAGTT
 TCCAGAACGAGAATGTGACCATCATGGACCAACTGGCTGCAGAACATCTCATGAAGTACATGCAGAA
 TGAATACCGGTCCCGTGGGGCTGCCCGCAGACTGGATTGGCTGGTCCCTCCATGTCCTGGAGCATC
 ACCCCCCTGTTTACCAAGGAGATGCTGAACACTGCCCTGCCCCCTTACTACTATCAGGTAGAGGCCT
 GGAAAACCCATGTCGGCAGGACGAGAACGGAGACCAAGAGAACGAGAGATTCATTGAAAGTCTGGT
 CAAAGCTGTGCTCTTGCTGTATGCTGATGCCAAGACAATGGCGTCCCGAGTCAGAGTCACCACCTC
 TTTGCGACAGAGACAGGAAATCAGAGGCCTGGCCTGGGACCTGGGGCCTTATTGAGCTGTGCTTCA
 ACCCCAAGGGTGTGACATGGATAAGTACAGGCTGAGCTGCTGGAGGAGAACGGCTGCTGTTGGTGGT
 GACCAGTAGCTGGCAATGGAGACTGCCCTGGCAATGGAGAACGAGAACGAGAACGAGAACGAGAAC
 AAAGAGCTCAACACAAATTAGTACGGTACGCTGTGTTGGCCTGGCTCCAGCATGTAACCTCGTTCTG
 CCTTGCTCATGACATTGATCAGAACGCTGCTCCACCTGGGGCCTCTCAGCTCACCCGATGGAGAAC
 GGATGAGCTCAGTGGCAGGAGGACGCCCTCCGAGCTGGGGCGTGCACACCTCAAGGCAGCCTGTGAG
 ACGTTGATGTCGAGGCAACAGCACATTAGTACCCAGTCTACACCTCAATGTGACCTGGGACC
 CGCACCAACTACAGGCTCGCAGGACTCACAGCCTTGGACCTCAGCAAAGCCCTCAGCAGCATGCATGC
 CAAGAACGTTGACCATGAGGCTCAAATCTGGCAGAACGAGCTCACCCGATGGAGAAC
 ATCCTGGTGGAACTCTCCTGTGAGGATGGCAAGGCCTGAACACTGCCGGGGAGCACCTGGGGTT
 GCCCAGGCAACCAGCCGGCCCTGGTCCAAGGTATCCTGGAGCGAGTGGGGATGGGGCACACCCCCACCA
 GACAGTGCCTGGAGGCCCTGGATGAGAGTGGCAGCTACTGGTCAGTGACAAGAGGCTGCCCTGC
 TCACTCAGCCAGGCCCTCACCTACTTCTGGACATCACCAACACCCCAACCCAGCTGCTGCCAAAGC
 TGGCCCAGGTGGCACAGAACGAGCCTGAGAGACAGAGGCTGGAGGCCCTGTGCCAGCCCTCAGAGTACAG
 CAAGTGGAAAGTTCAACACAGCCCCACATTCTGGAGGTCTAGAGGAGTTCCCTGCCCTGGGGTGTCT
 GCTGGCTTCTGCTTCCCAGCTCCCCATTCTGAAGGCCAGGTCTACTCCATCAGCTCCTCCGGGATC
 ACACGCCACAGAGATCCACCTGACTGTGGCGTGGTACCTACCAACCCGAGATGGCAGGGTCCCT
 GCACACGGCTCGCAGCACATGGCTCAACAGCCTGAAGCCCCAAGACCCAGTGCCCTGCTTGTGCGG
 AATGCCAGGGCTCCACCTCCCGAGGATCCCTCCATCCTGCATCCTCATGGGCCTGGCACAGGCA
 TCGGCCCTCCGAGTTCTGGCAGCAACGGCTCATGACTCCCAGCACAAGGGAGTGCAGGGAGGCC
 CATGACCTTGGTGTGGGTGCCGCCAGATGAGGACACATCACCAGGAGGAGATGCTGGAGATG
 GCCCAGAAGGGGTGCTGCATGCCGTGACACAGCCTATTCCCGCTGCCCTGGCAAGCCCCAAGGTCTATG
 TTCAGGACATCTGGCAGCAGCTGGCAGCGAGGTGCTCCGTGCTCCACAAGGAGCCAGGCCACCT
 CTATGTTGCCGGGATGTGCCATGGCCGGAGCTGGCCACACCCCTGAAGCAGCTGGTGGCTGCCAAG
 CTGAAATTGAATGAGGAGCAGGTGAGGACTATTCTTCAAGCTCAAGAGCCAGAACGCGTATCAGAAG
 ATATCTTGGTGTGTTCTTACAGGGCAAGAACGAGACAGGTGGGGTGCAGCCCAGCAGCCTGG
 GATGTCAGCGCTCTGAGGGCTACAGGGGGTTAAAGCTGCCAGAACAACTTAAGGATGGAGCCAGC
 TCTGCATTATCTGAGGTACAGGGCTGGGGAGATGGAGGAAGTGTGATATCCCCCAGCCTCAAGTCTTAT
 TTCCTCAACGTTGCTCCCATCAAGCCCTTACTGACCTCTAACAAAGTAGCACCTGGATTGATCGGA
 GCCTCCCTCTCAAACTGGGCCCTCCGGTCCCTGGAGACAAAATCTAAATGCCAGGCCCTGGCAAGT
 GGGTGAAGAGATGGAACCTGCTGAGTGCACCAACTCAAGTGACCCAGGAGGTGCTATGCCACCACT
 GTGTATTAACTGCCCTGTGACAGTTATTATGCCCTGTGTTAAAAAAACTAACACCCAGTCTGTTCC
 CCATGGCCACTTGGGTCTTCCCTGTATGATTCTGATGGAGATATTACATGAATTGCAATTACTTAA
 ATCACAAAAAAAAAAAAAA

>gi|4504788|ref|NM_002220.1| Homo sapiens inositol 1,4,5-trisphosphate
 3-kinase A (ITPKA), mRNA

GAATTCCGAAATGACCCTGCCCGGGGCCAACGGCATGGCGCGGCCGGGGCGGAGGGCCCTGCAG
 CCCGGGCTGGAGCGGCCCGCGCCGGAGTGTGGAGCTGCGCTGCTCTCGAGGCGCCTGTGCG
 GCGGTCGCTGCGGCCGCCGGGGAGCCCCGGGCCAAGCGGCTGGGGACAGGTCC
 CCAACGGCTTCCGGGCTCCCCGGCCGGAGCGGGAGAGGGACTGCCTCCGGCAGCGGGCTTCGCAC
 CGTCCCCCGACCAGCCCTGGCCGCCGGAGCGGGAGAGGGACTGCCTCCGGCAGCGGGCTTCGCAC
 CTGCAGCAGCCGCCCTTCCACCTCGTCGGCTCCTCCACTGGCTCCCTCGCTGCTCGAGGACT
 CGGAGGACGACCTGCTGAGCGACAGTGAGAGGCCGGAGCCGCCAACGTCAGCTGGAAGCGGGGAGGA
 CGTGGGTCAAAAAACACTGGCAGAAGATCCGGACCATGGTCATCTGCGGTCTAAGCCCTTCAAG
 AAGCCTACGCCCTGGTGCAGCTGGCAGGGCACACTGGAGTTTAAGCGGGCACCAGCGGGCTGA
 TCCTGAAGCGCTCGGAGCCGGAGCGCTACTGCCTGGCGGCTGATGGCTGACGCCTGCGCGCTG
 CGTGCCTGCCTTCCACGGCTGGTGGAGCGCAGGGCAAAGCTACCTGCACTGCAAGCTGCTCGAT
 GGCTTGCACGGACCTGTGCTGACTGCAAAATGGCGTCAGGACTTACCTAGAGGAGGAGCTGACCA
 AGGCCGTAGCGGCCAACGTCGGAAGGACATGTACAAGAAAATGCTGGCGGATCCTGAAGCTCC
 CACGGAGGAGGAGCACGCGAGCGGCCGTCACCAAGGCCCTACATGCACTGGCGGAAAGCATTAGC
 TCCAGCACCACCCCTCGGCTTCCGATCGAGGGCATCAAGAAAGCGGACGGCTCTGCACTGACCA
 AGACTACCGGAAGCGAGAGCAGGTGCTTCGCTTTGAAGAGTTGTGCAAGGAGATGAGGAAGTGCT
 GAGCGGTATCTGAACCGCCTGCAGCAGATCCGGACACCCTGGAGGTATCCGAGTTCTCAGGAGGCAC
 GAGGTGATGGCAGCTCGCTCTCTTGTGCACTGCACTGCCATCGGCCGGCGTGTGGCTATCGACT
 TCGGCAAGACCACGCCCTCCCGATGCCAGATCTGGGACCCGGCCCTGGGAGGAGGGCAACCG
 CGAGGACGGCTATTGCTGGGCTGGACAATCTCATTGGCATCCTGGCAGCCTGGCTGAGAGATGAGGC
 TGGACTCTGTCCCAGGGCGTCACCTGACATGTGGACCTGCACTGGCTTGTCCCCACTGTGCACTGCC
 GCTTGAGACTGGAGCCCCCGGGTGCAGGGCAGTTGACCGGGCTGCAAGGACCAAGGTGCCAGCCACTAAG
 GGGGGCACCGCCATGCCAGGGTTTGCCCACCCGGGCCCCAGCGTCCCAGAGCCAATGACACTAA
 CTTATAGAAGGGAGGGGAAAGGGCTTCTCCTCAGGCCAGCTTCTGAGGAGGCTCTGCCCTCTCC
 AGAGGTGCCAGACCGCGGATTTTAGCAAGCCCAGACCTCGGTCTAACGTCACACCACGACGG
 ACTCCCTTCTTAATAAAACTCAAAGACAAAA

>gi|38569399|ref|NM_002221.2| Homo sapiens inositol 1,4,5-trisphosphate 3-kinase B (ITPKB), mRNA
 GGAGCCGCGGGCGGGCGGGCAGCGCGGGACCCAGTACTATGGCTGTACTGCTATGGCTCAATAGCCTGG
 TGATCATGAATAGCGCAACCGAGATGAAGAGCGGGCGGCCGGGGCCAGTGGCAGCGAGACGCC
 GCCCCCGAGGAGGGCAGTGTGAGCCCCGGCAGCGTTTCAGCCCCGGAGAGGCCCTCTTCCCTCTTC
 CCCCCAGCCAGTCGCTGCCCCGGAGGAGCCCCGGAGGCCGGGGCTGGCGAGCGGCCGGCGCAGGC
 TGAATAGTAGCAGCGCAGTGGCAGCGCAGCGGCAGTAGCGTGAGCAGCCAAGTTGGCTGGT
 CCTGCAGGGGACGGCAGCAGGTGGCAGCCCCGTACCCCTCTCCCCCGCAGGGCGGAGGAGGCCAAG
 AGGAAGCTGGATCTTGAGCGCAGTTGAGAAGCTGAGGAGACCTGGGATGTTGAG
 CGCACATCCAGGCACAGAGCTCCGCATTCAAGGCCCGCAGCCCCTGGGAGGGCTCGCTCGCC
 CTCCCCGTGCCCTTCCGAGCAGCAGTCAGCCCCGTGGAAAGGGCTCTGGTCAGGGCGCCGGAGCGAG
 GAACGGAGGACAAAGTCCCTGGGGAGCAATGTCAGAGACTTCAGGAACCGACTCCGGAGGAAAGGAG
 GGCCCAGCCTATGCTCTCGCAGGTGAAGAAAGGAATGCCACCTCTTCCGGCCGGCTGCCCTACAGG
 ATCAGAGGCTCAGGGTCCATCCGCTTTGTAAGGATGGAGAAGGGTATCCCTGCCAGTCCCCGTG
 TCACCCACAGCTATGAAATTGACAAAAGGGCTCCTACCCGGGAACTCGGAGCTGCCAGTCCCT
 CATTGGGCTGTTGGAGCTAGCTAACGATGCCACGGAAAGTGGCAGCGAGAGTTACATCCACTGGG
 ACACCGTCCACAGGATCTTGCCTCACTGAGCGCTCTGGGAGAGGCCGTGAGCTTGAGGACCTGCAG
 CCAGAGGCCCTGGGGAGGGCAGGGCAGTTCTGGGAGTGAAGACAAGGCCAGCCCCAGAAAGGGG
 GGCCCCGGATGGAGAACCCCTGGGAAGATGGGAAGGATATCTGCCCTGTGGCATGCCGGCTCTGG
 GGAGCCTGAAGTGGCAAAGGCCAGAGGAGACGACTGTGAGCGTGCAGCGAGTCCTGATTCC
 CTGAGCTGGTCCAGGCTGCCAGGGCTGGCCTCCGTAGGCCCTGAGGAGGGCCGAAGTGGGCCCC
 TGGCGGGGGCGTTGGCAGCTCCGACAGAGTGGAGGGAGGGTCCCAACGCTGGCTTGTGGGG
 CAGCCCCCTCAGCACAGCGGGACCGGGAAATGTGGAGGCGGAATTCCCTCTGGCAGAATGCTGGAG
 TTGCCCCGTGTTGGAGCCTGCAAAGATCTGAAAGAACCTCAGTGCCTCTGGGACAGGGTGGGTG
 AGCCTGGGAACTCCAGGGTTGGCAGGGCACCATGGAGAAGGCCGGTTGGCTTGGACCGTGGCACAGG
 GGTGCAATCAGAGGGACTTGGAAAGCCAGCGCAGGACAGTGTGCCCCCTCAAGTCCGGAGCTG
 CCCCACAGATCAGGACAAGCCTTCCCTGAGGAAGGCCCTGCAGCCCCAGAACATACCTGCTG
 CATCATTACAGACATGGGCACCCAGGAGATGGGGCTTGGAGGAGACGAGGGAAAGCCCTGGGG
 CAGAAGACTGTCCTCTTCCCTGGCCTCCACGGGCTTCTCTCATCTACGAAGACTCAGAGGGAG
 GACATCTCCAGTGCACCCCTGGACCCCAACTCAGCCTCTGACATACCTGGGACAGCAGAAC

CTAGAGTGAGCAAATCATGGAGGAAGATAAAAACATGGTGCACTGGTCTCCCTCGTCATGTCCTTCAA
 GAAGAAGTACCCCTGGATCCAGCTGGCAGGACACGCAGGGAGTTCAAGGCAGCTGCCAATGGCAGGATC
 CTGAAGAACGACTGTGAGTCAGAGCAGCGCTGCCCTGGACCGCTGATGGTGGATGTGCTGAGGCCCTCG
 TACCTGCCTACCATGGGGATGTGGTGAAGGACGGGAGCGCTACAACCAGATGGACGACCTGCTGGCCGA
 CTTCGACTCGCCCTGTGTGATGGACTGCAAGATGGAATCAGGACCTACCTGGAGGAGGAGCTACGAAG
 GCCCGGAAGAAGCCCAGCCTCGGAAGGACATGTACCGAGAAGATGATCGAGGTGGACCCGAGGCCCCA
 CCGAGGAGGAAAAGCACAGCGGCTGTGACCAAGGCCACGGTACATGCACTGGCAGGGAGACCATCAGCTC
 CACGGCCACCCCTGGGGTTCAGGATCGAGGGAAATCAAGAAAGAAGACGGCACCGTGAACCAGGACTTCAAG
 AAGACAAAACGAGGGAGCAGGTACCGAGGCCCTCAGAGAGTTCACTAAAGGAAACCATAACATCCTGA
 TCGCCTATCGGGACCGGCTGAAGGCCATTGCAACCAACTCTAGAAGTTCTCCCTTCAAGTGCACGA
 GGTCACTGGCAGCTCCCTCCTTCATCCACGACAAGAAGGAACAGGCCAAAGTGTGGATGATCGACTTT
 GGGAAAACCACGCCCTGCCAGGGCCAGACCCCTGCACTGACGTCCCCCTGGCAGGAGGGAAACCGGG
 AGGAATGGCTACCTCTCGGGCTCAATAACCTCGACATCCTGACCGAGATGTCCCAGGA TGCCCCACT
 CGCCTGAGCTGCCACGCCCTCCCTGGCCCCCGCTGGCCCTCCTTCCCTCCTGTGCTTCCCTTCTC
 GTTCCTAACTTTCCCTCACTTACACCTGACTGACCCCTCTGAACGTACAAGACACTTTGTAGAAG
 AGGAGATGAGAGTTCTAGTCATTTCTTAACCTCAGGGCTTGGAGGTGGTTGCAGTGTCTTTGTA
 GAGAGGGTCACCTACTAGAAGAGAAATGCCCAAGTCTTAGAGGTGGTCAGGTAGAGCTGGAGGGGTC
 CCTGGCTGCTGAGGGGACCCCTACCAGATGAGCCCTGCCCTGGGAGCCCCCTAGGAAGCACCAGCCTGGA
 CCTACCACCTGCCAGGGCTGCTGCCCTGGCGCCAGTGTGTTAGAGTGCTGCCAAGCACAGCCTTA
 TTTCTGCCGGGGCTCCCCACCGAGAGCCCAGGGGGCCGGGTTCTGGTCCCTGGCTGGAGCAG
 GGCTTCTGGTAGTTGGGCACAAACCATGGGAACCATGTTGACTGTGAGCAAAGTGTCTCCGA
 TTAGCAGCCTCAGGGATGCCCTGGTGGCTCTCCAGGGCTGTCAGGCAAGGCCAGCTGGCTGTGTTCTC
 TGGAAACCTGCCGGCTCCAGGCCAGACCCAGGAGCAAGAGAAGGCTGAAGCCAGCTGGCTGTGTTCTC
 TGATCTAGGCCCTCCAGAGGGAGGCGAGCAGAACGCTGTGCCACTTGAATTGCAACCCATGAGTTCA
 GGCACACTCTGCCATGCTGAGCTCCAAGGGTCTACCAGGGAAAGATGGATCTAGAGTCTCTGGGCC
 CTGGCCCAGGGAGGAGCACATTTCCTGACCCCTCACCTACCTGGTCTAGTTGGTCAACCTGCCTGC
 ATACATGGGCTCTGTCATGGGCCAGAGTCCCTGCAGATATAGAAATAGGGAGGAGCTAGGTCTG
 CGCCAGGCAGGAAGAAGGAGGCTCTGGCTTCCAGGGTGGCGGTGGCTCTGGCATCTTGT
 TTGCTCTGAAACAAAGCCTACTGCCCTGGAGGGCTTAGATTCTGCTTCTCAATGTAGTGTGGTATCT
 TGTAGGGTATGTGGGATGCCAGGGCTGCTCCAGGCACCTCTCTGAAGTCTGCAATTGGAGATT
 CGTGGAGAACCTATTAAAGCCAATTAAACTGAAAGCCAGTGAGTGTGATATGGAAGGGAAATGTAAAAT
 TTGCTGACTCTTAAGAACAAAACCCCAAGCTCTGTGCCCATGCTCTGGGCTTGGCCACCCACTCC
 TTTGCTGTCAGAGGTACAGGAGCTGGGAGAGTCCAGGAGCTAGGGACACAGAGGGAGACTATGGACCAAG
 GTGTGTGTCAGGGAGGACACTGCCACCCCCACCACCCGGGCTCTGGGAACGTCAACCTGCC
 ACGGGACATGTACATTCCCCCTTGTGCTGGAAAGTGTGAGTGACACTGCTGGGGTGGAGGGAG
 ACATGAGGATGTATAAGTACAGATTAAAAAGAAATCAACTTACACTTCCCTGGCTCTGGTTAAAAC
 AGTGGTAGGCTCTGTGGCCACTGCTAAAGGTACACACAGCGCCGGTGGAGCACGAGAGACCTC
 GTGGCAGCATGTGATCTGAAGGCAGGCAGGACGGGGCGTGGGGAGCCAAAGTCAACTCTGGCCTCT
 GGAGCTATGTACTTTGGCTAGAAAGGGACCCCTGGTGGCTGTGCTCTGCCATTGCAAGGGCAGGGG
 CATCATTAATTCAAGCTAAAGATTCTATGAATATGGACTGCCAAAGTTATCCTACTCCATCTGTGA
 AAGAAGTTGCTAAAGCAAATCATGATATGAACAAAATTACAGGGGACCTGTTAAGAGAACAAATGT
 TCCAAGCACTTACGGCAGACACCAGCTGTTGCAAACAATGTGTAATATGCAAATGATGTGTTATTAA
 AGGAGGCCATGGGCCCTTATTGGCAATACTGGCTGTGGTTACATTAAATAATGTAACATAGTATG
 AAGTAGCATCATTAGGGTTATTCTGTTACTTACGGGTTTTCTGTTTTTTCTCTTTTT
 GTATTACCGTGCTAGTTCTCTTCAACACTCTGTCTCTCAAGGCCATTGCCACTCGCTCCCTGC
 CATCTGCCCTTCTCTTGTCTCAGTGGGATAGATGGATTGTGAAATGAACTCCAGAACCCCTGCC
 TGGCAGCCTGGAAAGACCGTGCTGCCAGCCCTCGTCACCACAGGGACTCCTGGTCTGGCAGTGCAT
 GTGCCAGCAGGAGGACAAACTCTGTGACCTGTGCTGCCAGGTGAATGGCGCAGGGCTCTGCCCTGT
 CCTGCCGGGGGCCACGAGTTCTGCCATTCACTGCTTAGCATTCTGCCAGGGTTCTCAACTGC
 TTGCTTTCTCCAGGCTTGGCTTACTGTGATGTAAAGACATTAAAGTTATTTTGTGGTTTT
 AAAATTGCAAGAACACTAAGACCGAAAGGCTGGACTCTTGTGTTCTCCTGAAAGCTTGCCTTGT
 GAACTCCCTTCCACTGGTAGAAAGAGGCCAGAAGCAGCCCTGCCCTGTAAGATGGACTTTCATC
 CTTCAGTTGATTAGCTTGTGAGTTCTGCATCTGTCCACCCCATGTGATATAACCCAGCCCTGGC
 TCTGGGGTGGTCACCTCGTCAGTGCCTTGTGAGGAGGACCCCCCCCCTGCCAGAGGGCTC
 TCTCCCTGTTCTGCACCCCTCTCCCCATGGGACCTGGAGAAAATGAACTGTTACAACCCCTGCACAG
 TGCCTGTCAAACAGATGCAAACCTCTGAATAAAGCCTGGAGACCAAAAAAAAAAAAAAA

EX04-007P

>gi|40254974|ref|NM_025194.2| Homo sapiens inositol 1,4,5-trisphosphate 3-kinase C (ITPKC), mRNA
GGGTCGCCGAAGCCGAACCGAAGGAGCGGGCATGAGGCCTGCCGTGGAGCCTAACGAGGCGAGGGCGGGCGGGCA
CGGAGGCCGGGGCGCTGCCCGGGCGGGCCGATGGACTGGAGGCGCCCGAGGGAGGGCGGGCGGGCGGGCGGGCA
GCCGGGACAGCAGCGACCTGGCCCGGGCGAGGGCCCCGGGGCGGGCGGGAGGGGGCGGGCGGGCGGGCGGGCA
GCCCGGACAGAGGGTCCAGGCCACAGCGAGCCCTGGGCGAGGGGGCGGGCGGGCGGGCGGGCGGGCGGGCGGGCA
AGAGTCGCAGGCAGAATTCTGGACAGACGGACAGACTGAGGCCCGGGCAGCTGGCCTTGAGTAGAGAC
CGAGAGGCCAAGCAAAGACGGAGCCAGACAGGTCCAGGCCCGGGCAGCTAGAATGGAGCTGGTCA
GAGCTGGAGACGACTTGTCTTGAGCGAGACCGGGAGAGATGGCCTTGAGACTGATCCGCACAGGTCC
ACCTCCAGTTCCAGCCCAGGGCCAGGCCCTGGACACAGCCAGGGGTTATGGCCCTGGACAGAGCT
GGAAACGCATGGGTACAGACTCAGCCAGAGAGGGTCAAGTCCCTGGCTGATAACCTCTGGACACCACAG
AACAGTCCAGGCCACAGACTCACCCAGAAGGAGCCCTGTCCTCAAAGAGCCAAGTGTGATGGCTCCT
GGAAAGAATTGTATACTGATGGCTCAGGACACAACAGGATATTGAAAGGTCCCTGGACAGAGCCATATA
TGATGGCTCCAGAAAAAACAGGATACTGAAAGCAGCCAGGAAACAGCCTGGCACTGGTGGTTCCAAATA
CAACAGGATACTGATGGCTCCTGGACACAACCTAGCACTGACGGTCCAGACAGCACCTGGACAGAGCT
GCCTCTGGGAGAGCCTGAGGATGGCCATTAGAGGAACCAAGCCTGGAGAATTGCTGACTCACCTGTA
CTCTCACCTGAAGTGTAGCCCCCTGTGCCCTGTGCCCGCCTCATCATTACCCCTGAGACCCCTGAGCCT
GAGGCCAGCCAGTGGGACCCCCCTCCGGGTTGAGGGGGCAGCGGGGCTTCCTCTGCCCTTCT
TCGACGAGTCTGAGGATGACGTGGTGGCCGGGGGGGGAGGTGCCAGCGATCCGAGGGACAGGTCTGGGAG
CAAACCTGGAAGAAGCTGAAGACAGTCTGAAGTATTCAACCTTGTGGTCTCCTCCGAAAACACTAC
CCTGGGTCCAGCTTCTGGACATGCTGGAACTTCCAGGCAGGAGAGGATGGTGGGATTCTGAAACGTT
TCTGTCAGTGTGAGCAGCGCAGCTGGAGCAGTGTGAAAGACCCGCTGCACTTCTGAGG
CTATGGCATGGTGTGCAAGGATGGCCAGACCTTCACCAAGATGGAAGACCTCCTGGCTGACTTGAGGGC
CCCTCATTATGGAAGTGGCAGGACAGTGTGAGGAGATGGTGGGCTTGGGACCTACCCCTGAGGA
GTCCCCGTCGGAGGACATGTGAGGAGATGGTGGGCTTGGGACCTGGGACCTACCCCTGAGGA
GCATGCCAGGGTGCAGTCACCAAGCCCCGCTACATGCACTGGAGGGAAACCATGAGCTCCACCTCTACC
CTGGGCTTCCGGATCGAGGGCATCAAGAAGGCAGATGGGACCTGTAACACCAACTCAAGAAGACGCAGG
CACTGGAGCAGGTGACAAAAGTGTGGAGGACTTCGTGGATGGAGACCGTCACTTGCAAAAGTACGT
GGCATGCCTAGAAGAACTTCGTGAAGCTCTGGAGATCTCCCCCTCTCAAGACCCACGAGGTGGTAGGC
AGCTCCCTCTCTCGTGCACGACCACACCGGCCTGGCCAAGGTCTGGATGATAGACTTCGGCAAGACGG
TGGCCTGCCGACCACAGCAGCTGCCACAGGCTGCCCTGGCTGAGGGCAACCGTGAGGACGGCTA
CCTCTGGGCCTGGACAACATGATCTGCCCTCTGCCAGGGCTGGCACAGAGCTGAGCTGCTCAGCCACCA
TCAGGTTAATTGGATGGCGCAGTCTGGCTGGAGGAGCCCTGGATGCACTGGGAGGCTTGAGGTTGGCC
ACGGGGAGCTGGCTCCAGGGACGGGAGAGATTGTGATCTGCCGGACAGGCTGGAAAGGCTTCTGAGGG
TGAAGGGCCTGGAGACCAAGGTAGCACCTGGCCCATCATGATGCAAGGGTTTGGGACCTGGAAAGGA
AGGTGATGAGGCAGTCAGGAAACAGAACGGGCTCCGGATCTGCCGGACAGGCTGGGACACATGAATC
CTGCCCTGAGGACATTCACTGACATGTCACAGGGTATGGTGTGACAGGGTGCCTGTGGACACATGAATC
ACTTCTAACCTGCCCTGTCAGGCCCTGCCAGGCTGCCAGCTGGCTGAGGCCAGGGACTGGTCAAGGCTCA
TCTGTGGCCTCAGAGGTCACTGATCTGGTGAACAGATGCAAGGCTGCTGGGACCATCTGGGAGAG
TGACAGTCCATGTCCTCACCAAGGGAGCATTGAGTGTGCTGAGCAGAAGAGGCTCAGAGGGCATGACCCC
ATGGGACTGGATGCCCTGAGGGCTGATACCGCTGGCGGTATCCTGCCCTGCTGTGGCCCTGTGGGAT
CCTCCGTGTCCTCGGCCGACTCTGTCAGCTGCCAGACCCAAACACAGCCACATCCCAGCTCTGT
GCCAGCACTGTGACAGTACCTCGCTCTGCAACAGATCCGGCTCAGGACTTACACCTCTGCC
ACCCCCAGGCTCTCTCTCTCCCTGCCAGCAAACCTGCACTGGCAGAAAGGAGGTTCAAGGGCTGGGAAA
GTGGGCTCCCTGCAACTCAGAGCTGCTGCACAGGAGGGCCCATCCAATCCGGGCCCCCTGCA
GAAAAGCGCTGGGTGTGTCAGAGGCGCAGGGGGGGCTGCCAGCCAGGACCCCTGGCTGAGCC
TGATCAAACCAAGACTGTAGAACCCCTGGGTGTGGCTAACGGCCCTCCAGCACCCATAGCCAGGTCT
TCCTGGCCCTTGAGGGCTGGCGGACAGGCACCTACCTCTCCTTAAGCTGAAGCTCCACACTGTC
TTCCAGGGCTGAGGAGATGCTCTCCTTTCTACTGACCATCTTGATACTTATTTATACGAGAGGCAGTT
CTGGACGGGGTAGTACTGGAAAGCAGGAGGCAGAATGGCTCTGCTGAGGCCCTACCCATGACAACACCC
CAATAAACAGAACATTCAAGAGCCAAAAAA

>gi|4758697|ref|NM_002372.1| Homo sapiens mannosidase, alpha, class 2A, member 1 (MAN2A1), mRNA
GGCTCCTCGCGATCTGTTCTTCCCTCCGCTCTCTGACCTAGCTGCGCGGCCCGGCCGGAGCT
GCCGAACCCCGCGCCTCCCTGGGTGAGGAGGACACGCCCTGCCCTGTCAGAAAACCTTCTGCCGACT
CAGTTGGGCGGGCGGTGGCAGGAAGTGGGGCAGCGACCTCTCCGCCCTGCCCGCGGCCCTGCCGG

AGGTCGGCGCTGAGCTTGCATCAAGTTGTGGGGCCCCCTCCAGTTGCCGGCAGTCTGCCTCG
 AGAGGGCGCCCGACCCCGGGGAGGGCGCAGGCCAGGGCAAGGCCAAGGGCTTTGTGGCGCCGGAG
 ACTAGGTGCGGAGCAAGGCGGGACTCGCACCCGATCCGAGAGCGCGAGGTGCGCAGCCGGAGAA
 GGGAGCCTCCGGGGCTGCTCCTAGAGTCCACAGTGCCTGCTCCTTGCTGAGGAGAGTGTCTGG
 CCCCAGTCTATCGAGGAAAATGAAGTTAACGCCAGTTACCGTGTGCGAGTGCATCTCTGTGT
 GGTGATTTCTCGCTTACCTGATGCTGGACCGGGCACTTAGACTACCCAGGAACCCGCCCGCAG
 GGCTCCCTCCCTCAGGGCCAGCTCTCAATGTCAGAAAAAAATAGACCATTGGAGCGTTGCTAGCTG
 AGAATAATGAGATCATCTCAAATATTAGAGACTCAGTCATCAATTGAGTGTGAGTCTGTGGAGGATGGTCC
 GAAAAGTTCACAAAGCAATTTCAGCCAAAGGTGCTGGCTCACATCTCTGCCCTCACAAATTATCCCTCTCA
 GTTGACACTGCAGACTGTCGTTGCTCACAAAGTGGAAAGTCACAATTTCAGATGTGCAGATGTTGGATG
 TTTACAGTCTAATTCTTTGACAATCCAGATGGGGAGTTGGAAGCAAGGATTGACATTACTTATGA
 ATCTAATGAATGGGACACTGAACCCCTCAAGTCCTGCTCATTCCCATAACGACCCAGGTTGG
 TTGAAGACTTTCAATGACTACTTAGAGACAAGACTCAGTATATTAAACATGGCTCTAAAGCTGA
 AAGAAGACTCACGGAGGAAGTTATTGGTCTGAGATCTTACCTTCAAAGTGGGGATATTATAGA
 TATTCAAGAAGAAGGATGCTGTTAAAGTTAATAGAAAATGGTCAGCTGAAATTGTCAGAGGACATCAGTGGC
 GTTATGCCATGAGCTACTCCACATTATTGCTTAATTGATCAACTATTGAAGGACATCAGTGGC
 TGGAAAATAATATAGGAGTGAAACCTCGGTCCGGCTGGCTATTGATCCCTTGGACACTCACCAACAA
 GGCTTATCTCTAAACCGTGTGGACTTCTCACATGCTTACAGAGAGTCTATTGAGTTAAAGCTT
 CACTTGCACTGCATAAAACATTGGAGTTTTGGAGACAGAATTGGGATCTGGGATCTGTACAGATA
 TTTTATGCCACATGATGCCCTCTACAGCTATGACATCCCTCACACTTGTGGACCTGATCCTAAATATG
 CTGCCAGTTGATTTAAACGTCTCCGGAGGAGATTGTTGCTCCCTGGGGAGTCCCCCAGAAACA
 ATACATCCTGGAAATGTCCAAGCAGGGCTGGATGCTACTAGATCAGTACCGAAAGAAGTCAAAGCTT
 TTCGTACCAAAGTCTCCTGGCTTCACTAGGAGATGATTCCGCTACTGTGAATACACGGAATGGGATT
 ACAGTTAAGAATTATCAGCAGTTTGATTATGAAATTCTCAGTCAAGTTAAAGTTAAGATAACAG
 TTTGGAACTTTATCAGATTTTGATGCGCTGGATAAAGCAGATGAAACTCAGAGAGACAAGGGCCAGT
 CGATGTTCCCTGTTAAGTGGAGATTTTCACTTATGCCATGAGATGATCATTACTGGAGTGGCTA
 TTTTACATCCAGACCCCTTTACAAACGAATGGACAGAATCATGGAATCTCATTAAAGGCTGCTGAAATT
 CTTTACTATTCGCCCTGAGACAAGCTACAAATACAAGATAAATAATTCTCATCATCACTTACA
 CGGCACGTGACAGAACGCCAGAAGGAATTGGGACTGTTCAACATCATGATGCTATCACAGGAACGTGCAA
 AGACTGGGTGGTTGGATTATGGTACAGACTTTTCACTCGTTAATGGTTGGAGAAGATAATTGGA
 AATTCTGCATTTCTTATTTGAAGGACAAACTCACATACGACTCTACTCTCTGATACCTCCTGG
 AGATGGATTGAAACAAAATCACAAGATTCTCTGCCACAAAAAATAATAAGGCTGACTGCCAGGCC
 AAGGTACCTTGTGGTCTATAATCCTTAAAGACAAGACCGAATCTCGTTGGTCTCAGTCTATGTGAGTCC
 CCGACAGTGAAGTGTCTCGCTCAGGAAACCTGTGGAGTTCAAGTCAGCGCAGTTGGGATACAG
 CAAATACTATTCAGAAACAGCCTATGAGATCTCTTCGAGCACATAACCGCATTGGGACTGAAAGT
 GTATAAGATTGGAATCAGCAAGTCAAATTCACTTGTGATTATGTCTTGATAAGAATAAGTA
 GAAGATAGCGGAATTTCACCATAAAGAATATGATAAAACTGAAGAAGGTATAACACTAGAGAACTCCT
 TTGTTTACTTCGGTTGATCAAACGTGACTTATGAAGCAATGACTAAAGAAGATGGTAAACACCA
 TGAAGTAAATGTGCAATTTCATGGATGGAACCAATTAAAGAGACAAAAGTGGTGCCTACCTCTTC
 TTACCTGATGGTAATGCCAACCTTATGTTACACAACACGCCCTTGTGAGGTGACACATGGAAGGA
 TTTATTCGGAAGTGAATTGCTTTGACCATGTTACTCATAGAGTCCGACTATACCACATACAGGGAAT
 AGAAGGACAGTGTGGAGTTCCAATATTGTGACATCCGAAAAGTATATAACCGTGAGATTGCAATG
 AAAATTCTCTGATATAAAAGCCAAAATAGATTATACTGACCTAAATGGTACAGATTCAACCTA
 GAATGACACTGAGCAAATTGCCCTTCAAGCAAATGTCTATCCCATGACCACAATGCCCTATATCCAGGA
 TGCCAAACATCGTTGACACTGCTCTGCTCAGTCTTGTGGAGTTGAATAGTGGTCAGATT
 GAAGTTATCATGGATCGAAGACTCATGCAAGATGATAATCGTGGCCTTGAGCAAGGTATCCAGGATAACA
 AGATTACAGCTAATCTATTGCAATACTACTAGAAAAAGAAGTGTGTTAATCGGAAGAAGAAAAGAA
 GTCGGTCAGTTATCCTCTCCTAGGCCACATAACTTCTCTCATGAAATCATCCAGTCATTCAATG
 GCAAATAAGTCTCACCTACCTTGAGCTGCAAGGTGAATTCTCCTACAGTCATCTTGCTTGT
 ACATTCACTGGTTAATTGAGAACATACAGTCAAAGGTGGCAATGGCAGTCCAAATGAGGCAAGCCT
 GATCCTCCACAGAAAAGGGTTGATTGCGGTTCTAGCAAAGGCACAGGGCTTTGTTCTACTACT
 CAGGGAAAGATATTGGTACAGAAACTTTAAACAAGTTATTGTCGAAGTCTCACACCTCATCACTAT
 CCTTGATGCATTCACCTCCGGCACTCAGAACATATAAGTGAGATCAACTTGAGTCCAATGGAACATGAC
 ATTCCGAATCCAGTGAGGTGAACCTGACTTTACATTTGGATTGAGAATCATTGGCTTTACCTTTC
 TTGGTTGACGTGCAATAAAGAAGCACATTATTAGCTTCTGGCTACTGTGAGAACATGAATTCTGTGA
 TTCTGTGGTTTTCTTTTACAGTACAGTAAG

>gi|5540099|ref|NM_006122.1| Homo sapiens mannosidase, alpha, class 2A, member 2 (MAN2A2), mRNA

GGCAGCTCGGCCGACTGGGCCGGAGCGGCGGGAGGCCGGCTGACGGTGTGTGGAGGCCAGTAT
 GAAGCTAAAAAGCAGGTGACAGTGTGGGGCTGCCATCTCTGTGTGGCAGTCTCTCGCTACCTC
 ATGCTGGACCGAGTGCAACACGATCCCACCCGACACCAGAACGGAACTCCCCCGAGCCAAATT
 CTGTGCTGCAGAACCGCATTGAGCAGCTGGAGCAGCTTTGGAGGAGAACCATGAGATTATCAGCCATAT
 CAAGGACTCCGTGCTGGAGCTGACAGCCAACGCAGAGGGCCCGCCATGCTGCCCTACTACACGGTC
 AATGGCTCCTGGGTGGGCCACGGAGCCCCGGCCAGCTCTTCTCCATCTCCCCGAGGACTGCCAGT
 TTGCTTGGGGGGCGGGGTCAAAGCAGAGCTGAGATGCTCACTGTGTGGAGGAGCTGCCGTTGA
 CAACGTGGATGGTGTGTGGAGGCAAGGCTCGACATCTCTACGACCCGACAGACTGGGATGCTGAA
 GACCTGAGGTGTTGTGGTCCCCACTCTCACATGACCCAGGCTGGATCAAGACCTTGACAAGTACT
 ACACAGAGCAGACCCAAACACATCCTCAATAGCATGGTGTCTAAGCTGAGGAGGAGCCCCGGCGCTT
 CCTCTGGGAGAGGTCTCTCGCCAAGTGGGGACAACATCAATGTCCAAAAGAGAGCCAGTC
 CGAAGGCTGGGGAAACGGCAGCTGGAGATTGCGACAGGAGGCTGGGTGATGCCAGATGAGGCAATT
 CCCACTACTTGCATTGATTGACCAGCTCATCGAAGGACACCAGTGGCTGGAGAGAAATCTGGTGCAAC
 CCCCCGCTCTGGCTGGGAGGCTGGGACCCCTTGGATACAGCTCCACCATGCCTACCTGCTGCCCGTGC
 AACCTCACCAAGCATGCTGATTCAAGAGAGTGCACATGCCATCAAGAACACTTGTGTGCCACCCACAGCC
 TAGAGTCATGTGGAGGCAGACATGGGACTCGGACTCCAGCACAGACATCTCTGTACATGATGCCCTT
 CTACAGCTATGACGTCCCCATACCTGTGGCCAGATCCAAGATCTGTGCCAATTGATTCAAACGC
 CTGCCCTGGTGGGCGATCAACTGCCCTTGGAAAGGTGCCACCCGGGCATCACAGAGGCCAACGTGGCAG
 AGAGGGCAGCCCTGCTTGTGACCAATACCGGAAGAAGTCCCAGCTGTTCCGAAGCAACGTCCCTGGT
 GCCTCTGGAGATGACTTCCGATATGACAAGCCCAGGAGTGGATGCCAGTTCTCAACTACCAACGG
 CTCTTGACTTCTCAACAGCAGGCCAACCTCCATGTGAGGCCAGTGGTCTGTACAGCCTGGCTGAGCTC
 TTGATGCCCTGTACAAGAGGACAGGGTGGAGCCAGGGGCCCTCAGGGTTCTGTGCTGAGCAG
 GGATTTCTCTCCATGCGGACCGGGAGGATCATTAAGTGGACAGGCTATTACACTTCCGCCCTCTAC
 AAGAGCTTAGACCAGCTGGAAAGGCCACCTGCGGGGGCAGAGGTTCTGTACAGCCTGGCTGAGCTC
 ACGCTGCCGCTCTGGCTGGCTGGCGTACCCACTGTCTGATTCAACCTCCTGACGGAAGCTCGGCC
 CACATTGGGCTTCCAGCATCACGATGCCATCACTGGCACGCCAAGGAGGCTGTGGTGGACTAT
 GGGTCAGGCTCTCGCCTCTGTCAACCTGAAGCAGGTATCATTGACAGGCCACTATCTGGTGC
 TGGGGACAAGGAGACCTACCAACTTGAACCTGAGGCCCTCCCTCCAAGTGGATGACACTCGCTTAAG
 TCACGACGCCCTCCAGAGCCACGGTGTGATCCAGCTGGATTCTCGGCCAGGTTGTGGCTTCTAC
 CCACTGGAACAGGAGCGATTCAAGCATGGTGTCCCTGCTGGTCAACTCTCCCGCGTGTGCTCTTGG
 AGGAGGGTCAAGCCCTGGCGTGCAGATCAGCGCACACTGGAGCTGTGCCACCGAGGCGGTCCCTGACGT
 CTACCAAGGTGTGTGCGCTGCGCTGCCAGCCCTGGGCTGGCGTGTGAGCTACAGCTGGGCTG
 GATGGCACCGCACGCTGCCCTCTGTGCGCATCTACCTGACGCCGGCAGCTGTCCGTAGCAGGC
 ACGAAGCGTTCCCTCCGTGTACTGACTCTGGCACAGCGACTTCGCCCTCAGCAACCGCTACATGCA
 GGTCTGGTCTCAGGCCCTACTGGCTCTCAAGGGCTCAGGGCTGTGTTTTGGCAGAGCATCCGAAG
 GGTGGATGAGGAGCACGAGCAGCAGGTGGACATGCAAGGTCTGTCTATGGCACCCGTACGTTCAAAGAC
 AAGAGTGGAGCCTACCTCTTCTGCCGATGGCGAGGCAAGCCCTACGCCCCAAGGAGCCCCCGTGC
 GCGTGCACTGAAGGCCCTTCTCTCAGAGGTGGTGTGCTACTATGAGCACATTACCAAGGCCGTC
 CTTTACAATCTGCAAGGGTGGAGGGCTGTCTGGACATATCATCCCTGGTGACATCCGGACTACG
 TCAACAAGGAGCTGCCCTGCACATCCATACAGACATCGACAGCCAGGGTGCAGCCCCGACGGTATCTGA
 AGAAGCTCCCCCTCCAGGCCAACTCTACCCATGCCAGTCATGCCCTATATCCAGGAGCAGAACAGC
 CCTCACCGCTGCACACTGCCAGGCCCTGGGTGTCTAGCCTCAAAGATGCCAGCTGGAGGTGATCTTG
 GACCGGGCGTGTGCAAGGAGCACAGCAGCTGACGCTTCTGAGGCAAGGACAACAAGAGAACCTGCA
 ACCGTTCCGCCCTCTGCTAGAGCGGCCAACCGTGGCAGTGGTCAAGAGATAGCCACTCTACCAAGCTA
 CCCATCCCTCCAGGCCACCTGACCTCCATGTACCTGAACGCCCGGCCCTGCTCTGCCCTGTAGCCAGG
 ATGCAGCTCCAGGCCCTGGTGTGCGCTCATTCATCTCTGGCTTCTCACTGCCCTGTGACTTCCACC
 TGCTCAACCTACGTACGCTCAGGCTGAGGAGGACACCCTACCCCTGGCGAGACCGCACTCATCTTACA
 CCGCAAGGGTTTTGACTGCGGCCCTGGAGGCCAAGAACCTGGCTTCAACTGCCACCAAGCCAAGGCAAG
 GTAGCCCTGGCAGCCTTCCATGCCCTGGATGTGGTATTCTTCAAGGCAACCTCCTTGACGTTACTGT
 ACCCTCTGGCCTCCCCGTCCAACAGCACTGACGCTTCTATTGGAGGCCATGGAGATTGCTACCTTC
 CCGCTGGGTTAGGGCTTCTGTGGCTGAAAGAGAAAGTTCATTCAACAGAGACTGCCCTTAACATGAAG
 ATCATTGGACAAGCCACACGGTATCCCATCCGATCTGCCCTCCAGAACACTGTGACACACTGGGCTCTGC
 CCTCATTTCTGTTATTGCTGCTGCTGTGTTTCCGGCGAACCCACAAACCCAGTGTGATGGTAAATAGG
 GCAGACGCCAGTGGAGATCAGGGAGAGAAGGCCCTGGTCAAGAGTGGCAGTGGCAGTGCCTGCTTGGG
 TGTGAGTGGACACCAACTGGGCACAGGCTCAGGCCACCCATCCTTCAAACAGGGATATAGAAGTGG

TGGAAGCAGACAGAAGAGGTAAGGGAGGCTAACAGGGTAAACAGCCCAGCATCAGGGTCACTGTGGCAACA
 GCAGGCCTAGGGATCCTGTGTTATGTAGAGACTCCATGTCCTGGTGTATGAGCAGGATCAGAGTG
 ACTCTGGGAGGACAGGGTGGGACCCAGAGTTAGCAGTGGGATGGAGCAGTAGAAGGAATCACTGTT
 CTCCTAGGAGTCTGAAGGCCCTCGCTGCTTCTGTGATGGCTTGCAGTAAGTGCCTGCGCTGCATGC
 ATTGGCTAACAGGGTGCAGAATGGCAGGAAGGACTCGCTAGAGATTGTATGCCAGAGATCATAGGTCA
 CTTCAGGTAGCAAGACCCCTGGCAAACCTGGGACTTGCCTATGACTGATTGTGGATGGTGGCAGGG
 GTGTGGGTCTTCACCCTGCCTGAATTCTCTTGGCTCTGTGCTGTATGCTGCTGTCCCCAAGGGC
 TCTTCTTATTATGGCAGGGAGTGGGATTGGCTACTTCTTCTGGAAAGGAAAGCCTCCAAGAC
 TCCATGTGCTTGGCAGCTTGAGAAGGGTTCAGCACCCCTAGCAGGAGACCTTGAGCAGCTCACCT
 TTAGTCTATCTGAGAGGTATTCAAGTCCCTGGCACAGGGACTAGGGCATGTAGAGTATAGGAGGC
 AGTATGGCTGTGAGGAGCCTCATTCAATTAAAGGAAGAATTATGATAGCTATAGAT
 GCTGAAAAGGTATTCGTAAGATTAAATCCATCCCTATTAAACTCTTAGTAATTAAAGTCTGGAAA
 GAAACACCTAATCTAGATAAAGGTCTTTCAGAAACCAACAGTGATGGCATTCAGAGTCAGACGC
 CACAGGATTCCCATAAAGTCAGAAACTAGCCAAGGGCAAGCTATTATTCAGCAGTGTCCGGCACTAC
 TAACCCCTGCAACAAGCCAGATGAGGAACATAAGGAAGAATTATAATTGTCATTATTGTAGACAATAAA
 ACTGCCTACCTGTAAAA

>gi|10835172|ref|NM_000620.1| Homo sapiens nitric oxide synthase 1
 (neuronal) (NOS1), mRNA
 AGAGCGGCTCTTTAATGAGGGTTGCGACGTCTCCCTCCCCACACCCATAAACCAAGTCGGGTTGGACGTC
 ACTGCTAATTGTTCAAGTGTATGATAGATAAAGGAGGGACATTAAGAAATAATTCCCCCTACGACCC
 TCGCTGAGCTCACGGCTCAGTCCCTACATATTATGCCGCTTCCAGGCCGCTGGTGAGGAGCTACTTA
 GCGCCGGCTCCCGAGGGCGGGCCAGCAGCAGGGCCGAGCGGAGCAGGGCTCATGATGCCCTCA
 GATCTGATCCGATCTAACAGGCTGGCAATGAAGATAACCCAGAGAATAGTCACATCTATCATGCCCTCA
 TTCTAGACACAGCCATCAGACGATCTCCCTCCCTTCTGCCGCTGACCTAGGACACGTCCCACGCCCT
 CTTGACGTCTGCCGCTGGTCAACCATCATTCTTAGAGAATAAGGAGAGAGGGCGATGCAGGAAATCATGC
 CACCGACGGGCCACCAGCCATGAGTGGGTGACGCTGAGCTGACGTCAAAGACAGAGAGGGCTGAAGCCTT
 GTCAGCACCTGTCACCCGGCTCTGCTCCGTAGCCTGAAGCCTGGATCCTCTGGTCAAATCATC
 TTGGCTGATAGCATTGTGAGGTCTTCAGACAGGACCCCTCGGAAGCTAGTTACCATGGAGGATCACATG
 TTCGGTGTTCAGCAAATCCAGCCAATGTCATTCTGTTGCTCTTCAGCGCAAAGTTGGGGCCTGG
 GATTCCTGGTGAAGGAGCGGGTCAAGCCGCCCCTGATCATCTGACCTGATTCTGTTGGGGCGCCGC
 AGAGCAGAGTGGCCTCATCCAGGCCGAGACATCATTCTGGGTCAACGGCCGGGCTTGGTGGACCTG
 AGCTATGACAGGCCCTGGAGGTACTCAGAGGATTGCCCTGAGACCCACGTGGCTCTCATTCTGAGGG
 GCCCTGAAGGTTTACCAACGACCTGGAGACCACCTTACAGGTGATGGGACCCCAAGACCATCCGGGT
 GACACAGCCCCCTGGTCCCCCACCAGGCCGTGGATCTGCCCCACCAGCCACCGCCGGCAAAGAACAG
 CCCCTGGCAGTGGATGGGCTCGGGTCCGGGAATGGGCTCAGCATGCCCTACGATGATGGCAGGAGG
 CTGGCTCACTCCCCATGCCAACGCCCTGGCCCCCAGGCCAGGACCCCGCAAGAAAGCAAC
 CAGAGTCAGCCTCAAGGAGGGGAGAACATGAACTGCTCAAGGAGATAGAGCTGTGAGCCTT
 CTCACCAGTGGAGCAGAGGGTCAAGGGAGGGCACCTGCCAAGGAGAGATGAAAGATATGGGAATCC
 AGGTGGACAGAGATTGGAGGGCAAGTCACACAAACCTCTGCCCTCGCGTGGAGAACGACCGAGTCTT
 CAATGACCTATGGGGAAGGGCAATGTGCTGTCCTCAACAACCCATATTCAAGAGAAGGAGCAGCCC
 CCCACCTCAGGAAACAGTCCCCACAAAGAACATGGCAGCCCTCAAGTGTCCACGCTCTCAAGGTCA
 AGAACTGGGAGACTGAGGTGTTCTCACTGACACCCCTCCACCTTAAGAGCACATTGAAACGGGATGCAC
 TGAGTACATCTGCATGGGCTCCATCATGCACTCCTCTCAGCATGCAAGGAGGCCGTAAGACGTCCGCACA
 AAAGGACAGCTCTCCCTCGCCAAAGAGTTATTGATCAAAACTATTCAATTAAGGAGTCTTGGCT
 CCAAAGCCACATGAAAGGTGGAAGGGTGAACAAAGAGATGACACCAACTGACACTTACAGCTCAA
 GGACACAGAGCTCATCTGGGCCAAGCACGCCCTGGGAATGCCCTCGCGTGTGGAGGATCCAG
 TGGTCCAAGCTGCAAGGTATTCGATGCCCTGACTGACCCAGGACCTAGGTCTGCCATCAGGATCTTCC
 ACCATGTCAAGTATGCCACCAAAAGGGAACCTCAGGTCTGCCATCAGGATCTTCCAGGAGGACAGA
 CGGCAAGCAGACTCCGAGTCTGGAACTCCAGCTACGCCCTACGCTGGCTAACAGCAGCCTGACGCC
 TCCACCCCTGGGGACCCAGCCAATGTGCAAGTTCACAGAGATATGCATACAGCAGGCTGGAAACCGCCTA
 GAGGCCGCTCGATGTCCCTGCCGCTCTGCTTCAGGCCAACGGCAATGACCCCTGAGCTCTCCAGATTCC
 TCCAGAGCTGGTGTGGAAAGTCCCATCAGGCCACCCAGTTGAGTGGTCAAGGACCTGGGCTGAAG
 TGGTACGGCTCCCCGCCGTGTCACATGCTCTAGAGATTGGCGCTGGAGTTCAGCGCCTGTCCCT
 TCAGTGGCTGGTACATGGGACAGAGATTGGTCCGCGACTACTGTGACAACCTCCGCTACAATATCCT
 GGAGGAAGTGGCAAGAAGATGAACTTAGACATGAGGAAGACGTCCTCCCTGTGAGGACCGAGCGCTG
 GTGGAGATCAATATCGCGGTCTCTAGCTTCAAGAGTGACAAAGTGACATTGTCAGCGCCTACTCCG

CCACCGAGTCCTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGCTGCCACTGGGT
 GTGGATCGTCCCCCATGTCGGAAGCATCACCCTGTGTTCCACCAGGAGATGTCACACTACCGGCTC
 ACCCCCTCCTCGAATACCAGCCTGATCCCTGAAACACGCATGTCTGGAAAGGCAACACGGACCCCA
 CAAAGCGCGAGCCATCGGCTCAAGAAGCTAGCAGAACGCTGCAAGTCTCGGCCAAGCTGATGGGCA
 GGCTATGGCAAGAGGGTGAAGCGACCATCCTCATGCCACAGAGACAGGCAAATCGCAAGCTATGCC
 AAGACCTTGTGAGATCTCAAACACGCCCTTGATGCAAGGTGATGTCATGGAAGAATATGACATTG
 TGCACCTGGAACATGAAACTCTGGTCTTGTGGTACCAGCACCTTGGCAATGGAGATCCCCCTGAGAA
 TGGGGAGAAATTGGCTGTGTTGATGGAATGAGGCAACCCAACTCTGTCAGGAAGAAAGGAAGAGC
 TACAAGGTCCGATCAACACGGCTCCTCCTACTCTGACTCCAAAATCATCAGGCATGGGCCGACC
 TCAGAGACAACTTGAGAGTGGACCCCTGGCCAATGTGAGGTTCTCAGTTTGGCCTGGCTCAGC
 AGCATAACCTCACTTTGCGCCTCGGACACGCTGGAACACCCCTCTGGAAGAAACTGGGAGGGAGAGG
 ATCCTGAAGATGAGGGAAAGGGATGAGCTCTGTGGCAGGAAGAGGCTTCAGGACCTGGCCAAGAAGG
 TCTTCAAGGCAGCCTGTGATGTCCTCTGTGGAGATGTCACATGAAAAGGCAACAAATTCCCT
 CATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCTCACCTTGTGGCCAGCTCCAGAACTC
 ACACAAAGGTCTATCCAATGTCACAAAAGCAGTCTCAGCTGCCGCTCTTAGCCGTAAAACCTCC
 AGAGCCCTAAATCCAGTCGGTCAACTATCTCGTGCCTCCACACCAACGGGAGCAGGAGCTGAGTA
 CCAGCCTGGGACCACCTGGGTCTTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCG
 CTGGAGGACGCCGCTGTCACCAGATGGTAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTAG
 GTGTCATCAGTAACGGACAGACGAGCTCCGCTCCGCCCCCTGCACCATCTCCAGGGCTTCAAGTACTA
 CCTGGACATCACCAACGCCACCAACGCCCTGCACTGCAGCTGAGCAGTTGCCCTCAGTACCAAGCAGAAG
 GAGAAGCAGCGTCTGCTGGTCTCAGCAAGGGTTGAGGAGTACGAGGAATGGAATGGGCAAGAAC
 CCACCATCGTGGAGGTGCTGGAGGAGTCCCCTATCCAGATGCCGCCACCTGCTCCTGACCCAGCT
 GTCCCTGCTGCAAGCCCGTACTATTCCATCAGCTCCTCCCGACATGTACCTGATGAAGTGCACCTC
 ACTGTGCCATCGTTCTACCGCACTGGAGATGGAGAACCGAACATTACACGGCTATGCTCCTCCT
 GGCTCAACGGATAACAGGCTGACGAACTGGTCCCTGAGGAGCACCAGCTTCCACCTG
 CGGAACCCCCAAGTCCCTGCACTCTCGTGGACCAGGCACCGGATTGCCCTTCCGAAGCTCTGG
 CAACAGGGCAATTGATATCCAACACAAAGGAATGAAACCCCTGCCCATGGCTCTGGTCTCGGGTGCC
 GGCAATCCAAGATAGATCATATCTACAGGGAAAGAGACCCCTGAGGCAAGAACAAAGGGGCTTCAAGA
 GCTGTACACGGCTACTCCGGGAGCCAGACAAACCAAGAAGTACGTGAGGACATCCTGAGGAGCAG
 CTGGCGAGTCTGTGTACCGAGCCCTGAAGGAGCAAGGGGGCACATAACGTTGTCAGGAGCTGCA
 TGGCTGCTGATGTCCTCAAAGCCATCCAGCGCATATGACCCAGCAGGGGAAGCTCTGGCAGAGGACG
 CGCGTATTGATCACGCCATGAGGGATGACAACCGATACCATGAGGATATTTGGAGTCACCCCTGCGA
 ACGTACGAAGTGACCAACCGCTTAGATCTGAGTCCATTGCCCTCATGAAAGAGAGCAAAAGACACCG
 ATGAGGTTTCAGTCTTAACGGACCCCTTGCCCTGAGGAGCAGCTGCAAGTTGTAAGCGCGACAGACA
 CTGCTGAACCTTCTCTGGACCCCTGAGGCTCTGCTCTGCTCTGCTCTGCTCTGCTGAGTTCC
 TTCCCTCCTGGCTCTGCCCTCACTGGTTCTCGGCCCTCTGGTTACTCCTTGAGTTCC
 TGCTGCGATGCAATGCTTTCTAATCTGCACTGGCTCTTACAAAACCTGTTCCACTCCCTCTTG
 GACAAGGGCAACTACGGGTGCATGAAACCACTGGAACATGCCGTGAGGAGCTGCTGGCAGAGGACG
 GGTTCCCTGGAAAGGCTGAGGACTAGGCACAAGCTCTGAGCCAGTCCCTCAGCCACTGAAGTCCC
 CCTTCTCCTTTTATGATGACATTGGTTGCGCTGCTGTGTGTGTGTGTGT
 GTGTGATGGGCCAGGTCTGTCCGCTCTCCCTGACAAGTGTGTCATTTAGATTGCCACTGCTT
 TCATTGAAGACCCCTCAATGCCAAGAAACGTTGCTCTGCCCATATTAAATCCCTGTCATGAAATTAG
 GGTCCACGCCATGTAACATTGGAAGCCCCATAATTGTTAGTTAGAAAGGGGTCAGGGCAT
 GGGGAGAGGAGTGGAAATTGATTAAGGGGCTGTCCTCAATGAAAGAGGCATTCCAGAATTGCTGC
 ATTGATTTGATACCACTGAGCAGAGCCCTCATGTGACATGAAACCATCAATGGATTGCAAAATCC
 CCTCCCCAAACCCACCCATACCAAGCTAGAATCACTTGACTTGCACATCCATTGACTGACCCCTCCTC
 CAGCAATAGCATCCAAGGGGCTGGAAGTTATGTTCAAAAGAACGCTGGCAATAAGGATCTTCCC
 ACTTGGCACTGGATGACTTGGATGGCTACTTGTCTCAGTTTCTCTAGTCATAATGTCATACGAAC
 CTAAGAAATGATGGATTAATGTTAAAGCTTGGTGCCTGGAAACAAATATCAAGTAACAAATATGATT
 ATTATTTTTTATCCCCAAAGCGGGCTGCTGCTGCTCACCTTGGGATGAAATAATGGAAGCTGGTTA
 AAGTGGATGAGGTGGAAAGAGTTGCCATAATGAGGCTCCACGTGGCTTCTCGATAGGAGCCACA
 ACTTGGGTGGAAAGAACTTGTCCCTCAGGCTTGTGCCCTCTGCAGTTGATCTCAAAGTTAAACCTG
 TTAAATTGACAAATAAGTTACCCCTCAACTCAGATCAAAATGGGAGCAGCAAGCTTCGGTAGGAATT
 GGAGCCGGTGTAACTCCTCTAAGAGGCAACCTGTTGAATTACTCTCAGAGTAAATGGTGGGAAGG
 GATCCCTTGTATACTTTTAAATACAAATTAGTGTCAAGGAGCTCCAGAAAGAGACAAGAAATC
 CTAGTGGCCTCCAGACTGCAGGGTCCCAAGGATGGAAAGGGAATGTTCTGTCAGGTTCTACCC
 TTGTCAGGTTCTGCTATACAGAAAAACACATTCTTTATATACTGTCAGTGGGCAATCTGTTAGT

TTGGGTGTCTGCTAAAGAGGAAGTGCAGTGGCCCTTTGAAAGGGCTTACAGTGGGGCACCAAGACC
 CCAAAGGCCAGGCCAGGAGACTGTTAAAGTGAAAAGGCAATCTATGACTCACCTGCTGCCATCCCT
 GGCAGCCCCCACCCTGTCCTGTCACATGGAGCTTGACTTCATGCCAGCTATAATCTCCCCTGC
 CTTCCTTAATCCAATTCCCTGTCACTCTTCACAGATATAAAGAACAAACACTTAGCATCCACA
 CTCACCCCTCTAATCTGAAGGGAGGCCATTCTAAACTCCTTCTGCAAACCCATTCCAGCTCTA
 GTAGCTTCCTCCAAAGGCTTCTTCAATCCTTATAGCTTGGAGACGCCCTCCAAATTCCCCAGG
 GAAGGAAACTGTTGTCCAATCCCCATTAAAGACAAATTGATCAGTGCTTCCC

>gi|37540251|ref|XM_291315.2| Homo sapiens hypothetical protein
 FLJ23309 (FLJ23309), mRNA

GGCGGGGCTGTCGGGGTTGGGCGGGTGGGCTGGCAGCTGAGGCTCGTGGCCATGGAGTGGGTTCTG
 AGTCGGCTGCTGTGAGGCGGCCACCGCGTCGGAGTAGAGCGTCGAGAGGGAGCGGGCCGCCACCGCC
 GGAGAGGGAGGCCCGAGCGCAGGCCCTCGGTGATGGGTGCAGCGCCGGGGAGGACGCCGAAGAGG
 AGCCCCGGGGTAGCGGCGGCCGAGCAGGGCGGGGACCGGGCTGTGAGGTGCGCGCCGCGCTGG
 GGCTCGCGCTCACCTGATCGCCTGCGGACGCTGGTGCAGCTCGCTGCAGCAGCTCGTGTACGCGG
 GGCGCTGGACACCGCGGGAGTCACGCGCTCCAAGCCAGGGATTATCTGAACACATAACCTCCATT
 GGCCCAGGACTACAGGAAGTCAGAAAATGAAATTCTGACCGTGACTACCTTTGAAACAGATTAAAC
 TGATTGAAGTGCAGAACAGCTTCATAAGATTCACTAGATGTACAACGCCAACAGGCTTTAG
 CATTGATTCTGGGAGGTTTACAAGCTATTATGACAACATCACCAATGTTGTGTAAGCTGGAACCC
 AGAGATGGAGGCCAGCATGCTGCTTGGCTAATTGTCAATTGACTCAGTAGCAAACACTACCAGGTGCCA
 GTGATGATGCACTAGCTGCTCAGTGATGCTGGAAGTCCTCGCTTGTCAACATCTCAGAACGCTT
 GCATCATGCTGTCAATTCTCTTAAATGGTGCAGGAAAATGTCAGGAACTGATGTTCAAGCCAGTCATGTTCAATT
 ACTCAGCACCCCTGGCTAGCTGATTGCGATTCATTCACTAACCTAGAGGCAGCAGGTGAGGAGGGAAAG
 AACTTGTATTCCAACAGGCTCTGAAAATCTTGGTTCAAGCTTATGTTCAGCAGCTAAACACCC
 TTTGCTTCTGTGGCTCAGGAGGTTTCAGAGTGGAACTCATTCTCAGATACTGACTTCGTATC
 TACAGGGATTGGAAACATCCAGGAATAGACTTAGCTTTATTGAGAAATGGGATACTTACACACCA
 AGTATGACACAGCGGACAGAATTCTAACAGATTCCATTAGAGAGCAGGTGACAACATTAGCAGTTCT
 TAAGCATCTAGCTACATCTGATATGCTGGCTGCTGCTTCTAAGTATCGACATGGAAACATGGCTTCTT
 GATGTGCTGGGCTGTTGTCATTGCCACCCCTCGTATTGGCTCAATCATAAACTACATGGTGGTAA
 TGGGTGTTGTTGACCTGGCAAAAAAATTTGCAAGCCAAACATAAGACTGGTAACTACAAGAAGGA
 CTTCTGTGTGGACTTGCATCACTTGATCAGCTGGTCACTAGCCTGTTACGGTCTCATTATAGCA
 GTGTTCATCTCTTATTGGACAGTCTCTCATGGTATAACCACCTCTATGTCCTCGTTGTCTGTATG
 GAACTGCAACTGTAGCCAAATAACTTATACATACTCTGCGAAAAGATTATTACATGAATGCCAG
 TGCCCAAGTATCTGGAGAAAGTATTGACATTGCTGTTGTCCATTGCTGTTCTGTTACCCCT
 ACTTACCAAGGACTTGTCTGGCTTATTAGTGTGCTGGTAGCATCCATTGCTCACAAGCTCT
 GTGTGCAAAAGGACTTCAGCAGCATGGTGCCAAGGAAAATTATTGCTTTACCTTGGGATGTT
 TATTCCCTATCTTATGATGCTGACCTCTCATGGCAGTATTGAGATGTTACCCCTATCTGGGAGA
 AGTGGTCTGAAATCCCACCTGATGTTGTGCTGGCATCCATTGCTGGCTGTACAATGATTCTCGT
 CCTATTATTAACTCATCACCTTCCAAGAGACAAAAAAACATGCTAACCTAACCTTGGTATG
 TGCAATTACATTCCCTTGTGCACTGGAAACATTTCATAGCTCAATCCGTAATCCGAAG
 CCAAAGAGAGTGTCTTCAGCATACTGACTAGAACATTCCATGACTTGAAGGAATGCAGTAAACGGG
 ACTCTGGAATATGGATCAATGGGTTGATTATACTGGAATTCTCACATAACCCCTCACATTCTGAGAT
 CAATGATAGTATCCGAGCTCACTGTGAGGAGAATGCACCTCTTGTGGTTCTGGTATCTCCAGTG
 CACTTCTGATCAGGAAAAACTGGTATCTCCTGCCAGAAGTTCTCAAGAAATCTCCTCATTCC
 GACTCATATCCAAGAACAGACACCTGGGATTCTATAAAATTGACTTTGAAGCAACAGGACCAAGCCA
 TATGTCCTCTATGTCGAGGCCACAAAGGTCAACACTTCTCAGTGGTCTTGGCAATGGCACCCCA
 GTCACAAGTAAAGGAGGAGACTACTTGTCTTTACTCCATGGACTCCAGGCCCTGCTGCATGGCAGTTCT
 GGATAGAAGTGCAGGTTTCAAGAACATCTGAAGGAATGGTCACCGTGGCCATTGCTGCCACTATCT
 GTCTGGGAAGACAAGAGATCCCTCAACTGGATGCTGTGAGGAAAAGTCCCAGATTGGACATTCCC
 TCTGCTGGGTGTCACCTACGATCTTTGTATTAACTTGTGGATGAGCTCAAGTACATGCCAG
 TGGATACTCCATGTCAGATGGTTCTCCCTATGTTACGTGGATGTTGTAACGTAAGTCAATGAATTAA
 ATGATCATATGTCAGAACAGGTTCTGGGTAACGCTTTCAAGGGCAAGCACTATAAGGTTAGCTGT
 GGCGCAGTGTGCAATGGCTGTTGACACTTGAAATGCCAGTCTTGGCACTTCAGCACATGTGGTAC
 TGCCACTACACACGTCAATTATGACCTTAAGGACAAGCAACAATCCACTCAATAGCTGCC
 TTTAGGATCAAGAAAGATGTACACTGTCAGAGCATTGTTAAATGAGACAAAAGTGTGTTCCAATTAAAGCC
 CCAAAACCATTGTTGATTAGTGGATGGTGGGAAAATATCATTCACTGAGGTAATGATTCCCCTGAG
 AATATAACTCTGTGTAGGTCACTGGAAAGTGATTGCCATAGGGCTGGGAGAGAAGCATTGCACTCTGAG

GCTGTAGCCTGTGTCAGCTGGCAGGCCCTCAAAATGTGCTTGTCTCTGTGCTGAGGCC
 TGGACCCCTGTGCTGAGCTGGACTCACTGCTCTGACAAGTGGACACACAGATGCAGTGCTGCTGCTT
 TCCTGAGGTGGTTCTATGCCTGTTCTGAAACATGTCTGTTACCCCTCTCCATCTAACAGTT
 GAAAAGGGAAATATTGGCCACATACCCCTCTGGTTCTCGTAGGTTCTTGGTTCAAAGATATTGTTGT
 GCCAGTACATGACCTTAACCTCCCTCAGAGCACTGAGCTGCCATCTGGCTATTCTGGGTAGAAGG
 AAGGCTGGAGTGGGGAAATTTATAAAATTTATTCTCTTCTTGTTCATAGGAGTCTGTGTTA
 TACAAGGTTAGTCCTCATGGTATAATCTTACTGATGCACTGGGCTATCTTTGTTCCAGGCCAGTT
 GAATAGATTAGTTTCTCAGTAACCTACTATCCAGCAGACTGGCTTCTGAGACTTGAGGTTGTGGCT
 TATACTGGAATGAGACCACGTACGTAGGTGGTCAGATCTCGCTAATGGCAGCATGAGGACTTAAA
 AGGTGGTTTCATTGAGATGGCTATGTAGCTGAAAGGTATCACAGCAGTACCTCTCATGGCTTT
 TTGGTCCAGCAGTGAGGGCATTGGTGAGATCAATGGTAAACTGTGCAAGCTTCTTTATCATTAGGA
 AATGTGAAACGTTGGACAAATTGAGTTAACAAAGGACAAAAAGTGAAGAAAAGGCACAGTTAACAA
 AAAAAGGGTGGCTAGATTATCTGGGTGATGGAGGAATGAGAGAGGAATGCTCTGAAAGGTGGCTG
 TGGATCTGTCTGAATAGAAAGAGCACAGTAAGTATGCATTGCCGGAGAAAAGTCCCTGAAAGCTGCTTGT
 CTCATGTGTATGATGTGCTTTAAATCATGCCCTCGTGCCTGCCTAATCTGACTCCCTAAAAACT
 AACTGGCCCATGTAGATGGGCTGCAACCAGAGCTGAATAACATGTTAGGCTCACACATGCATCAGCAC
 TGCACACTGGAATCATTGCTTCCCTGACTTGTAGAAATCAGTCTCAAGTGTCAAGAGTCTGGCTC
 CTGCTACTTTATCTGTCAGGTAGCACATAAGGTTGCAGGGTTATATTGTATAGAATCACAGTTGT
 GGAGAAAAAGTAATAATTCTCAATGAATTAAAAATGGGCTATTTCTATCCCCGTGGTCATCTGA
 TATAATTAGTGTCCCTGTGAATTCCCCCCTCTATGGGAAGGATGCCTTACTCTTATCAGTAATAAA
 TTATGACTGTTTCATATTGCCCTAGGTTATTCCCTGTGTAACACCATTGCTTTGTTGGTTTCT
 TTAGCATTATGAAGCTTGGATTGTACAAGGTCAAGTAGATGCTACTAGTCTCAGGGCTGTGTA
 ATATTCTGGGAGGTCAATTAAATGCCAGAAATGGTCAAGCAATTATACACAGTATTATGACTCTGTTAA
 GCATACCGTTGTCACATTAGTAGATTCTGAGATTAAAAAAATTAAAGAGTGTGATCATTTAAA
 TAATTCTAAAGGGCTTTCAAGCTAACAAAGTCACTAACAAATGCATTATTCTACAGAATTAG
 ATGTTAGTAGTACAGTACTGCATATTCAAGGGAAAAAGTGTGAGGAATTGATTCAAAATAGTCGTTCTT
 GTGTTGACCTAAGAATGATTGCGATGAAGTGTGTTTACAGTTAGCATATATAACAAACATG
 ATAGGATTCTTAAGATGTTACCAACCCAGGGGCCACAAGCCAGCCTGCTGTCTCAGGAAGCTGTAGAAG
 GAGTGTGTTGTCATTCTGCACTGGTTGCTACTGAGGATTAATTGTTGCTTACAATGTTAC
 TGAAATAAAACTGTTAATAT

>gi|21361381|ref|NM_007171.2| Homo sapiens protein-O-mannosyltransferase 1 (POMT1), mRNA
 CCCGCAGGCTCGGTGAATCGAACAGTTGAGCAGGGCGGTGGGTGGTGGAGTGCCAGCGGCCCTACCCCC
 CAACCGTGGCCCAGTCGGACGGTCCAGGGCGTGCCTGGGGAGCCGGCGCGCTGTGTGACTCGGA
 GAAACCGGGCGTCTGCCTGAGCCCCTTTCTACAAGATGTGGGATTGTAAGCGCCCTGTAGTGG
 TGACGGCTGACATCAACTTGAGCCTTGTGGCCCTGACTGGGATGGGTTACTGAGCCGGCTGTGGCGACT
 CACCTACCCGGGGCTGTGGTTTGACGAAGTATATTATGGCAGTACATCTCTTTACATGAAACAA
 ATCTTCTTCTGGATGACAGTGGGCCATTGCCACATGGTGTGCCCTGGGAGGTTATTAGGAG
 GATTGATGGCAATTGGAAACAGAATTGGAGCAGAACATAGTAGCAACAGTGCCTGTGGTCCCT
 GCGCTGCTGCCAGCACTCGCGGGGCTTGTGCGTCCCAGGCCTACCAAGATAGTGTGGAGCTCCAC
 TTTCTCATGTGCCGCATGGAGCTGCTCTGTTGATGCTTACAGAATGCTCTCATCACTCAGTCAA
 GGCTAATGTTGGAACTAGTGTAAATTGTCATCTATTGCCGTGTTGCTTACCTGAAGTTCT
 CAACTGCCAAAGCACAGCCCTTTCTGAGCTGGTGGTCTGGCTAACACTGACAGGGTCGCTTGT
 TCCTGTCAGTGGCATCAAGTACATGGGTGTGTTCACGTACGTGCTCGTGTGGTGTGCAAGCTGTCC
 ATGCCCTGGCACCTGCTTGGAGACCAGACTTGTCCAATGTAGGTGCTGATGTCAGTGTGCA
 GGCCTGTATGGGCAGATGCGGATGTACAGGGGCTGTGTTCTGCACTTGCTGCCAGCAGTG
 GCTTGTGTCATCCCGTCCTGTACTTACTGTTCTACGTCCACTGATTCTAGCTTCCGCT
 CTGGGCCCCACGACCAATCATGTCCAGTGCCTCCAGGCAGCTTAGAGGGAGGACTAGCTCGGATCAC
 CCAGGGTCAGCACTGGAGGTGGCTTGGGTCCAGGTACTCTGAGGAACGTCTTGGAAACCTGTG
 CCCTGCTGGCTTCATTCCCACCAAGGACACCTACCCCATGATATATGAGAACGGCCAGGCA
 AGAACACAGGTGACTGTACCCCTCAAAGACGTCATAACTGGTGGATTGAAAGGATCCCAGGAGGCA
 CCAGCTGGTGGTGAGCAGCCCTCCAGACCTGTGAGGCACGGGACATGGTCAGCTGGTCCACGGCATG
 ACCACCCGCTCCCTGAACACGGCATGATGTTGCAGCCCCCTGAGCCCCATTACAGGAGGTCTCCTGCT
 ACATTGACTATAACATCTCCATGCCGCCAGAACCTCTGGAGACTGGAAATTGTAACAGAGGATCTGA
 CACAGACGTCTGAAAGACCATCCTCTCAGAGGTCCGTTGTGCACTGTAACACTCCGCTGTCTAAAG
 CTGAGGGGGCTACCTCCCTGACTGGGGTATCGGCAACTGGAGATCGTCGGGAGAAGCTGTCCCGG

GCTACCACGGGAGCACGGTGTGGAACGTGGAGGAGCACCGATA CGGCCGAGCCAGGAGCAGAGGGAGCG
 GGAACGGGAGCTGCACTCACCTCGCAGGTGGACGTCA CGCAGGAACCTCAGCTTCATGGCAGATTCTCG
 GAGCTCAGTGGAGGATGCTGGCGCTGAGAAGTGATGACTCGGAACACAAGTACAGCTCCAGCCCCACTGG
 AGTGGGTCAACCTGGACACCAATATTGCCTACTGGCTGCACCCCAGGACCAGCGCTCAGATCCACCTACT
 TGGAAACATAGTGTATCTGGTTTCGGGAGCCTCGCTCTGGCATCTACGCCCTGCTGTCTTGTGGTAC
 CTGCTCCGACGGCGAAGAAATGTCCATGACCTCCCTCAGGATGCCCTGGCTCGCTGGGTGCTGGCTGGG
 CGCTGTGTGCCGGTGGCTGGCAGTGAACTACCTCCCGTCTCCTGATGGAGAAGACACTCTCCTCTA
 CCACTACCTGCCCGCACTCACCTCCAATCCTCTGCTCCCTGTTGCTCTGCAGCACATCAGCGACCAC
 CTGTGAGGTCCCAGCTCCAGAGGAATTCTTCAGCGCCCTGGTGGCTGGTACTCCTCCGCGTGCC
 ACGTCCAACACCGCTGCCACTCACCTACGGGACAAGTCACTCTGCCACATGAACTCAAGGCCCT
 TCGCTGAAAGACAGCTGGGACATCTTGATCCGAAAACACTAGAACAAAGAGTGTGCAAAGAACACCCGT
 GCTGGGGTGGGAGGTTGAAGGGTCTGGTCAATGTACGTAATGAGCAGGGTGGGCCACGCTGGGA
 GGACACGGGCTGGCTGAGCAGGGCCTCTAGTGAACACATGGGGTCTCATGAAAAGCTCTGATG
 AGCACCTCCTTTGTGCAAAGTTAATTTCGACAATAAGATATTCCGTGCTTCACCCCTGAACT
 AAGACACAGGGAGTATTCAGAGGCCAGCGTAGGAGTCATCGACAACGAAAAGCCGAGAACCCAGGGCCA
 GCAGTGAAGCTCAAGCAAGACCAGGGCCTGGTCTTGTCAATTGTCAGGGTGGAGTTGATCTGGC
 AGACCCGATCCTCCTCATGAAACACCCAGCAACCTGAGCAAGTCCCGCCCTGCCCTCAGCGAGGCCGGC
 AGGCGTCCCGGGACAGCTCAGTGGAGGGCCACCTGAACACAGGCCAGGGTGGGCCATGTCA
 TTGTCTATGACAGCGTCAAGACTGCCCTGGCACCGTGTGGAAACCCCTCCCTTGAGACTCCAC
 TGAGACGGTGGCTGAGTGAATCTTCCTCGTCAAGGTGTGTCATCCATACAGCTCCATGCC
 GTCTTTTAAATGTAATTAAAAAGGAACCAACTGGCGTTGTAAAAAAAAAAAAAAAAAAAAAA

>gi|18860905|ref|NM_002846.2| Homo sapiens protein tyrosine phosphatase, receptor type, N (PTPRN), mRNA

GCGGCAAGCCCCGCCCTCAGCCCCCTCTGGCAGGCTCCGCCAGCGTCGCTGCCGCTCCGCCGGGGAGCGA
 GCGCCCGGAGCTGGAAAGATGCGGCCGCCGCCGCGGGCTGGGGTCTGGGGGATCCGGGGTCTCCGG
 CTGCTCCTCTGCCCTCTGCTGCTGAGCAGCGCCGGGGGGCTGCAAGGCCGTTAGTGCCACGGCTGTC
 TATTGACCGCAGGCTCTGCTCTCACCTGGAAGTCTGTATTAGGATGGCTTGGCAGTGCAGGT
 GGGAGTGGGGCAGGCCGGCCCTTTGCAAGTCACCTCCCGTCTCCAAACGCTTACAAGGTGTGTC
 CGACAACTCATGTCCTCAAGGATTGTCCTGGCACGATGACCTACCCAGTATGTGATCTCAGGAGATGG
 AGCGCATCCCCAGGCTTCGCCCTCAGAGCCCCGTCAGGGACAGGTCTGGCTGGCACCCAAGAGACC
 TGGTCTGCTGGAGAGCTGCTTTACAGGACATCCCCACTGGCTCCGCCCTGTCGCCAGCATGGCTT
 CCACAAACCACCAAGTGGCAAAGGTGGAGCTGGGGCAGCTCCCTCTGTCCTCTGCAAGGCTGAGCTGC
 TCCCGCTCTCTGGAGCACCTGCTGCTGCCCTCACAGCCTCCCACCCCTCACTGAGTTAGAACCTGC
 CTTGCTGAGCCCTACCTGTTCCACCAAGTTGGCTCCGTGATGGCTCCAGGGTCTCAGAGGGCTCCCCA
 GGGATGGTCAGTGTGGCCCCCTGCCAAGGCTGAAGGCCCTGCCCTCTCAGCAGAACTGCTTCAAGG
 GCATATTGGGACCACCTGGCACTCTACGGGACCTTCAGGGCCTCACCTGCCAGCTTTCA
 AGACTCTGGCTGCTTATCTGGCCAGGAGTGTGCCAGCACCCAGCAGGGCCAGGGTGCCAGGGCTGCA
 GAGCAAGGGAGCAGCAGCCGGCAGAGGACTCCCCAGAGGGCTATGAGAAGGAAGGACTAGGGGATGTC
 GAGAGAAGCCTGCTTCCCCAGCTGTGCAAGCCAGATGCGGCTCTGCAAGAGGCTGGCCGTGCTGGCGGG
 CTATGGGTAGAGCTGCGTCAGCTGACCCCTGAGCAGCTCTCCACACTCTGACCCCTGCTGCACT
 CCCAAGGGTGCAGGAAGAAATCCGGGAGGGGTTGTAATGTTGGAGCTGATATCAAGAAACAATGGAGG
 GGCCGGTGGAGGGCAGAGACACAGCAGAGCTCCAGCCGCACATCCCCATGCCGACACCCACTGC
 CAGCCCTACCTCCAGTGAAGTCCAGCAGGTGCCAAGCCCTGCTCCCTGAGCCTCCAAAGCTGCCAGA
 CCCCCCTGTGACACCTGCTCTGCTAGAGAAGAAAAGCCCACGGGCCAGAGCCAGCCCACGGTGGCAGGAC
 AGCCCTCAGCCCCCCCAGCAGCAGAGGAATATGGTACATGGTCACTGATCAGAAGGCCCTGAGCCTGG
 TGCAGGAGTGAAGCTGCTGGAGATCTGGCTGAGCATGTCACATGTCCTCAGGCAGCTCATCAACATC
 AGTGTGGTGGGACCAAGCCCTCACCTTCCGCACTGGCACAATGAGCAGAACCTGTCCTTGGCTGATGTGA
 CCCAACAAAGCAGGGCTGGTGAAGTCTGAACTGGAAAGCACAGACAGGGCTCCAAATCTGCAAGACAGGAGT
 GGGACAGAGGGAGGGAGGGCAGCTGCACTTCCCCAAACTGCCAGGCCACAGCACCTCACCCATGCCCTCAGTG
 CTGCTCACTCTGGTGGCCCTGGCAGGTGTGGCTGGCTGCTGGCTGGCTGGCTGTGTG
 GGCAGCATGCGCGGCAGCAAGACAAGGAGGCCCTGGCAGGCCCTGGGCCAGGGGCCATGGTACAC
 TACCTTGAGTACAGGACCTGTGCCGCCAGCACATGCCAGCAAGTCCTGTTCAACCGGGCAGAGGGT
 CCACCGGAGCCTCACGGGTGAGCAGTGTGCTCCCAAGTTAGCAGCAGGCCAGGCCAGCCCCAGCT
 CCCACAGCAGCACCCCGTCTGGTGCAGGAGGCCCAAGCCAACATGGACATCTCACGGGACACAT
 GATTCTGGCATACATGGAGGATCACCTGCGGAACCGGGACCCCTGCCAAGGAGTGGCAGGCCCTGT
 GCCTACCAAGCAGGCCAAACACCTGTGCCACCAGCAGGGCAACATCAAAAAGAACCGGCATC

CTGACTTCCTGCCCTATGACCATGCCCGATAAAACTGAAGGTGGAGAGCAGCCCTCTCGGAGCGATT
 CATCAACGCCAGCCCCATTATTGAGCATGACCCCTGGATGCAGCCTACATAGCCACGCAGGCCCGCTG
 TCCCATACCATCGCAGACTTCTGGCAGATGGTGGAGAGCGGCTGCACCGTACATCGTCATGCTGACCC
 CGCTGGTGGAGGATGGTGTCAAGCAGTGTGACCGTACTGGCAGATGAGGGTGCTCCCTTACACGT
 ATATGAGGTGAACCTGGTGTGGAGCACATCTGGTGCAGGACTTCTGGTGCAGGAGCTTCTACCTGAAG
 AACGTGCAGACCCAGGAGACCGCAGCCTACGCAGTTCACCTCCAGCTGGCCGGCAGAGGGCACAC
 CGGCCTCCACGCCGCCCCCTGCTGGACTTCCGCAGGAAGGTGAACAAGTGTACCGGGGCCCTGCCC
 CATCATCGCACTGCAGTGTGATGGTGGGGAGGACCGGCACCTACATCCTCATCGACATGGTCTGAAC
 CGCATGCCAAAAGGAGTGAAGGAGATTGACATCGTGCACCCCTGGAGCATGTCCGTGACCGAGGCCCTG
 GCCTGTCCGCTTAAGGACCAAGTTGAATTGCCCCAGTGGACAGCCGTGGGGAGGAAGTGAATGCCATCCT
 CAAGGCCCTGCCCCAGTGGACCCCTGGGGCCCTGGCGGGAGCCCAGCCTCTGTCCTCTTGCGCTGT
 GTGAGCATCTCTGTGTACCCACTCTCACTGCCAACCTGGGAGCATGCTCAGCCCTTCTA
 GAAGAGTCAGGAAGGGAAAGCCAGAAGGGCAGGCCCTGCCAGCCTGCATGCCAGAGCCTGGGCATCC
 CAGAGCCCAGGGCATCCCCTGGGGTGTGCAGCCAGGAGGAGAGGAAGGACATGGTAGCAATTCTAC
 CCAGAGCCTCTCTGCCTACATTCCCTGGCCTGCTCTGGCTAGCTCTCTGGGTTCTGGGAGTTCC
 CTGAACATCTGTGTGTGCCCCCTATGCTCAGTATGGAAGAATGGGGTGGAGGGTGCACACCCGGCT
 CCCCCCTGTTCTCAGCCCCGGGCTGCCTGTGACTCACACTGGGCGCTCTGCCCTCCCTGGCCTCACGC
 CCAGCCTCCCTCCCACCCCTCCACCATGCGCTGCTCAACCTCTCCCTGGCGCAAGAGAACATT
 CTAGAAAAAAACTACTTTGTACCAAGTGTGAATAAAGTTAGTGTGTGTGCAGCTGCAAAAAAAAAA
 AAAAAAAA

>gi|19743910|ref|NM_002847.2| Homo sapiens protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2), transcript variant 1, mRNA

GCCTCCCGCCGCCCTCCGCGCGGCCATGGACTGAGCGCCGCCAGGCCGCGGGGATGGGGCCGCCGC
 TCCCGCTGCTGCTGCTACTGCTGCTGCTGCCACGCCCTGCCCTGCCCTGCCCTGCCCTTCGTCCGTCCC
 CCGCGGCCGGCAGCTCCCGGGCGTCTGGCTGCTCGAGGAGGGCCTCTGGAGCGTCCGAGGCC
 TGTGTGAACGATGGAGTGTGGAGGTGCCAGAAGGTTCCGCAATGGACTTTACCGTACGAGGTGT
 CGCCCGTGGCCCTGAGCGCTGCGCTGGCGTTGAGAAGCTTCCGGCACAGGTTACGTGGCAGGA
 TGACTATACTCAGTATGTGATGGACCAGGAACTTGAGACCTCCCGAAACACTACCTGAGGCGTCTGAA
 GCATCCAGCCAGGCCAGGCCCTCAAAACACAGCGTTGGCAGCGAGAGGAGGTACAGTCGGAGGGCGGTG
 CTGCCCTGGCAACGCCCTCCGACGCCACCTGCCCTCTGGAGGCCCTGTCCCAGGCCCTGCCCTCAGA
 CGTGTGCCAGGACCCATACGGCGCAGGACAGACCCCCCGCTGAGGGTGATGACCGCTTCCGAGAGC
 ATCCTGACCTATGTGGCCACACGTCTGCGCTGACCTACCCCTCCGGGCCGGACCCAGCTCCGCGAGG
 ACCTCTGCCGCGGACCCCTGGCCAGCTCCAGGCCAGATGAGCTCAGCCCTAACGGTGACAGTGGTGTGA
 CAGACACCCTGTGATGGCGCCCTCAGTGCCTATGCTGCCAGAGGCCCTCAGCTCCCCCGGGAGGGC
 AGCCTGGAGCCACAGTACCTCTGCGTGACCCCTCAAGAATGCCAGGCCCTTGCTGGCACCCAGGCC
 CCCAGAAGTGGCTTCACCTCTGGAGATTCCGAAGACCCCTCAGCACGGCGATGGAGCACGGATTCA
 TACCCCTCTGAAGGACCTGCAAGAGGAGGCCCTGAGGTGAGGGGCTGAGTGGCTGGAGCTGGACGGC
 ATGGCTGAGCTGATGGCTGGCTGATGCAAGGCGTGGACCATGGAGTAGCTCGAGGCAGCCCTGGAGAG
 CGGCCCTGGAGAGTCTGGAGAACAGGGGGATGGCCCAAGGCCACCCCTCCGTGGAGACAGCTTCCAGA
 TGACGGAGTGCAGGACGACGATGATAGACTTACCAAGAGGTCCATGCTGAGTGGCACACTCGGGGGC
 CTCCCTGCAGGACCAAGGGCTCGACTTACCTGGAGCCCTCCCTTGCAAGGCCCTCGACATGGAGA
 GGAAGAAGTCCGAGCACCTGAGTCTTCCCTGTCTCAGAAGAGGAGACTGCCGGAGTGGAGAACGTC
 GAGCCAGACGTATCCAAAGATCTGCTGGGGCAGCAGCCGCTTCCGGAGCCGGCTGCGTTGG
 GAGCTCAAACACAGATGCCCTGGCCCTCGAAGGAGGAGCAGAGCCTTCCAGCGGGTGTCAAGGAGGCC
 TCAGCGACGGCTGCAATTGGAGGTCCAGCCTCCGAGGAAGAGCGGGGCTACATCGTACAGACAG
 AGACCCCTGCGCCCCAGGAAGGAAGGCAGGACGTGCCCCCTCTGAGGTGCGCCAGCAG
 AGTGCCTCGCTGACGTGGAGGTTCTGGACCGAGCAGTGCACCTCAAAGTGAAGCGCAATGTC
 TGACCAACTGAGGATGTGGAGAACGGCACAGTTGACAACAAAGACAAACACTGGAGGAACCTCTGG
 AATTCTCAAACCGGAGTCGGTCGAAAGCAAAACTCAAGTCTGCCCTCAGGCCAGCAAGAAC
 TCCACCAAGTTCATCGCGCTACCCCTGGCTCCCTGCCATCCCTGGCGTCCCTGGCCTCTGGC
 TCATCTACTGCCCTCGCCATAGCTCTCAGCACAGGCTGAAGGAGAAGCTCGGGACTAGGGGGCGACCC
 AGGTGCAGATGCCACTGCCGCTACCAAGGAGCTGTGCCGCCAGCGTATGGCACGCCACAGACCGA
 CCTGAGGGCCCGCACAGTCAGCAGCGTCTCATCCAGTGCAGCAGGGCGATCCCCAGCC
 CCTCCGCACGCAGCAGCGCTCATCTGGTCCGAGGAGCCTGTGAGTCCAACATGGACATCTCCACCG
 CCACATGATCCTGCTTACATGGAGGACCACTGAAGAACAGAACCGCTGGAGAAGGAGTGGAGCG

CTGTGCGCCTACCAGCGGAGCCAACAGCTCGTCGTGGCCCAGAGGGAGGAACGTGCCAAGAACCGCTCCCTGGCTGTGACCTATGACCCTCCCAGGGCTCTGTAAGGGAGAACAGCCACAGCCACTCAGACTACATCAACGCTAGCCCCATCATGGATCACGACCCGAGGAACCCCGTGTACATGCCACCCAGGGA
CCGCTGCCCGCCACCGTGGCTGACTTTGGCAGATGGTGTGGAGAGCGGCTGCCTGGTGTACCGTACGACCTACTGGCCGGATGAAGGCTCCAATCTCTACACATCTATGAGGTGAACCTGGCTCCGAGCACATCTGGTGAGGACTTCCCTGGTGAGGAGCTTCTATCTGAAGAACCTGCAGACCAACGAGACGGCACCGTGACGCAGTCCACTTCCTGAGTTGGTATGACCGAGGAGTCCCTCCTCAAGGTCCTGGACTTCAGCAGAAAAGTAAACAAGTGTACAGGGCCGTTCTGCAATTGTTAATTCAGTGCAGTACGTCTGACATGGTTCTCAACAAAGATGGCAAAGGTGCTAAAGAGATTGATATCGCAGCAGCTGGAGCAGTGAGGGACAGAGACCCGGCATGGTCCAGACGAAGGAGCAGTTGAGTTCGCGTGCAGGCCGTGGCTGAGGAGGTGAACGC
CATCCTCAAGGCCCTCCCCAGTGAGGGCAGCCTCAGGGGCTCAGGGGAGGCCACCCACGGATGTTGCAAGGAATCATGACTTAAATGTGTGCTCTATTTATAACTGCATAGTAATAGGCCCTTAGCTCTCCGTAGTCAGCGCAGTTAGCAGTTAGCAGTACGTTGAGGAGAGA
TTTGTGAAAAATCCAGTTACGGGTGGAGGGAAATCGGTCATCAATTTCAGTGCTTAAAGGAGA
TTTTCTTAAAGCACCGTTCACCTTCTGGTTGAAGTTGTGTTAACATGCAGTAGCCAGCACGTTGAGCGGTTCCAGGAAGAGTGTGCTGTACGCCACTTCCGAGCTTGGAGGGTGGATCCACTGTGAGGAGTGG
CCGGGGAAAGCTGGCAGCACTCAGTGAGGCCGCCGGCACACAAGGCACGTTGGCATTCTCTGGAGAGAGTTTATCATTGGAGAAGCCGGGGACAGAACTGAACGTCCTGCAGCTCGGGCAAGTGAGACAATC
ACAGCTCTCGCTCGTCTCCATCAACACTGCGCCGGTACCATGGACGGCCCGTCAGCCACACCTGTCAGCCAAAGCAGAGTGTGATTAGGGCTCCGGCAGACACCTGTGACCCCCATGAGTAGTGCCACTT
GAGGCTGGCACTCCCTGACCTCACCTTGCAAAGTTACAGATGCACCCCAACATTGAGATGTGTTTTAATGTTAAATATTGATTCTACGTTATGAAAACAGATGCCCCCGTGAATGCTTACCTGTGAGATAACAC
AACCAGGAAGAACAAATCTGGCATTGAGCAAGCTATGAGGGTCCCAGGACACAGAACCTGCCCAG
CCCCCGTGGCTCCAGGCACGTCCGGACCTGTGGGCCCCAGAGAGGGGACATTCCCTCCGGAGAGGGAGATCAGGGCAGCTGCACCGCAGGGCCCTGGCCCTTCCGG
ATCACTTAATGAACCACGTGTTTGACATCATGTAACCTAAGCACGTAGAGATGATTGGATTGACAA
AATAACATTGAGTATCCGATTGCCATCACCCCTACCCAGAAATAGGACAATTCACTTCAATTGACCA
GGATGATCACATGAAAGCGCGCAGAGGCAGCTGTGTTGAGGCTGAGATTCTGTGAGGTTTCAGCGTAGAAAACGCACCTCCATCCGG
CCCTACCAGAGGGAACACGGCTACTGAGCGGACAGAAATGATGCCAAATATTGCTTATGTCTCTACATG
GTATTGTAATGAATATCTGCTTAATATAGCTATCATTTCTCCAAATTACTCTCTATCTGAA
TTAATTAAATCGAAATGAATTATCTGAATATAGGAAGCATATGCCTACTGTAATTCTAACTCCTTAT
GTTGAAGAGAACCTCCGGTGTGAGATATAAAATATTAAATTGTCATATTAAACTCTGATTCA
AAAAAAA

>gi|4507334|ref|NM_003895.1| Homo sapiens synaptjanin 1 (SYN1), mRNA
GAGGAGGAGCCGGAGGAAGAGGGCTGCCCTCGAACGAAAGGAGAACGGCTTCAGTAAAGGATCCGGATCTATCACAAATTGGATCCCCCACCTTCAGCCTCATAGTGGAAACTAGGCATAAGGAAGAACGGATCTCATGTTGAGTCTGGCTGTGCTCTCATCTGCAAGAAAAGAGGCAATCAAGGGTACATACTCCAAAGTACTGGATGCAATTGGACTCTAGTGTGTTGAGGACTCTAGTGTGTTGGAAAAATTCAAGAACATCTGAGTTTCCAGTTCCACTGAGTTATATCAGTGCAGATTCTCAGATGAGGATCGCATTTCAGAAGTGCAGGAAAGTTGAATTCAAGGAAACCTTCTGCATCTGGAGGTTAGTTGAGCTTAAATGCGCATTGCGATCGTAGCATGCAAGAACAGACAACTGATAATAGATTTCAGTGGAAATCAGTCTTGCATTGCACTCAACACTATGGCGTGAATTGTTGAGCTGGTTATTACGTCTTATGTGAGGAGTAGAAATCAGAACAAATTATGCTGCTCA
TAAACAGGCGAAGGCTTGCCTCATTCAAGATTAAGCTGTGAACGAGCTGGACCAGGTTAATGTCCGG
GGAACAAATGATGATGGTCATGTTGCCATTGGTAGAAACAGAACAGGTTGAGCTTAAAGTGAACAGTGGGATCTGCTCTGGAGCAACCAGGGTGCAGTGGGATCTCATCGTGTCCGTATGTCAAGGGGATTGAAGCCAATGCACCTGCTTTGACAGGCAATTAGAACACT
AAGAACATTATGTTGAGACAAATAATAGTAAATTGCTTGGATCTAAGGAAGGTGAACATATGCTAAGTA
AAGCTTCCAGAGTCATTGAAAGCTCTGAACATGCTGCTGATATCCAGATGGTGAATTGACTATCA
TCAAATGGTTAAGGGAGGAAGGCAGAAAAATTACATAGTGTCTTAAACCTCAAGTCCAGAACAGTTCTA
GATTATGGATTTTTATTCAATGGAAGTGAAGTTCAAAGATGCCAGAGTGGTACAGTTGCAACAAACT
GCTTGGATTGTCCTGATAGAACAAATAAGTGTGCAAGGCTATTCTGGCTTAGAGATGCTAGCTAAACAGTT
GGAAGCTTGGTTAGCTGAAAAGCCTCAGTGGTACTCGCTTCAAGAACAGTTTCGGTCAATGTGG

TCCGTGAATGGTGATTCAATCAGTAAGATATATGCAGGAACCTGGAGCTTGAAGGGAAAGCGAAGTTAA
 AAGATGGTCTCGCTCTGTTACCGAACATTAGAATAACTTCTTGACAGCTCCAAGCAAGAGGCCAT
 TGATGTTTGCTACTGGAAATACTCTGAATAGTATTAGCTGACAAGCTCGAGCACTTTAACTACT
 GGAAGTTTGCGTGTTCAGCAGACATTACAGTCAGCATCTCTAAAGTACTAAAGAGCATGTGTGAGA
 ATTTCTACAAATATTCAAAGCCTAAGAAAATTAGTGTGAGTATGTGTGAGAACCTGGAATGTGAATGGTGGAA
 GCAATTTCGACAGCATAGCTTTAAGAATCAGACACTCACTGACTGGCTCTTGATGCACCCAAAGTTAGCT
 GGCATCCAGGAGTTCAAGATAAAAGAAGTAAGCCAACGTGATATATTGCAATTGGTTGAAGAAATGG
 TAGAATTGAATGCTGGAAACATTGTGAGTGAAGCACAACAAATCAGAAGCTCTGGCTGTAGAAACTTCA
 GAAGACAATCTCCAGAGACAACAAGTATGTGCTGGCTCTGAACAGTTGGTGGCGTGTGTTGTT
 GTTTTATCAGACCACAGCATGCTCTTATCAGGGATGTGAGTTGATACTGTGAAGACTGGAATGG
 GAGGTGCAACTGGAAATAAGGGAGCAGTTGCAATCCGAATGCTCTCCATACAACCCAGCCTTGCTCGT
 CTGTAGCCACTTGCTGCAGGGCAGTCACAAGTCAAAGAAAGAAATGAAGATTATAGAAATAGCACGA
 AAATTGAGTTTCTATGGAAAGGATGCTATTCCCAGTACTATGTTAGGGATTAGAGGATTAGAAGGAAAGGTAACC
 TTTGCTCGACATATAAGTATGACTTGTGTTCTGACGACTATGACACCAGTGAAAGTGCACCCCTG
 CCTGGACAGACCGTGTCTTGGAGAAGGAGGAATGGCTTGATAGATCAGCTGAAGACTAGATCT
 TCTAAATGCTAGTTCAAGATGAAAGAAAATTCTGTACACGTTGACTCCAGGCACCTTGCTGCACTAT
 GGAAGAGCTGAGCTGAAGACTCTGACCACAGGCCGTCGTTGCCCTGATTGATATAGATATATTGAAG
 TTGAAGCTGAAGAGAGGCAAAACATTATAAGAAGTAATTGCAAGTTCAGGGTCCACAGATGGTACAGT
 ATTGGTCTCAATCAAAGTCTTACCAAGAAAATAATTGATGATGCTTGATGAGCTCTG
 CAGCAGTTGCAAGTTGGTGAAGTTACTTATAAGATTGATGAGGAAATTGAGTTAGAGAAAATTAGCATTGCA
 TTGCCATCATCAACAGCTACCTGTTGGTGAAGATGCAAGAGGTTGAGCAGATTGATATGGAAG
 GTGATGTTGACTATAGTGTGAAAGTGGAGGAACTTCTCCCTCAGCATCTCCAGGCATCTCAAGTT
 CGGCCCTGGTACTCCCCAGCTCTCACCCGAACTAGTCCCTGCCAGTCACCTACAATATCAGAGGGT
 CCTGTACCTCCCTCCATCAGACCAAGCCGAGCACCGTCAGAAACTCTGGCCTCCAGTCACAGA
 GTTCTCTATTGACCGCGCAGCAGCAACGCCGTCGCGCAGAAAGACCCGCCAGCCCTGGAGCCCAA
 CGGCCGCCGCCGCCGCCGCCGCCGCCACACGCCGCTCCCCACAGAGACCTCCGCC
 TCAGGGCTAGGAGTCTGCACCACTAGAAAGGAATTGGAGGTATTGGAGCCCTCCAGTCCTGGGG
 TAGCTAGGAGAGAGATGGAAGCACCCAAAAGCCCTGGAACAACAAGGAAAGATAATATAGGACGCAGTC
 GCCTTCACCTCAAGCAGGACTTGCAAGGCCAGGACCTGCTGGATACAGTACAGCCAGACCGACGATTCT
 CCTCGTGTGGAGTTATCAGTCCCCACAGGCCACGCCGGCATCTGCTGGAAAGACTGACTCCTGAAA
 GCCAAAGCAAAACATCAGAACGTCGAAGGTTCAACTTCTTCTGAAACCACCTGCAAGCCTCAGGCTGC
 TTTTCTCCGCACTCTTGTGCCCCCTGCTAAAGGTTGCAAGAGCCTTTGCTGCCCTGAGCA
 CCTATGCCCTCAGTCTGGCCCCAGCCAATTGAAACCCACCAACCACCTGCAAGCAGGTCAT
 CCCATAGCTGCCCTCAGAAGCTTCTCACAAACCGCAAGTAAAACAAATGGAATCTGTGAGGCAAAAG
 AGAATCACCATTAAAGATTGACCCATTGAAAGATCTGTCATTAACTGCTGTATCAAAGGCTCAG
 CTATCTGTCACCGTCACCTGTTCCCACCCAGACCCAAAGAGGTTGATTGAGTTCAGTGCCTCTGCAACGC
 AAAGTAATGTTAATACTTGAGTTCTGTAAGTTGATGCCAACATGCTCCAATTCCAGCTGGAGTC
 ATCCCAGGAAAATATGCGAAGTTCTCAAACCCATTAACTGCTTGACCAGGACAATCTTCAGT
 GACAGGACTGCTGCTCTGGAAACCCATTAGAGCCAAGTCTGAAAGAATCAGAGGAACTTCATGGTTCT
 CCAAAGAAGAGCCGTTACTATCAGTCCTTCCCTCTGCAAGCCTCTGGTCATAACAAAAGCAGGGC
 TTCATCTTCACTTGATGGCTTAAGGACAGTTGATCTACAGGGCCAGTCTACATTAAAAATTAGCAAC
 CCGAAAGGATGGGTAACCTCGAGGAAGAAGAGGATTGGTGTGAAAGGGAAAGTCAGCTGTT
 CAGACTACTGGGTAATCAGCCAAGTTCAATTCTGGCTCAACCTGACATTGAAATGATGACTGGAATAA
 AGGGACAAATGTCCTCTGTGTTGCGTCAAGAAGACCTCCACCTCTGCTGCCCTGCTCCCG
 CCCGGCACAGCCCTCAGTAGATCCTTCACGACCTTGGCCTCAAGGCTTCACCCACACTGGACTTTA
 CAGAAAGATAACGCCAGCCCC

>gi|26190607|ref|NM_003898.1| Homo sapiens synaptojanin 2 (SYNJ2), mRNA
 GGCACGAGGCAGGGAGCTGTCGCGGGCAGCGCCCTCGGGAGGACGTGGCCCCGCCAGT
 GGGCCCGACCTCATGGCCCTGAGCAAAGGCTGCGGCTGCTGGGGCGCTGGGGGCCAGGGGGACTGT
 AGCGTGTGCTGGAGGCGCGCGACGACTGCTGCTGTTGAGGCCGGCACGGTGGCACGCTGG
 CTCCAGAAGAAAGGAAGTCATTAAAGACAGTATGGCAAGCTCACGGACGCGTACGGCTGCTGGGGGA
 GCTGAGGCTGAAATCTGGTGGCACGTCTGAGCTTCTGGTGTGACAGGCTGCACATCTGTGGGC

AGAATTCCAGATGCTGAAATCTACAAATCACTGCCACTGACTTTACCCCTTCAGGAAGAGGCCAAGG
 AGGAGGAACGCCCATAGCTTGAAGAAAATCCTCAGCTCGGGGTGTTCTATTCTCATGCCAACGA
 TGGGCTCGCTTGACCTGACTGTCCGCACGCAGAAGCAGGGGATGACAGCTCTGAATGGGGAACTCC
 TTCTCTGGAACCAGCTGTTGCACGTGCCCTGAGGCAGCACCGAGTGAAGCTGCTGACTGGCTGCTGA
 AGATCATCTGCGGGTGGTCAACCATCCGACCGTGATGCCTCCCACAAGCAGGCCAAGGCCATGCTCGT
 CTCTCGGTTAGCTGTGAGGCCACAGGCACTCGCTCCACACCGTGGCGTAACGACGCCATGTG
 TCCAACCTCGTGGAGACAGAGCAGATGATTACATGGACGATGGAGTGTCACTTTGTCCAGATCAGAG
 GCTCCGTTCCGCTGTTCTGGAACAGCAGGGCTCAGGTTGGCTCCATCATCTGAGACTCCACAGAG
 CCTGGAAGCCAATGCCCTGTTGCACAGGCACATGGTGTCTGAAGGAGCAGTACGGCAGCAGGTG
 GTCGTGAACCTCTGGGAAGCAGAGGGAGAGGAGGTGCTCAACAGAGCCTCAAGAAGCTGCTCTGG
 CTTCTGCCACGGGGCGACGCCATGATCAATTGACTTCCATCAGTTGCCAAAGGTTGGAAAGCT
 AGAGAAATTGGAGACCTCTGAGGCCACAGTTAAAGCTGACTGGGAAGACTTCGATGTGTCACAAAG
 GGGGAGAACGTCACTGCCACGTTTCAAGAAAGGCACTTGCAGGATGAACTGTCTGACTGCCCTGGACCGAA
 CCAACACTGTGCAGAGCTTCATCGCCTCGAGGTCCCTGCATCTGCAGCTCAAGACCCCTGGGCTGAGTTC
 AAAACCCATCGTTGACCGCTTGTGGAGTCTTCAAAGCCATGTGGTCTCTGAATGCCACAGCCTGAGC
 AAGGTGTTCACAGGCAGCAGGCCCTGGAAGGGAGGCCAAGGTGGGAAAGCTGAAGGATGGAGCCCGT
 CCATGTCCTGAACCATCCAGTCCAACCTCTGACGGGGTAAGCAGGAGGCCATCAAGCTGCTGCTGGT
 TGGGAGCTCTACGGCGAGGAGGTGGCAGACAAAGGGGGCATGCTGTCGGACAGCACGGCCTCTGGT
 ACTCCCCAGGATCTGAAAGCTATGACTGAGCGTCAGTCCGAATTCAAATTCAGCGGATCCGGATTG
 CTATGGGACCTGGAACGTGAACGGAGGAAAGCAGTCCGGAGCAACGTGCTCAGGACGGCAGCTGAC
 AGACTGGCTGCTGACTCGCCCCAGCTCGGGAGCTACCGACTCCCAGGATGACAGCAGCCAGCTGAC
 ATATTTGCTGTGGGTTGAAGAGATGGGAATTGAGCGCAGGAATTGTCATGCCAGTACTACCA
 ACAAGAAGATGTGGGTTGAACAGCTTCAGAAAGCCTACCGCTCTCATAGATACTCTGTTGACTTC
 GGCACAGCTGGTGGCGTCTGTCTTATCTTGTACGTCATACCAGTCCCGTTCATCAGGACGTA
 GCCATCGACACAGTGAAGACGGCATGGGGCAAGGCGGGACAAGGGCGCCGTCGGCATCCGCTTC
 AGTTCCACAGCACCAGCTCTGCTTCAATGTAGTCACCTGACGGCCGGCAGTCCCAGGTGAAGGAGCG
 GAATGAAGACTACAAGGAGATCACCCAGAAACTCTGCTCCAAATGGGAGAAATGTTTCTCATGAT
 TATGATTTGGTGTGGCATTCAACTACCGCATTGATCTTACTATGAAGAAGTCTTCTATTGTTA
 AACGCCAAGACTGGAAGAAACTCTGGAATTGATCAACTACAGCTACAGAAATCAAGTGGAAAAATT
 TAAGGACTTCACGAAGGAGCATTAAACTTGGACCCACCTACAAGTATGACGTTGGCTCAGCGCCTAC
 GATACAAGCGACAAATGCCGCACCCCGCTGGACAGACAGGGTGTGTTGGAGGAAGAACATCCCT
 TTGATAAAACAGCTGGAGAACCTCAACCTCTAGACAGTGTAGATGGACACCAAAGTCAGACACAC
 CTGGCTCCTGGTGCCTGCAGTATTATGGCTGCGGAGCTACAAGCGTCTGATCACAGACCTGTGCTG
 GCGATCGTGGAGGTGGAAGTCAGGAAGTCGATGTGGTGTGGAGAGGGTTTCCAGGAAGTGTCT
 CCTCCAGGGCCCCCTGGATGCCACTGTTGTTAGTAAACCTTCATCACCGACCTTAAAGAGAAAAGCA
 GTTTCCAGAGGACTCGTACTGAGCTCATGCAAGACCTGGGAGTTATGGACAATTGTTCTGTCAGG
 ATCAACCAAGGGCAGATGCTGTAACTTTGCAAGACAGTCAGTCCCTGTCAGTGTCTGGACGTGGACG
 GTATGAAGGTGAAAGCAGAGCAGTGAAGATTAGACCGAAGACCAAGGACTGGCTGAAAGGTTGCGAGA
 GGAGATCCTCGGAAACGAGACAGCATGGCCCCGTGTCTCCACTGCCAAGTCCCTGTTGCTGGAGGA
 AACTTTGACTTCACAAGTTGACTATGAGTCAGAAGGGGATATTCTGAAGACGATGAAGACTACTTG
 TGGATGAATTCAATCAGCTGGAGTCGGACAGTGAACCTGGGGAGACGACCTCTGATGTCCCCGG
 CCCCACAGCACTGGCTCTCCAGCAAGTCACCTGCTCTCACCAAAAGCAGCATCCAACGTACAAA
 GATGACCGGACCTGGTGGAGCTCAAGCGGAGCTGGAAAGCGTCGGGAGTTCCGCCACCGTTCTCGA
 GCAGGGCTCTGCGGCCCCAACCGGCCCTGGCACCTCAACCCCCCGCAGAGACCCCCCTCCAACCGG
 TTTAATGGTAAAAAGTCGGCTTCAGATGCGTCCATCTCTCCGGCACCCATGGACAGTATTCAATT
 CAGACGGCAAGACTTCTACCAAGGAGCACCTCAGCAACCTCCAAGGCTGGACTGGAATAAGTAAACCT
 ATAATGTCAAGCAGATCAAACCAACCAATGCCAGGAGGAGCAAGCAGCAATCCGGTGTCTCTGGAA
 CAGAGGAGGTGCTCCCGAAGAACGCCCTAAGTGCGGCCCCAAGGGACCTTGAAAGCATCCTCTGAA
 GAGCCCACACGGGGCAGCCAACCCAGAGACCCACAGGGCCCCACTCTCTCCGGCTGGCCCCAC
 CCAGAGTCTGCCATCAAGAAGCCAACCTTGAGAAGGAGACAGGAAAGCCCCCTGTCACCGGAAGAACAGT
 TGAGCAACAGACTGTCCTTACAATCGGCCCCGGAGACAAGCGTGTAGGCCCCCTCTGCGTGTGACA
 GCCCTCGAGTCCCTCTGTCCTGAAAGAACATTTCAGCCTGGGAAAGCTGAGAGAGGCCAAGCC
 ACAGGAAGCCAGCATCAGACGAAGGCCCTCTGGGCAGGAGCCTGTGCCCCACCTCTGAGGTCTG
 GCCTCTGTGCCAAGGTACCCCGAGGAGGAAGAAGTCAGGCCCCCGCAGCCTTCACCTGCGAGGTCTG
 CAGAGCAACAGCCAGCTCTCAGGGCCTCACTTACAATAGCAGTGAACAGCCCCCTGTCAGGCCCC
 CCGCGGGCACCGTCTCCCACAAGGGACTTTCTCAGCACTCATCTGCTACAAGCCCCGACAGCGATGG
 CACCAAAGCGATGAAGCCAGAGGAGGCCACTCTTGGTATTATCAGGACCCCTCTGGAAACCTCTT

CACCAACCTAAACTGTTGAATAACACTTGGCTTCTAAGAGCTCAGACCCTTGGACTCAGGAACCAGGA
 GCCCCAAAAGAGATCCCATAAGACCCAGTGTCACTGGCGCTTCAGCTGCCAAGGCAGAGCTGCCACCAGA
 TCATGAACACAAAACCTTAGGTCACTGGGTGACAATCAGTGACCAAGAAAAGAGGACAGCACTGCAGGTG
 TTTGACCACGGAAAAACATGACTGAGCAGCTTGAAGGCTGAGTCTATAGAATGCATACCTTCCT
 CCCTCTAGACATCCCTCCACAGAACAGACATCTATTAAAGGCACACTGGCCAAAACGTTGTGCATCT
 GTCACTCTGTAGTTACAAAATCGTCTCTTATTCACTAAGATGGTTACTCAGCCACCAAAATAT
 ATTTCACTCAAGGCTGTACATCTGAAGTTGCTCTCAAGGAATGGAACCTTCCTGTTAAATTCGGTG
 TATGGATTTAAGAAAGGAATCTAGCCAATGAGGTCCAAGAAGTTCTCACCCATTGAATTTTAAATGGC
 TGTTAGTTCATGTTGATGGAGATTGCTTTGTTATTGCATTTCAGATTGGTATAA
 CATTGGGGAGCAGCTGAAGGTTGATGTATAAAGTAAGGATTAGAGAAAAGAGGTGTTGACCATTA
 ATAGCTGCCTGGCCACTTAAACAAGTTACAAAAAAATCAGAGTCGGAAGCAGCCAAATAGGTCAACCT
 AATGACTAGACTGTACATTCCCAGGACCTCATGTTAAGTGTACATGTGCTTAACCTTGATGATG
 CGTGAATCCGAGGGAGCCGGTGGCATACACCGTAGCTTAACCTTAGCTTAAACTAGCTGAAGGCTCCT
 GTGCCATGTCTTAGACATTGCATGCCCTATCAATTACTATAATCCTGAGCCATGGTGCTACTGAAACC
 AATTTCATCCACCATCTAGCCTTATTAAATGAAACCTCACGGATCCTTGTCCGTTATATTCCATG
 CATAACCACATAAAAGCACACAGTGCAGAAACTCTTGCTGATACGCGATATTGATTCTATTGTTAGAATA
 TGGAGAGTGTTCAGCCTCGCTGTCCGGCTGGAGCTCCTGGGATGGAAGTGCTATGTGTCCTGCATAT
 AAGAACACCAGGCCAGTGTCTGGGTTGCTTGCTATATGTTGCTATATTTCGCTATACATT
 TTTCCCACGTTCCAACAGCACTTCTCACCTATTCAATAACTGAAAAGACATTACCATAGTGTCTTACA
 TTTTAAAGTAATGTTACAAGGTCTGGAATCCATTGGAGCAGATAACCGTGTTCGCTATTAAATAAGA
 AGTTCACTAGTGAATCTTACTGTACCCGCTGTTGATCTGGGAGCCTGTCAGAGGGCTCGCACAGCAG
 TGATCAAGTGTACCCCTACGTGACTGGGGATGTCCTAAAGCTGACTGCTAGGATAGTAAGGA
 TCATCTGCCTGGCTATGCCACTGTCTGTTACCAATTAGACATCTGGAATTCTATAATTAGTTCT
 TGTCACTGTCAAGATATATTGAGATTACTTAAATATGCCATCAAAACAAAAGTACAACACGTATCTC
 TTTTCATCTGAAAACAATACCTGGAAAAGGATAAAAAAAAAAGGAATCCGTGACCCACAGAGCTAGAC
 AGATAAGATGCATAGTTGACAGTCATAAAAGGCGGTGTTAAGTGTACAGGATGCCGTTGGCATT
 ACGTGCTTATATGATTTCACCTCTGTAACAAACACAAGAAATAACAGAAATGGCTTAAACAGAGTT
 GGGGAGAGAGCAAGATGGGCTTGGAGAAGCTGATTGCAAGATGCACATCGCTATTAACAGCCAG
 AGTCATAAAATGAAATGAAATTGAGAATTCAATTCAAATGCTTTCCCTATAACCTTTCTCACCAA
 AAAGGAGATAATTGAAAACAGATAAATGTAACAAACCAGTCAGGAAAGCAGGGAAAAGTAAGCTCCTC
 CAAAGTGCTTGCAGTGCTGAAATAGATCTATTAGGTTCTCTGTTCCAGATACCAAAATAAA
 TGGGACAGAGAATAAAATTGTTAAAATATGTCATCTCTTAAGTAGCTCTCAGAGTGTGACCGT
 AAGTAAAACACACAGAATTGTTGACTGGGGAGGTGAATCACAAAAAGTTACGAGGAGTTAAGAG
 TTAAATATTATGTCATGCTGGCTGTCAAATTAGTGAACACATAGATTGGATTGGAGTTGGTAGTAAG
 TATGGTCTCATACCAGAATTCTCTT

>gi|37556102|ref|XM_209367.2| Homo sapiens similar to dj680N4.2
 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5))
 (LOC284767), mRNA

ATGGCGCTGAAACGGATTAATAAGGAACCTAGTGATTGGCCGTGACCCCTCCAGCACAAATGTTCTGCAG
 GTCCAGTTGGGATGATATGTTCACTGGCAAGCACAATTATGGACCTCATGACAGACCATATCAAGG
 CGGTGTATTCTTGGACAATTCTGTTCCACAGACTACCCCTCAACCCTAAGGTTGCTATTACA
 ACAAGAATTATCACCCAAATATTAACAGTAATGGCAGCATTTCTGACATTCTAAGATCACAGTGGT
 CGCCTGCTTAACACTTTCTAAAGTCTTTATCCATTGTTCACTGCTATGTGATCCAAACCCAGATGA
 TCCCCTAGGCCAGAGATTGCCACGGACTATAAAACAGACAGAGATAAGTACAACAGAAATCTCGGGAA
 TGGACTCAGAAGTATGCCATGTGA

>gi|19549332|ref|NM_015983.2| Homo sapiens ubiquitin-conjugating enzyme
 HBUCE1 (LOC51619), mRNA

GTGCAGCTTGGTGGCGCTGAGCCGGCAGCGGGCGCCCTCAGGCAGCCCCGGCCGGCCGGGTCCC
 CGGCAGCGGGTAGGATGGCGCTAAAGCGGATCCAGAAGGAATTACCGACTTGCAGAGGGATCCTCCTG
 CCCAGTGTCTGCAGGACCTGTCGGTGTACTGCTTCCACTGGCAGGCCACCATATGGGCCGAATGA
 CAGCCTTACCAAGGAGGTGTTCTCTGACCCTACAGATTACCGTTCAAGCCCCCA
 AAGGTTGCTTCAACCAAATTATCACCTAATATCAACAGCAATGGCAGCATCTGCCTTGATATCC
 TGCCTGCTCAGTGGCTCCAGCGTTGACTGTGTCAAAGTTCTTGTCCATCTGCTCGCTGCTGCGA
 CCCCAACCCCGATGACCCCCCTGGTGCCAGAGATAGCACACACCTACAAGGCCAGAGAGAGAAGTACAAC
 AGACTAGCAAGAGAGTGGACACAAAATATGCTATGTAAGTGCCTGGAGGTTACATGAGACACTGTC

CAAGAGAAGCTGGCAGAGAGGTCTTCCCTAAAACCTTGGGCTGTTGGCTGAGCCATTCAAAGAGCATCA
 TCTGTTCTCAAACAAATGTTGGTCACCCACTCTCTCCAGCTGCAGCATGTTGGTCCATTTCAGCAAT
 TACGGCTTGACAGTGCCACCTCTTGATGCCAAATCAGCAACCATTGTTATGATCTGCAGTCTTCC
 TGGTACACTGGAATCTCTCTCGCCGCCCTCAGTTGTCAGTGGCTCTGGGGGCCAGGCCCTGC
 ACGTCTCCTACCCGGCTCAAATGGTCTCTGCCATGATGGTACACACCAGGGCCTCAGCCTGGC
 CCCTCACACATACCCCTTGCTTTAGAACTCAGTGCACCTCTGGGTGCCAGGGCAGAGCAGGCTTTG
 TTGCGACCTCATCTGCTGCAGAACACATCCTGAGGAGTCTCAGCTTACCTGGAGGGAAATGGGAACAG
 TGTCACTGGGAAGTGAAGGCCTAGCCCTGTCAGCTCCTCTGCAGTGCCACGTGGTGGCA
 TTTCTGCCCTCACACCAAGAACAGCAAGTGGAAAATTTCAGGATAACAAAGCACATAACACCCATAAGA
 GATGATTATGTTTTAGAAGCAAGAGCAAATTATGAAACCTCTAGAGATTGGTCATGTTACTCCATT
 TGATGAAGATTCTACTACCGCCCCTCCCATAGGAGCCTACACTAAGTCCAAGTGTGAGCCATTCA
 CAGACTAGAACACAAGGAGGGAGAGAGACTCTTAAACGTAATTTAACATGCAATTCACTACAACCTCT

>gi|33188457|ref|NM_003339.2| Homo sapiens ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) (UBE2D2), transcript variant 1, mRNA
 GCTTCGAGCGTCACGCCCTCCGGGCGTGGCGCGACGGCGTAGCTTACTCACAGGGCGGCC
 CGTATCCCTCCGCCGCCGGCGCGCTCGGCCCTCCCTCCGCCGCCGCAATCCCCGCCCTCCGACC
 TGCCCCCTCGGTGCGGCCACCCCGTCTCGACGGCCCCACCCCGCGCGCAGCCGCCGCCGCCGCG
 TCCCTCGGTCCACCTGCAGCAGGGAGGAAGACAGGCAATCCCTCCGGCTGTCCGACCAAGAGAGGCC
 CGAGCCGAGGCTGGGCTTTGCTTCTGGCGGAGGGATCTGCGCGGTTAGGAGGCGGCGTGTAC
 TGGGAGGAAGAGGAGCTACGGCGGCGCGGGCTAGGGCGGCGAATAAGGGCGGCC
 CGGGGTATGCGGTGACCGCTGCGCAGGCCAGGAGCTGAGTGGGCCCGGCCCTCAGCCCGTCCCGCC
 GGACCCGCTTCTCAACTCTCCATCTCTGCCGACCGAGATCGCCGAGGCGCCTCAGGCTCCCTA
 GCCCCCTCCCCGTCCTTCCCCGCCCGTCCCCCGGGGGCGCCACCCCTCCACCATGG
 CTCTGAAGAGAACCAAGGAATTGAATGATCTGGCACGGACCTCCAGCACAGTGTTCAGCAGGTCC
 TGTTGGAGATGATATGTTCCATTGGCAAGCTACAATAATGGGGCAAATGACAGTCCCTATCAGGGTGG
 GTATTTTCTGACAATTCACTTCCCAACAGATTACCCCTCAAACACCTAAGGTTGCATTACAACAA
 GAATTATCATCAAATATTAACAGTAATGGCAGATTGCTTGTATATTCTACGATCACAGTGGTCTCC
 AGCACTAACTATTCAAAAGTACTCTTGTCATCTGTTCTGTTGTGATCCAATCCAGATGATCCT
 TTAGTGCCTGAGATTGCTCGATCTACAAACAGATAGAGAAAAGTACAACAGAACAGTAGCTCGGAATGG
 CTCAGAAGTATGCGATGTAATTAAAGAAATTATGGATAACCTCTACAAATAAAAGATAGGGAAACTCTGA
 AAGAGAAAGCTTTGATTCCATTGACTGCTTCTATGAGGCCACGCCCTCATCTCCCTGTGCACA
 TGTTTACCTGATACAGCAGTGCTGCGTGTGATACATACTTGAACAAACAAACTAGAAATACTGTA
 GTACCAACATTGCTCTAGCAGAGAACAGTGTGTGACAAGCCAGTCTACAGGCATTACCTAGGTGT
 GAGACTAAAGCTTTCTTATTGACTTAAATTGATAACAGCAAGGTGTGAGGGGGTGGTGGTATGG
 TGTGTGTTGGATGGAAAGAAAAGGCTCCACTCACCTATAGGAGATTATTTTAAGTGGAAATCCATT
 AACTCAAAACAGTATGAAAAGCAAGGTGAAGAACATGAAGCTGTGTATTCAATTATTCCGAAGG
 AGCTACGTCTTAGGTGAAAGTTATGACCAACCAGATTAAACTCTACCCACATCTGCATTAAAGGTCTA
 AGTTTAACTGGTCAACATTAAATGGATTGGAGCTATTAGTACATCAAGTGTGATGGCTTGTCCCAA
 CTCTTTACATCTCCCTACCCCTCAACCTTGGCTTCAAGCCTTCTCTCTCTCCATATTCTTTG
 GTTTGTATGTGGTTCTCAGTTAACATAGCTAATAGCTTATTCTTATGTTTAACCGCTTAG
 GTCTATTGGATGTAAGGTGAAAGATTCTTGTGATGGAAATACTTGTGTATTAAAGACCCAATTGCT
 CCTCTGGAGCTTGTACTTCAGAATGATTAATCTGTGAAATAAAACTGGTTACTACAGTCATTACATATA
 ATTTGTGTGAATAGGCTTTTCAATTAAAGAAGTTGTCTAGCTGAGATTAGTGGTGGATTCTCC
 ACTTCTGAAATGTCATTAACTGGTGCATTAAAGATCATGAAACAACTCCAGTACATTGTAAAAAA
 GGATATCTTACGAGTAATTATTGAAACAAGTTAGAGGCATAAGCTTAAGGACATTCCATGAAACAACA
 CATGCAGCATTCCAGGAACCTGATTGTTAAATTCAATAAGAAATTGCTTATTAAATGAAACTAAGCTGC
 ATTTCATCAAACCTTGTGACATTCCCTGGTACATAGGACATAAAACACAGAGGATTGCTATTGGTA
 AGTTAACGCTCTGTGATTGTAATTATAAAAGAGCAACATTGACCAACCTGGAAACAAGAGCACAGTCT
 TGTTTGGAGAGTCTACATAATTACTTGCACAAACATTGCAAGGATGTCACACAAATTAAATTGTACT
 GTATGTGGCTTTGAAAGTCTTCCCTGACCTAGTAAATAGCTTGAACATTGAAACTTGTAAACA
 TGCCAGAAACATCATTGAAACTAGGCAAGTACCTTTTCCCCCTCTTCTTAATTGTAAC
 TAGGCCAACCTGAAAGCCATGGCTGATGCTCTAGGCCATCAGGTTCTTCAAATGCATCTTACACTCTG
 CACAAAAGTTAAGGAATAATGTCACGTGTTGGTTAAAAAAAAAAAAAA

>gi|33149308|ref|NM_003340.4| Homo sapiens ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) (UBE2D3), transcript variant 1, mRNA

ACCAAGTGAGGAAACTGGGGACGCTGTGGGAGGGCGTGGGCTGGATCGCGCAGCGCTGTTCCCTT
 TACCTTCCATGGCTCCTCCGGTCTCGATGCTCTGAGCCTAAGGTTCCGCCACTCGTTC
 ACCCTCCCCCAGCTCATGATCTCCTCCCTCCCCGCCCTGGTCCAATCTCCGATCTGTTAGTAA
 GAAGGTGCTGTTCCGAGAAGGAGAAGGAAAAGGGCTGACACGTATTCACTCGGCCCCGGACGTGGGAAG
 CAAGCCGCTGGCTCGGCCACATCGGTCTGTGCTCGGACGGCGCTGGGACTGATCCGCG
 CGGTGAAGAGGCCCTGTGCTGGCAGAGCTGGTGTGAGACGAGACAATCCTGCCGCCGGATAA
 TCAAGAGTTTGGCGGACCTTGAGCATACACCGAGAGACTGAGGAGCCAGACGACAAGCACACACTAT
 GGCGTGAACGGATTAATAAGGAACTTAGTGTATTGGCCGTGACCCTCCAGCACAATGTTCTGCAGGT
 CCAGTTGGGATGATATGTTCATGGCAAGCCACAATTATGGGACCTAATGACAGCCCATAAGGCG
 GTGTATTCTTTGACAATTCTACAGACTACCCCTCAAAACACCTAAGGTTGCATTACAAC
 AAGAATTATCATCAAATATTAACAGTAATGGCAGCATTGTCATGCTATGATCAAACAGTGGTC
 CCTGCTTAACAATTCTAAAGTCTTATCCATTGTCACTGCTATGATCAAACCCAGATGACC
 CCCTAGTGCCAGAGATTGCACGGATCTATAAACAGACAGAGATAAGTACAACAGAATATCTGGGAATG
 GACTCAGAAGTATGCCATGTGATGCTACCTTAAAGTCAGAATAACCTGCATTATAGCTGGAATAACTT
 AAATTACTGTTCTTTTGTATTTCTATCCGGTCTCCCTATCAGACCTCATCTTTTAATT
 TTTTTGTTACCTCCCTCATTACATGCTCATCTGAGAAGACTTAAGTTCTCAGCTTGGAC
 AATAACTGTTTAGAAACTGTAAGTAGTTACAAGAGAACAGTTGCCAAGACTCAGAATTAAAAA
 AAAAATGGAGCATGTTATATGTCCTAACTCTGAGGGGGAGGGAGATGGATGCTCAGTTGTCACATCAA
 GGATACAGCATTATTCTAGCAGCATCCATTGTTAACGCTTCACTGTTAGAGATTGAGGTTACAT
 GATATGTTATGCTCATAACTGATGGCTGGAGAATTGTTAGAATTATAGCATCAGCAGAACAGA
 AAATGTTGATGTTATGTCATGTCATAAAAGGAATGACCTGTTCTACAGAGAATGAAATTGG
 AAGTCAAACACCCCTGTATCCAAATAGGGTCTCAAACATTGTAATTTCATTAAATTGTTAGGA
 GGCTTGAGCTATTAGTTAACTATCTTCAATACACTGTTAATATAGCACTGAAATAATGATGCAAGT
 TGTCAATGGATGAGTGTCAACTAATAGCTCTGCTAGTAATTGATTATTTCTCAATAAGTTGCA
 AACCAATGAGTTAGCTGCCTGGATTAATCAGTATGGAAACAATCTTGTAAATGCAAAGCTGTT
 TGTATATACTGTTGGATTGCTCATTGTTGACATCAAATGATGATGTAAGTCAGAAAGAGTGAATA
 TTTGCCATGTTCAAGTGCACAGTCTTACAGGTTGACACATTGCTGACCTGATTATGCAGA
 ATTAATAAGCTATTGGATAGTGTAGCTTAATGTGCTGCACATGATACTGGCAGCCCTAGAGTTCA
 ATGGACTTTGGGACCCAGCAGTTGAAATGTGTTATGGAGTTAAGAAATTATTTCCAGGTGCA
 CCCCTGCTAACTGAAATTCTTCTCACCTTGACACTGACAGCTGAAAAAACACATGGAGTAAT
 AATGGGTCAAAATTGCAAATAACTGTTGGTGTGGAGTTGTCATGAGGCTGTGAAAGTGA
 CTTATCTATGTTGGATATTGAGTATCCATTGAAATGGATTGTCAGCCATTACATTAATGAGCATT
 AATGCAACAGATATCATTCAAGGTGACTAACATGAATGAATAAAAGTCATGCTATTGGAAAAAAA
 AAAAAA

>gi|37539364|ref|XM_353788.1| Homo sapiens similar to dopamine beta-hydroxylase-like (LOC378372), mRNA
 ATGGCCATGACCTCTTCAGGCTTTCCACTTTGCCCTGGGAGTCCCTACAAAGCAACGCC
 TTGGCCCCACATCTGCCGTGGCTATCCAGGTTCTAGATCCTCTAAATGTCATTTCCTGCCTGG
 CTTGACCTTGAGGCTGAAATCATCAGTTGAGCTCCAGTCCGTACAGCTGGCTGGTGGCTCGGT
 GTCACAAATCGTACACCAACGTGGGAAGTGATCTGGTGTGGAGGAGTCTGCTTAATGGCAATGTC
 ATTCTCGGATCAGCACTGGGAGGAAAGACACTCTGAAGGAGGATGGGAGGCCAGGATGTCAGCTGCT
 GGGCTGACGGAAGATGCTGTACACCACATGCACTTCCAGGCCCTCCGCTCGACCCCTCAT
 GACCTGGATATTACGAGCAACACCGTGAGGGTGTGGCGCTATGGCTGGATGACACTCTGAAGCTGT
 ATCGGGAGCGTACTTTGTCAGTCCATCTTCTGCTACAAGTCGTCACCCACTGACGATCTGGATGTC
 TGAGGACACCACATCCATGACTTGGAGATCACTAATTCTCATTCCAGAGGATGACACCAACGTATGCC
 TGCACCTTCTTCCCTCCATTGAGCGAGAACGATCACATTACAAGTTGAGCCTAAGTTGGTCT
 ACCACAATGAGACAAACGGTGATCACATCCTGGTGTACGCTGGCAATGCTAGCGTTCTCCCCACAGG
 CATCAGGACTGCTATGGGGCCACCTGCCCTCCCTTGCTCACAGGTGATCGTGGCTCGGCTGTC
 GGGGGCACACTGTGCAAATACGACACGGATGCTCCAGCTGGCTTCTCACGTTCCACACTTCA
 TCCCCCGGGCGCTGAGTCCTCATGTCCTATGGCTGTGAGGACGGAGAAGTTGAGGAGATGAATGG
 AGCTCCTATGCGTACAGGTGATGGCTACCTGCTGCACACCCACTGGCTGGACGGCTGCAA
 GCAGTGCAATACAGGAATGAAACACAACCTCGAAAAATCTGAAAGACGATTCTATGACTCAACCTG
 AGGAGACTCGAGATTGCCCTCTAGAGTGGAGATCAAGCCGGAGATGAATTGCTGGTAGAATGTC
 ACTA
 CCAGACACTGGACCGTGACTCCATGACATTGGAGGCCACGACCAATTAAATGAGATGTC
 CTCTTCACTATCCCCAAAATAACATCTCCAGCTGATGGGTACCCGACATTATCTACGTGGCC
 CAG

EX04-007P

AGCTAGGGAGGAGGCATCAGAGTGA

>gi|24308084|ref|NM_015529.1| Homo sapiens monooxygenase, DBH-like 1 (MOXD1), mRNA
TTTCCAAGGAAGGAAAGGCACACAATGGTATCAAATGTTCAATTCCATCTCTTGATGCTTACGATA
TTATCAGTCTACACTATGTTCTGAAAGGCCAGAAGTCAGTGTGACTAGTTCCAGGGACCTGA
TTCCCCAGTGGAAACTCCAGCCCTGGAAATTCGGGATTATAAAATACTCTAGACAACAAGAC
TTTGTCTTAAAGGTCTATGAATTCTTCTCTCTGTATTTAGGTATCCTGATTTTCTTTCCATATT
TTCCACAGGATTATTTACAAATGCAAATAGAGAGTGAAAAAGATGCTCAGCAAGATTACCATCTAGA
ATATGCCATGGAAAATAGCACACACAAATAATTGAATTACAGAGAGTGCTGACATACATGTGACATAAAT
GACAAGAGTATAACGGATAGCAGTGTGAGAGTGATCTGGGCCTACCACCATGAAGATGCAGGAGAACGTC
GTCCAAGTACCATGACTCCAATAGGGCACCAAGAGTTGCGGTATTGAATCTGAGAAAACACTAGTGT
GCTATCTACAGCCTTACCATACTTGTATCTGGTAAATCAGGACGTCCCCATCCAAACAAAGATACAACA
TATTGGTGCAAATGTTAAGATTCTGTGTTCCAAGAAAAGCATCATGTAATAAGGTTGAGGCCAGTGA
TACAGAGGGCCATGAGAGTCTGGTGACCACATCCTGCTATCAGTCAGCAACAACCTTAACGACAG
CGTTCTGGAGTCCGCCACGAGTGCTATCACCCAAACATGCCGATGCATTCCCTCACCTGTGAAACTGTG
ATTTTGCCCTGGCTATTGGTGGAGAGGGTTTCTTATCCACCTCATGTTGGATTATCCCTGGCACTC
CATTAGATCCGCATTATGTGCTCTAGAAAGTCATTATGATAATCCCCTTATGAGGAAGGCTTAATAGA
TAATTCTGGACTGAGGTTATTTACAAATGGATATAAGGAAATATGATGCTGGGTGATTGAGGCTGGC
CTCTGGGTGAGCCTCTCCATACCATCCCTCCAGGGATGCCTGAGTCCAGTCTGAGGGTCACTGCACTT
TGGAGTGCCTGGAAGAGGCTTGGAGAGGCCAAAGCCAAGTGAATTCTGTTGCTGTTCTTCTCCA
TGCTCACCTGGCTGGCAGAGGCATCAGGCTGCGTATTTGAAAGGAAGGAAATGAAATTACTTGCC
TATGATGATGATTGACTTCATTTCCAGGAGTTTCAGTATCTAAAGGAAGAACAAACAAATCTTACCAAG
GAGATAACCTAATTACTGAGTGTGCGTACAACACGAAAGATAGAGCTGAGATGACTTGGGAGGACTAAG
CACCAGGAGTGAATGTGCTCTCATACCTCTTATTACCAAGAATTAACTTACTCGATGTGCAAGT
ATTCCAGACATTATGGAACAATTTCAGTTCAATTGGGTTAAGGAGATCTACAGACCAAGTCACGACCTGGC
CTTCATTATCAAAGTCTCAAGCAATATAAAACCTTCTTCAATTGGATGCTATGAATAAGTTAAATG
GACTAAAAAGGAAGGTCTCCTCAACAAGCTGGCCTCAGCCTGCCAGTGAATGTGAGATGTTCCAAG
ACAGACAATGCTGAGTGGTCATTCAAGGAATGACAGCATTACCTCAGATATAGAAAGACCCATATAAG
CAGAACCTTGGTGTGGCACGTCTCTCCCTGCACAGAGATTCTCCATCAACTGCTTGT
TTGCCTCTGCTACTCAGTCAGCTGAGCACAAGAGCTTGTGATCAAATTCTGTTGGACTGACAA
TGTTTCTATGATGTAACCTGTCAATTGAAGTACAGGTTAAAGACTGTGTCACCTTGGGATGAAGAG
TGTGGAGACTTTCTCCCCATTTCCTCCCTTCTTCCATTGTTACATGAGAGACATCAATC
AGGTTCTCTCTTTCTTAGAAATATCTGATGTTATATACATGGTCATAAAATAAAACTGGCCTGA
CTTAAGATAACCATTAAAAAATTGGCTGTCATGTTGAAATAAGAATTCTTCTTCAACTACAT
TCTGTTTATTTAAATACTCATGTTGCTATTCACTTTGACTTGTGTTATTTCTTCTTGTGTTCTTCTA
TCCTCCCTTTAAAAAATATAAAAGGGACTACTGTTCAATTCCAGTTCTTCTTCTTGTGTTCTGTA
GTGTGACTTTCAAGTGTAAACAGCCATTCTCCTGACTTAAATTGTCCAGTTCTGGCTTTCTGTGA
ATTACCACTGGGCCCTTACCTCAATGCTTTGATGCCACTCTGGTCCCTGTTACTGAGTC
TGTGGTACCCCAAATGACCCCACACCATYTTAAAGTACTTTTCACTTCCCTGTTAGTACTGGC
CAGATGAGTTTCTAGAGCTCTGTCACTATCTGAAAAGAAAGAGGCTATGGAAACATAGAAATGGTA
TGTATTAATAACTGATCATAGGCTGAGGAGAAAAATGTAGCTGGCTGCAAACCCAGTGTGAGGTGA
CTTATATGAGGTTCCAGATCAAAGACAGGCCGTGAGCCAGTCCAGGAGGGTGAAGTTCTGAATGGTT
CCTTGCTGACTTTGGGTGACACATGTACCAACTGGCTCAGTTAAGTCATGGTTTATTGTAGATT
ATTTTTATATTAGTTAATAAAATGACTTAAATTGTCACCAATTGAAAATCTGTCACCTTTGGTTTC
TTTATATAGCTCAGCAAATCTGTTTATGTCCTGTCATCTCTTAAGCTAAATCTGTTGGATCA
TATTAATAAACCTCGTGGCG

>gi|40254422|ref|NP_000594.2| nitric oxide synthase 3 (endothelial cell) [Homo sapiens]
MGNLKSVAQEPCGPPCGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPR
VKNWEVGSITYDTLSAQAAQDGPCTPRRCLGSLVPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKR
SGSQAHEQRLQEVEAEVAATGTYQLRESLVFGAKQAWRNAAPRCVGRIQWGKLQVDARDCRSAQEMFTY
ICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWT
PGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNLLEIGGLEFPA

APFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDH
 HAATASFMKHLENEQKARGGC PADWAWIVPPISGSLTPVFHQEMVNFLSPA Fry QPDPWKGSAAKGTGI
 TRKKTFKEVANAVKISASLMGTVMAKRVKATILYSETGRAQSYAQQLGRLFRKA FDP RVLCMDEYDVVS
 LEHETLVLVVTSTFGNGDPPENGESFAAALMEMSPYNNSSPRPEQHKSYKIRFNSI SCSDPLVSSWRRKR
 KESSNTDSAGALGTLRCVFGLGSRAYPHCAFARAVDTRL EELGGERLLQLGQGDEL CGQEEAFRGWAQ
 AAFQAACETFCVGEDAKAARDIFSPKRWSKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRS VENLQ
 SSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRGLVEALLS RVEDPPAPTEPVAVEQLEKGSPGGP
 PPGWVRDPRLLPCTLRQALTFFLDITSPPS PQLLRLSTLAEEPREQQEAL SQDPRRYEEWKWFCPT
 LLEVLEQFPSVALPAPLLL TQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWL
 SQLKPGDPVPCFIRGAPSFRLLPPDPSLPCILVGPGTGIAPFRGF WQERLHDIESKGLQPTPM TLVFGCRC
 QLDHLYRDEVQNAQQRGVFGRVLTAFSREP DNPKTYVQDILRTELAAEVHRLCLERGHMFVCGDVTMA
 TNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGTLRTQEVTSRIRTQSFLQERQLRGAVP
 WA FDPPGS DTNSP

>gi|4506061|ref|NP_002724.1| protein kinase, AMP-activated, gamma 1
 .non-catalytic subunit; AMPK gamma 1; Protein kinase, AMP-activated,
 noncatalytic, gemma-1 [Homo sapiens]
 METVISSDSSPAVENEHPQETPESNNSYVTSFMKSHRCYDLIPTSSKL VVFDTSLQVKKAFFALVTNGVR
 AAPLWDSKKQS FVGMLTITDFINILHRYYKSALVQIYELEEHK IETWREVYLQDSFKPLVCISPNA SLFD
 AVSSLIRN KIHRLPVIDPESGNTLYILTHKRILKFLKLFITEFPKPEFMSKSLEELQIGTYANIAMVRTT
 TPVYVALGIFVQH RV SALPVVDEKGRVVDIYSKF DVINLAAEKT YNNLDV SVTKALQHRS HYFEGVLKCY
 LHETLETIINRLVEAEVHRLVV DENDVVKGIVSLS DILQALVLTGGEKKP

>gi|33186925|ref|NP_057287.2| protein kinase, AMP-activated, gamma 2
 non-catalytic subunit; H91620p protein [Homo sapiens]
 MGS AVMDT KKKKD VSSPGGSGGKKN ASQKRRSLRVHIPDLSSFAMPLLDGDLEGSGKHSSRKV DSPFGPG
 SPSKGFSRGPQPRPSSPMSAPVRPKTSPGSPKTVFPFSYQESPPRSPRRMSFGI FRSSSKESSPNSNP
 ATSPGGIRFFSRSRKTSGLSSP STPTQVTKQHTFPLESYKHEPERLENRIYASSSPPDTGQRFCPSSFQ
 SPTRPPLASPTHYAPS KAA ALAA ALGPAEAGMLEKLEFEDEA VEDSESGV YMRFMR SHKCYDIVPTSSKL
 VVFDTTLQVKKAF FALVANGVRAAPLWE SKKQSFVGMLTITDFINILHRYYKSPMVQIYELEEHK IETWR
 ELYLQETFKPLVNI SPDASLFD AVYSLIKN KIHRLPVIDPISGNALYILTHKRILKFLQ LFM SDMPKPAF
 MKQNLDELGIGTYHNIAFIHPDTP II KALN IFVER RISALPVVDESGKV VDIYSKF DVINLAAEKT YNNL
 DITVTQALQHRSQYFEGVV KCNKLEILETIVDRIVRAEVHRLVVVNEAD SIVGIISLS DILQALILTPAG
 AKQKETETE

>gi|8394044|ref|NP_059127.1| protein kinase, AMP-activated, gamma 3
 non-catalytic subunit [Homo sapiens]
 ME PGLEHALR RTPSWSSLGGSEHQEMSFLEQENSSWPSPAVTSSSERIRGKRRAKALRWTRQKS VEEGE
 PPGQGE GPRS RPAAESTGLEATFPKTTPLAQADPAVGVTPTGWDCLPSDCTASAAGSSTD DVELATEFP
 ATEAWCECELEG LLEERPALCLSPQAPFPKLGW DDEL RKP GQIYMRFIEEHTCYDAMATSSKL VIFDTML
 EIKKAFF FALVANGVRAAPLWDSKKQSFVGMLTITDFILV LHRYYRSPLVQIYEIEQH KIETWREIYLQGC
 FKPLV SISPNDSL FEAVYT LIKN RIHRLPV LD PVS GNV L HIL THKR LLKFLHIFG SLL PRPSFLY RTI QD
 LGIGTFRD LAVVLETAPILTAL DIFVDRRV SALPVVNECGQV VGLYSRF DV IHLAAQQT YNHLDMSVG EA
 LRKRTLCLEGVLSCQPHE S LGE VIDRI AREQVH RL LVDETQHLLGVV SLS DILQALV LSPAGIDPSGPE
 KI

>gi|24041029|ref|NP_000616.3| nitric oxide synthase 2A isoform 1; NOS,
 type II; nitric oxide synthase, macrophage [Homo sapiens]
 MACPWKF LFKTKFHQYAMNGEK DINNNVEKAPCATSSPVTQDDLQYHNL SKQQNESPQPLVETGKKSPES
 LVKLDATPLSSPRHVRIKNW GSGMTFQDTLHHKAKGILTCRSKSC LG SIMTPKSLTRGPRDKPTPPDELL
 PQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNA PRCIGRIQWSNLQ
 VFDARSC STAREMF EHI CRH VRYSTNN GNIRSAITVFPQRSDGKHDFR VWN AQLI RYAGYQMPDG SIRGD
 PANVEFTQLCIDL GWKPKYGRFDV VPVLQANGRDPELFEIPP DLVLEVAMEHPKYEW FREL ELK WYALP
 AVANMLLEVGGLF PGCPFNGW YMGT EIGVRDFCDVQ RYNILEEVGRRM GLETHKL ASLW KDQAV VEINI
 AVLHSFQKQNV TIMDHHSAAESFMK YM QNEYR SRGGC PADWI LVPP MSGS ITPV FHQEML NYV LSPF YY
 YQVEAWKTHVWQD EKRRPKR REIPLKVLVKA VL FACMLR KTMAS RVR VTILF ATETGK SE ALA WDL GAL
 FSCAFNPKV VCMD KYRLS CLEE ERLL VVTSTFG NGDC PGNGE KKKSL FML KELNNK FRYA VFGLGSSM

YPRFCFAHIDQKLSHLGASQLTPMGEGLDELSGQEDAFRSWAVQTFFKAACETFDVRGKQHIQIPKLYTS
 NVTWDPHHYRLVQDSQPLDLASKALSSMAKNVFTMLKSRQLQSPTSSRATILVELSCEDGQGLNYLPG
 EHLGVCPGNQPALVQGILERVVDGPTPHQTVRLEALDESGSYWSDKRLPPCSLSQALTYFLDITTPPTQ
 LLLQKLAQVATEEPRQRLEALCQPSEYSWKFTNSPTFLEVLEEFPSLRVSAGFLSQLPILKPRFYSI
 SSSRDHTPTEIHLTVAVVTVYHTRDGQGPLHHGVCSTWLNSLPQDPVPCFVRNASGFHLPEDPSHPCILI
 GPGTGIAPFRSFQWQQRLHDSQHKGVRGGRMTLVFGCRRPDEDHYQEEMLEMAQKGVVLHAVHTAYSRLPG
 KPKVYVQDILRQQLASEVLRVLHKEPGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQ
 KRYHEDIFGAVFPYEAKKDRVAVQPSSLEMSAL

>gi|4504789|ref|NP_002211.1| 1D-myo-inositol-trisphosphate 3-kinase A
 [Homo sapiens]

MTLPGGPTGMARPGGARPCSPGLERAPRRSVGELRLLFEARCAAAAGAEPRAKGAKRGGQVPNGL
 PRAPPAPVIPQLTVTAEEPDVPPTRSPGPPERERDCLPAAGSSHLLQQPRLSTSSVSSSTGSSSLLEDSEDD
 LLSDSESRSGNVQLEAGEDVGQKHNWKIRTMVNLPVISPFKKRYAWVQLLAGHTGSFKAAGTSGLILKR
 CSEPERYCLARLMADALRGCVPAFHGVVERDGESYLQLQDLDGFDPVCVLDCMGVRTYLEEELTKARE
 RPKLRKDMYKKMLAVDPEAPTEEEHAQRAVTKPRYMQWREGISSTTLGFRIEGIKKADGSCSTDFKTTR
 SREQLRVFEEFVQGDEEVLRRLNRLQQIRDTLEVSEFFRRHEVIGSSLLFVHDHCHRAGVWLIDFGKT
 TPLPDGQILDHRRPWEENREDGYLLGLDNLIGILASLAER

>gi|38569400|ref|NP_002212.2| 1D-myo-inositol-trisphosphate 3-kinase B;
 IP3 3-kinase [Homo sapiens]

MAVCYALNSLIVMNSANEMKSGGGPGPSGSETPPPPRRAVLSPGSVFSPPGRGASFLLFPPAESLSPEEPR
 SPGGWRSGRRRNSSSGSGSSGSSVSSPSWAGRLRGDRQVVAAGTLSPPGPEAKRKLRLIQRELQN
 VQVNQKVMFEAHIQAQSSAIQAPRSPLRGRARSPSPCPFRSSSQPPGRVLVQGARSEERRTKSWGEQCP
 ETSGTDGRKGGPSLCSSQVKGMPPLGRAAPTGSEAQGPSAFVRMEKGIPASPRCGSPTAMEIDKRG
 PTPGTRSCALPSLGLFGASLTIMATEVAARVTSTGPHRPQDLALTEPSGRARELEDLQPPEALVERQGQFL
 GSETSPAPERGGPRDGEPPGKMGKGYLPCGMPGSGEPEVGKRPTEETTVSVQSAESSDSLWSRLP
 ALASVGPEEARSGAPVGGRWQLSDRVEGGSPTLGLGGSPSAQPGTGNEAGIPSGRMLEPLPCWDAAKDLKE
 PQCPPGDRGVQPGNSRVWQGTMEKAGLAWTRGTGVQSEGWTESQRQDSDALPSPELLPQDQDKPFLRKA
 CSPSNIPAVIITDMGTQEDGALEETQGSPRGNLPLRKLSSSASSTGFSSSYEDSEEDISSDPERTLDPN
 SAFLHTLDQQKPRVSKSWRKIKNMVHWSPFVMSFKKYPWIQLAGHAGSFKAANGRILKKHCEQRCL
 DRLMDVLRPFVPAHGDDVVKDGERYNQMDLLLADFDSPCVMDCMGIRTYLEEELTKARKKPSLRKDMY
 QKMICDPEAPTEEKAQRAVTKPRYMQWRETISSTATLGFRIEGIKKEDGTVNRFKKTKTREQVTEAF
 REFTKGHNHNLIAZRDRLKAIRTTLEVSPFFKCHEVIGSSLLFIHDKKEQAKVWMIDFGKTTPLPEGQTL
 QHDVPWQEGNREDGYLSGLNNLVLDILTEMSQDAPLA

>gi|18643383|ref|NP_079470.1| inositol 1,4,5-trisphosphate 3-kinase C
 [Homo sapiens]

MRRCPCRGSLNEAEAGALPAAARMGLEAPRGGRRQPGQQRPGPGAGAPAGRPEGGGPWARTEGSSLHSE
 PERAGLGPAPGTEPQAEGFWTDGQTEPAAAGLVETERPKQKTEPDRSSLRTHLEWSWSELETTCLWTET
 GTDGLWTDPHRSDLQFQPEEASPWTQPGVHPWTELETHGSQTQPERVKSWADNLWTHQNSSLQTHPEG
 ACPSKEPSADGSWKEYTDGSRTQQDIEGPWTEPYTDGSQKKQDTEAARKQPGTGGFQIQQDTDGSWTQP
 STDGSQTAPGTDCLLGEPEDGLEEPEPGELLTHLYSHLKCSPLCPVPRLIITPETPEPEAQPVGPPSRV
 EGGSGGFSSASSFDESEDDVVAGGGGASDPEDRSGSKPWKKLKTVLKYSFVVSFRKHYPWVQLSGHAGN
 FQAGEDGRILKRCQCERQRSLQLMKDPLRPFVPAAYGMVLQDGQTFNQMEDLLADFEGPSIMDCMGSR
 TYLEEEELVKARERPRPRKDMYKEMVAVDPGAPTPEEHAQGAVTKPRYMQWRETMSSTSTLGFRIEGIKKA
 DGTCNTNFKKTQALEQVTKVLEDVDGDHVILQKYVACLEELREALIEISPFKKTHEVVGSSLLFVHDHTG
 LAKVWMIDFGKTVLPHQTLHRLPWAEGNREDGYLWGLDNMICLLQGLAQS

>gi|4758698|ref|NP_002363.1| mannosidase, alpha, class 2A, member 1;
 mannosidase, alpha type II [Homo sapiens]

MKLSRQFTVFGSAIFCVVIFSLYLMRDGHLDYPRNPRREGSFPQGQLSMLQEKİDHLERLLAENNEİİS
 NIRDSVINLSESVEDGPKSSQSNSFSQLGSHLLPSQLSLSVDTADCLFASQSGSHNSDVQMLDVYSLİSF
 DNPDGGVWKQGFDITYESNEWDTEPLQVFVVPHSNDPGWLKFNDYFRDKTQYİFNNMVULKLKEDSRRK
 FIWSEİSYLSKWWDİDİQKKDAVKSLIENGQLEİVTGGWVMPDEATPHYFALİDQLIEGHQWLENNİG
 KPRSGWAIDPFGHSPTMAYLLNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGSVTDLCHMMP
 FYSYDIPHCTCGPDPKICCQFDKRLPGGRFGCPWGVPPETİPGNVQSRARMLLDQYRKKSKLFRTKVLL

APLGDDFRYCEYTEWDLQFKNYQQLFDYMNSQSFKVKIQFGTLSDFDALKADETQRDKGQSMFPVLS
 GDFFTYADRDDHYWSGYFTSRPFYKRMDRIMESHRAAEILYYFALRQAHKYKINKFLSSSLYTALTEAR
 RNLGLFQHDAITGTAKDWVVVDYGTRLFHSLMVEKIIGNSAFLILKDKLTYDSYSPDTFLEMDLKQK
 SQDSLQPKNIIRLASEPRYLVVNPLEQDRISLVSVYVSSPTVQVFASGKPVEVQSAVWDTANTISET
 AYEISFRAHIPPLGLKVKILESASSNSHLADYVLYKNKVEDSGIFTIKNMINTEEGITLENSFVLLRFD
 QTGLMKQMMTKEDGKHHEVNQFSWYGGTIKRDKGAYLFLPDGNAKPVYTTPPFVRVTHGRYSEVTC
 FFDHVTHRVRLYHIQGIEGQSVEVSNIVDIRKVYNREIAMKISSDIKSQNRFYTDLNGYQIOPRMTLSKL
 PLQANVYPMTTMAIYQDAKHRLTLLSAQSLGVSSLNSGQIEVIMDRRLMQDDNRGLEQGIQDNKITANLF
 RILLEKRSANTEEKKSVSYPSSLHSITSSLNMHPVIPMANKFSPTLELQGEFSPLOQSSLPCDIHLVNL
 RTIQSKVGNGHSNEAALILHRKGFDRCFSSKGTCSTTQGKILVQKLLNKIVESLTPSSLMSMHSP
 GTQNISEINLSPMEISTFRIQLR

>gi|3123244|sp|P49641|M2A2_HUMAN Alpha-mannosidase IIx (Mannosyl-
 oligosaccharide 1,3-1,6-alpha-mannosidase) (MAN IIx) (Mannosidase alpha
 class 2A member 2)
 MKLKKQVTVCAGAAFCVAVFSLYLMLDRVQHDPTRHQNGGNFPRSQISVLQNRIEQLEQLLEENHEIISH
 IKDSVLELTANAEGPPAMLPYYTVNGSWVPPEPRPSFFSIS PQDCQFALGGRGQKPELQMLTVSEELPF
 DNDVGGWWRQGFDISYDPHDWDAEDLQVFVVPHSNDPGWIKTFDKYYTEQTQHILNSMVSQKLQEDPRRR
 FLWAEVSFFAKWWDNINVQKRAAVRRLVNGNGQLEIATGGWVMPDEANSHYFALIDQLIEGHQWLERNLGA
 TPRSGWAVDPFGYSSTMPYLLRRANLTSMLIQRVHYAIKKHFAATHSLEFMWRQWTWSDSSTDIFCHMMP
 FYSYDVPHTCGPDPKICQCQDFKRLPGGRINCWKVPPRAITEANVAERAALLLDQYRKKSQFLRSNVLL
 VPLGDDFRYDKPQEWAQFFNYQRLFDFNNSRPNLHVQAFGTLSDYFDALYKRTGVEPGARPPGFVLS
 GDFFSYADREDHYWTGYYTSRPFYKSLDRVLEAHLRGAEVLYSLAAAHHARRSGLAGRYPLSDFTLLTEAR
 RTLGLFQHDAITGTAKEAVVVVDYGVRLRLSUVNLQVIHAAHYLVLDKETYHDFPEAPFLQVDDTRL
 SHDALPERTVIQLDSSPRFVVLFNPLEQERFSMVSLLVNSPRVRLSEEQPLAVQISAHWSSATEAVPD
 VYQVSVPVRLPALGLGVLQLQLGLDHRTLPSSVRIYLHGRQLSVSRHEAFPLRVIDSGTSDFALSNRYM
 QWVFSGLTGLLKSIRRVDEEHEQQVDMQVLVYGTRTSKDKSGAYLFLPDGEASPTSPRSPCCVSLKALS
 SQRWLRTMSTFTRSGFTICQGWRCGLWTYHPWWTSGTTSTRWPCTSQTSTARVQPRRYLKKLPLQAN
 FYPMPVMAYIYQDAQKRLTLHTAQALGVSSLKDQLEVILDRLMQDDNRGLGQGLKDNKRTCNRFRLLLE
 RRTVGSEVQDSHSTSYPSSLHTSMYLNAPALALPVARMQLPGPGLRSFHPLASSLPCDFHLLNLRTLQ
 AEEDTLPSEAETALILHRKGFDGCGLEAKNLGFNCTTSQGKVALGSLFHGLDVVFLQPTSLLYPLASPN
 STDVYLEPMEIATFRLRLG

>gi|10835173|ref|NP_000611.1| nitric oxide synthase 1 (neuronal) [Homo
 sapiens]
 MEDHMFGVQQIQPNVISVRLFKRKVGGFLVKERVKPPVIISDLIRGGAEQSGLIQAGDIILAVNGR
 PLVDSLSDALEVLRGIASETHVVLILRGPEGFTTHELETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPP
 AGKEQPLAVDGAAGPGNGPQHAYDDGQEAGSLPHANGLAAPRPPGQDPAKKATRVSLQGRGENINELLKEIE
 PVLSLLTSGSRGVKGGAAPAKAEMKDMGIQVDRDLGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYS
 EKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRP
 EDVRTKGQLFPLAKEFIDQYSSIKRGFSKAHMERLEEVNKEIDTTSTYQLKDTIELYGAHKARNASRC
 VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRWNSQLIRYAGY
 KQPDGSTLGD PANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKF EWFK
 DLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRNYILEEVAKKMNDMRKTSSLW
 KDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYCRGGCPADWWIVPPMSGSI TPVFHQEM
 LNYRLTPSFYQPDFPNWVHKGNTPTKRRAGFKKLAEAVFSAKLMQAMA KRVKATI LYATETGK
 SQAYAKTLCEIFKHAFAKVMMSMEYDIVLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
 EERKSYKVRFNSVSSYSDSQSSGDGPDLRNFESAGPLANVRF SVFGLGSRAYPHCAF GHAVDTLLEE
 LGGERILKMREGDELQEEAFRTWAKKVKFAACDVFCVGDDVNIEKANNSLISNDRSWKRNKFRLT FVA
 EAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVN
 ALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQQFASL
 ATSEKEKQRLLVLSKGLQEYEEWKWNKPTIVEVLEEFPSIQMPATLLLQLQPRYYSISSSPDMYP
 DEVHLTVIAVSYRTRDGEPIIHGVCSWLNRIQADELVPFCVRGAPSFLPRNPQVPCILVGPGTGIAP
 FRSFWQQRQFDIYQHKGMPNCPMVLVFGRQSKIDHIYREETLQAKNKGVFRELYTASREPDKPKKYVQD
 ILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRI MTQGKLSAEDAGVFI SRMRDDNRYHEDIF
 GVTLRTYEVNRLRSE SIAFIEESKKDTDEVFSS

>gi|37540252|ref|XP_291315.2| similar to KIAA1815 protein [Homo sapiens]
 MEWGSEAAVRRHRVGVERREGAAAAPP PEREARAQEPLVDGCSGGGRTRKRS PGSGGASRGAGTGLSE
 VRAALGLALYLIALRTLVLQLSLQQLVLRGAAGRGEFDALQARDYLEHTSIGPRTTGS PENEILTVHYL
 LEQIKLIEVQNSNLHKISVDVQRPTGSF SIDFLGGFTSYYDNITNVVKLEPRDGAQHAVLANCHFDSVA
 NSPGASDDAVSCSVMLEVRLVLS TSSEALHHAVIFLFNGAEENVLQASHGFITQHPWASLIRAFINLEAA
 GVGGKELVFGTGPENPWLVQAYVSAAKHPFASVVAQEVFQSGIIPSDTDRIYRDFGNIPGIDLAFIENG
 YIYHTKYDTADRIL TDS IQRAGDNILAVLKHLATSDMLAAASKYRHGNMVFFDVLGLFVIAYPSRIGSII
 NYMVMGVVLYLGKKFLQPKHKTGNYKDKFLCGL GITLISWFTSLVTLIIIAVFISLIGQSLSWYNHFYV
 SVCLYGTATVAKIILIHTLAKRFYYMNASAQYLGEVFFDISLFVHCCFLVTLYQGLCSAFISAVWVAFP
 LLTKLCVHKDFKQHGAQGKFIAFYLLGMFIPYLYALYLIWAVFEMFTPILGRSGSEIPPDVVLASIAGC
 TMILSSYFINFIYLA KSTKKTMLTLTVCAITFLLVCSGTFFPYSSNPANPKPKRVFLQHMTRTFHDLEG
 NAVKRDSGIWINGFDYTGISHTPHIPEINDSIRAHCEENAPLCGF PWYLPVHFLIRKNWYLPPEVSPR
 NPPHFRLISKEQTPWDISKLT FEATGP SHMSFYVRAHKGSTLSQWSLNGTPVTSKG DYFVFYSHGLQA
 SAWQFWIEVQVSEEHPEGMVTVAIAAHYLSGEDKRSPQLDALKEKFPDWTFPSAWVCTYDLFVF

>gi|21361382|ref|NP_009102.2| protein-O-mannosyltransferase 1 [Homo sapiens]
 MWGFLKRPVVVTADINSLVALTG MLLSRLWRLTYPRAVV FDEVYYGQYISFYMKQIFFLDDSGPPFGH
 MVLALGGYLG GFDGNFLWNRIGAEYSSNVPVWSLRLPALAGALSVPMAQIVLELHF SHCAAMGAALLM
 LIKNALITQSRLM LLESVLIFFNLLAVLSYKLFFNCQKHSPFSLSWWFWLTLGVACSCAVGIKYMGVFT
 YVLVLGVAAVHAWHLLGDQ TLNSVGDVQCCMRPACMGQM RM SQGCVFC HLLARAVALLVIPVVL YLLF
 FYVHLILVFRSGPHD QIMSSAFQASLEGGLARITQGQPLEVAFGSQVTLRNFGKPVPCWLHSHQDTYPM
 IYENGRGSSHQQVTCPFKDVNNWIVKDPRRHQLVSSPPR PVRHGMVQLVHG MTRSLNTHDVAAP
 LSPHSQEVCYIDYNISM PAQNLWRLEIVNRGSDT DVWKTILSEVRF VHVN TSAV LKLSGAHLPDWGYRQ
 LEIVGEKLSRGYHG STVWNVEEHRYGASQEQRERERELH SPAQV DVS RNL SFMARFSELQW RMLA RSDD
 SEHKYSSS PLEWV TLD TNIA YWLH PRT SAQI HLLGNIV WSG SLALA IY ALLSLW YLLRRRN VHDL P
 DAWLRWVLAGAL CAG GWAV NYLPFFLMEK TLFLYH YLPALT FQ ILLP VVLQH ISDHLCRSQL QRS NSF SA
 LVV AWYSS ACHV SNTL RPL TYGD KSL SPHE KAL RWK DSW DIL IRK H

>gi|4506321|ref|NP_002837.1| protein tyrosine phosphatase, receptor type, N precursor; islet cell antigen 2; islet cell antigen 512; islet cell autoantigen 3; protein tyrosine phosphatase-like N precursor [Homo sapiens]
 MRRPRP RGGLGGSGGLRLLLCL LLLSSRPGGCSAVSAH GCLFD RRLCSH LEV CIQD GLFGQCQVGVGQAR
 PLLQ VTSPV LQL QGVL RQL MSQ GLS WHDDL TQY V ISQ EME RI PRL RPP E PRD RSG LAP KRP G PAGE L
 LLQDI PTG S APA A QH RL P Q P P V G K GG AGA SSS LSP L Q A ELL PPL L EH L L L P P Q P P H S L S Y E P A L L Q P Y L
 FH QFG S RDGS RVSE GS PG M V S V G P L P K A E A P A L F S R T A SK G I F GD H P G H S Y G D L P G P S P A Q L F Q D S G L L Y
 LAQ EL P A P S R A R V P R L P E Q G S S S R A E D S P E G Y E K E G L G D R G E K P A S P A V Q P D A L Q R L A A V L A G Y G V E L R
 QLT P E Q L S T L L T L L Q L L P K G A G R N P G V V N V G A D I K K T M E G P V E G R D T A E L P A R T S P M P G H P T A S P T S S E
 VQQV P S P V S S E P P K A A R P P V T P V L L E K K S P L G Q S Q P T V A G Q P S A R P A A E Y G Y I V T D Q K P L S A A G V K L L
 E I L A E H V H M S S G S F I N I S V V G P A L T F R I R H N E Q N L S L A D V T Q Q A G L V K S E L A Q T G L Q I L Q T G V G Q R E E A
 A A V L P Q T A H S T S P M R S V L L T L V A L A G V A G L L V A L A V L C V R Q H A R Q Q D K E R L A A L G P E G A H G D T T F E Y Q D
 L C R Q H M A T K S L F N R A E G P P E P S R V S S V S Q F S D A A Q A S P S H S S T P S W C E E P A Q A N M D I S T G H M I L A Y M E
 D H L R N R D R L A K E W Q A L C A Y Q A E P N T C A T A Q G E G N I K K N R H P D F L P Y D H A R I K L K V E S S P S R S D Y I N A S P I
 I E H D P R M P A Y I A T Q G P L S H T I A D F W Q M V W E S G C T V I V M L T P L V E D G V K Q C D R Y W P D E G A S L Y H V Y E V N L V
 S E H I W C E D F L V R S F Y L K N V Q T Q E T R T L T Q F H F L S W P A E G T P A S T R P L L D F R R K V N K C Y R G R S C P I I V H C S
 D G A G R T G T Y I L I D M V L N R M A K G V K E I D I A A T L E H V R D Q R P G L V R S K D Q F E F A L T A V A E E V N A I L K A L P Q

>gi|11386149|ref|NP_002838.1| protein tyrosine phosphatase, receptor type, N polypeptide 2 isoform 1 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase [Homo sapiens]
 MG PPLPL L L L L L P P R V L P A A P S S V P R G R Q L P G R L G C L L E E G L C G A S E A C V N D G V F G R C Q K V P A M D F Y
 R Y E V S P V A L Q R L R V A L Q K L S G T G F T W Q D D Y T Q Y V M D Q E L A D L P K T Y L R R P E A S S P A R P S K H S V G S E R R Y S
 R E G G A A L A N A L R R H L P F L E A L S Q A P A S D V L A R T H T A Q D R P P A E G D D R F S E S I L T Y V A H T S A L T Y P P G P R T
 Q L R E D L L P R T L G Q L Q P D E L S P K V D S G V D R H H L M A A L S A Y A A Q R P P A P P G E G S L E P Q Y L L R A P S R M P R P L L

APAAPQKWPSPLGSEDPSSTGDGARIHTLLKDLQRQPAEVRLSGLELDGMAELMAGLMQGVDHGVARG
 SPGRAALGESGEQADGPKATLRGDSF PDDGVQDDDRLYQEVRHLSATLGLLQDHGSRLLPGALPFARP
 LDMERKSEHPESSLSSEEETAGVENVKSQTYSKDLLQQPHSEPGAAAFGELQNQMPGPSKEEQLPAG
 AQEALSDGLQLEVQPSEEEARGYIVTDRDPLRPEEGRRLVEDVARLLQVPSSAFADVEVLGPAVTFKVSA
 NVQNVTTEDVEKATVDNKDKLEETSGLKILQTVGSKSKLKFPPQAEQEDSTKFIAITLVSACILGV
 LASGLIYCLRHSQHRLKEKLSQLGGDPGADATAAYQELCRQRMATRPPDRPEGPHTSRISVSSQFSDG
 PIPSPSARSSASSWSEEPVQSNMDISTGHMILSYMEDHLKNKNRLEKEWEALCAYQAEPNSSFVAQREEN
 VPKNRSALVLTVDHSRVLLKAENSHSHSDYINASPIMDHDPRNPAYIATQGPLPATVADFWMQMVWESGCV
 VIVMLTPLAENGVRQCYHYWPDEGSNLHYIYEVNLVSEHIWCEDFLVRSFYLKNLQTNETRTVTQFHFLS
 WYDRGVPSSSRSLDFRRKVNCYRGRSCPIIVHCSGDAGRSGTYVLIDMVLNKMAKGAKEDIATLEH
 LRDQRPGMVQTKEQFEFALTAVAEEVNAILKALPQ

>gi|4507335|ref|NP_003886.1| synaptojanin 1; inositol 5'-phosphatase
 (synaptojanin 1); synaptojanin-1, polyphosphoinositide phosphatase
 [Homo sapiens]
 MAFSKGFRIYHKLDPPPFSLIVETRHKEECLMFESGAVAVLSSAEKAIKGTYSKVLDAYGLGVRLNL
 GDTMLHYLVLVTGCMVGKIQESEVFRTSTEFISLRIDSSDEDRISEVRKVLNSGNFYFAWSASGIQL
 LSLNAHRSMQEQTTDNRFFWNQSLHLHLHYGVNCDDWLLRLMCGGVEIRTIYAAHKQAKACLISRLSCE
 RAGTRFNVRTGTNDGHVANFVTEQVYLLDDSVSSFIQIRGSVPLFWEQPGLOVGSHRVRMSRGFEANAP
 AFDRHFRTLKNLYGRQIIVNLLGSKEGEHMLSKEFQSHLKASEHAADIQMVFQDYHQMVKGKAELHSV
 LKPQVQFKFLDYGFYFNGSEVQRCQSGTVRTNCLCDLRTNSVQAFLGLEMLAKQLEALGLAEKPQLVTR
 FQEVRFRSMWSVNGDSISKIYAGTGAEKAKLKDARSVRTIQQNFFDSSKQEAIDVLLGNTLNSDLA
 DKARALLTTGSLRVSEQTLQSASSKVLKSMCENFYKYSKKIRVCVGTWNVNGGKQFRSIAFKNQTLTD
 WLLDAPKLAGIQEFQDKRSKPTDIFAIGFEEMVELNAGNIVSASTTNQKLWAVELQKTISRDNKYVLLAS
 EQLVGVCLFVFIQPQHAPFIRDVAVDVTKTGMGGATGNKAVAIRMLFHTTSLCFVCSHFAAGQSQVKER
 NEDFIEIARKLSFPGRMLFSHDYVFWCGDFNYRIDLPNEEVKELIRQWNDSLIAQDQLINQKNAGQVF
 RGFLEGKVTFAPTYKYDLFSDDYDTSEKRTPAWTDRVLWRRRKWPFDRSAEDLDDLNASFQDESKILYT
 WTPGTLHYGRAELKTSRHPVVALIDIDIFEVEAERQNIYKEVIAVQGPPDGTVLVIKSSLPENNFF
 DDALIDEQQFASFGEVILIRFVEDKMWTFLEGSSALNVLSNGKELLNRITIALKSPDWIKNLEEE
 MSLEKISIALPSSTSSTLLGEDAEVAADFDMEGVDDYSAEVEELLQPHLQPSSSSGLGTPSSSPRTSP
 CQSPTISEGVPVSLPIRPSRAPSRTPGPPSAQSSPIDAQPATPLPKDPAQPLEPKRPPPPRPVAPPTRP
 APPQRPPPPSGARSPAPTRKEFGGIGAPPSPGVARREMEAPKSPGTTKDNIGRSQSPQAGLAGPGPAG
 YSTARPTIPPRAGVISAPQSHARASAGRTPESQSKTSETSKGSTFLPEPLKPQAAFPQQSSLPPAQRL
 QEPLVVAAPMPQSGQPQPNLETPPQPPRSRSSHSLPSEASSQPVKNTNGISDGKRESPLKIDPFDLSF
 NLLAVSKAQLSVQTSPVPTPDFPKRLIQLPSATQSNVNTLSSVSCMPTMPPIPARSQSQENMRSSPNPFIT
 GLTRTNPFSDRTAAPGNPFRAKSEESEATSWFSKEEPVTISPFPSLQPLGHNKSASSLDGFKDSFDLQ
 GQSTLKISNPKGWTFEEEDFGVKGKSKSACSDLLGNQPSSFGSNSLTNDDWNKGTNVFCVLPSPRRP
 PPPPVPLLPPGTSPVDPFTTLASKASPITLEDFTER

>gi|26190608|ref|NP_003889.1| synaptojanin 2; inositol phosphate 5'-
 phosphatase 2 (synaptojanin 2) [Homo sapiens]
 MALKGLRLLGRLGAEGDCSVLLEARGRDDCLLFEA GTVATLAPEEKEVIKGQYGLTDAYGCLGELRLK
 SGGTSLSLFLVLTGCTSVGRI PDAEIYKITATDFYPLQEEAKEERLIALKKILSSGVFYFSPWPDGSRF
 DLTVRTQKQGDDSSEWGNSFWNQLLHVPLRQHQVSCCDWLLKIICGVVTIRTVYASHKQAKACLVSRSV
 CERTGTRFHTRGVNDGHVSNFVTEQMIYMDDGVSSFVQIRGSVPLFWEQPGLOVGSHHRLHGLEAN
 APAFDHMVLLKEQYQGQVVVNLLGSRGGEELNRAFKLLWASCHAGDTPMINFDHFQFAKGKLEKLE
 TLLRPQLKLHWEDFDVFTKGENVSPRFQKGTLRMNCLDCLDRNTVQSFIALEVLHLQLKTLGLSSKPIV
 DRFVESFKAMWSLNGHSLSKVFTGSRALEGKAKVGLKDARSMSRTIQSNNFDGVKQEAIKLLLVDVY
 GEEVADKGMLLDSTALLVTPRILKAMTERQSEFTNFKRIRIAMGTVNVNGGKQFRSNVLRTAELTDWLL
 DSPQLSGATDSQDSSPADIFAVGFEEMVELSAGNIVNASTTNKKMWGEQLQKAI SRSHRYILLTSAQLV
 GVCLYIFVPRPYHVPFIRDVAIDTVKTGMGGKAGNKGAVGIRFQFHSTSFCFICSHLTAGQSQVKERNEDY
 KEITQKLCFPGRNFVSHDVFWCGDFNYRIDLTYEVFYFVKRQDWKKLLEFDQLQLQKSSGKIFKDFH
 EGAINFGPTYKYDVGSAAYDTSOKRTPAWTDRVLWWRKKHPFDKTAGELNLLDSDLVDVTKVRHTWSPG
 ALQYYGRAELQASDHPRVLAIVEVEVQEVDVGARERVFQEVSSFQGPLDATVVVNLQSPTELKEFPED
 LRTELMTLGSYGTIVLVRINQGQMLVTFADSHSALSVDVDMKVKGRAVKIRPKTKDWLKGREEIIR
 KRDSMAPVSPTANSCLLEENFDFTSLDYSESEGDILEDDEDYLVDEFNQPGVSDSELGGDDLSDVPGPTAL
 APPSKSPALTKKKQHPTYKDDADLVELRELEAVGEFRHRSPRSLSVPNRPRPPQQRPPPPTGLMVK

KSASDASISSGTHQYSILQTARLLPGAPQQPPKARTGISKPYNVKQIKTTNAQEAAAIRCLLEARGGA
 SEEALSAVAPRDLEASSEPEPTGAAKPETPQAPPPLPRRPPRVPAIKKPTLRRTGKPLSPEEQFEQQT
 VHFTIGPPETSVEAPPVVTAPRVPPVPKRTFQPGKAAERPSPHRKPASDEAPPGAGASVPPPLEAPPLVP
 KVPPRRKKSAPAAFHLQVLQSNSQLLQGLTYNSSDSPSGHPPAAGTVFPQGDFLSTSSATSPDSGDKAM
 KPEAAPLLGDYQDPFWNLLHPKLLNNNTLSKSSDPLDSGTRSPKRDPIDPVSAGASAAKAELPPDHEHK
 TLGHWVTISDQEKRATALQVF DPLAKT

>gi|27485630|ref|XP_209367.1| similar to dJ680N4.2 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5)) [Homo sapiens]
 MALKRINKELSDLARDPPAQC SAGPVGDDMFHWQATIMGPHD RPYQGGVFFWTIRFPTDYPFKPSKVAFT
 TRIYHPNINSNGSICLDILRSQWPALT SKVLLSIC SLLCDPNPDDPLVPEIARIYKTDRDKYNRISRE
 WTQKYAM

>gi|8393719|ref|NP_057067.1| ubiquitin-conjugating enzyme HBUCE1 [Homo sapiens]
 MALKRIKELTDLQRDPPAQC SAGPVGDDLFHWQATIMGPNDSPYQGGVFLTIHFPTDYPFKPPKVAFT
 TKIYHPNINSNGSICLDILRSQWPALT SKVLLSIC SLLCDPNPDDPLVPEIARIYKADREKYNRLARE
 WTQKYAM

>gi|33188456|ref|NP_862821.1| ubiquitin-conjugating enzyme E2D 2 isoform 2; ubiquitin carrier protein; ubiquitin-conjugating enzyme E2-17 kDa 2 [Homo sapiens]
 MFHWQATIMGPNDSPYQGGVFFLTIHFP TDYPFKPPKVAFTTRIYHPNINSNGSICLDILRSQWPALT
 SKVLLSIC SLLCDPNPDDPLVPEIARIYKTDRDKYNRLAREWTQKYAM

>gi|33149322|ref|NP_871621.1| ubiquitin-conjugating enzyme E2D 3 isoform 2; ubiquitin-conjugating enzyme E2-17 kDa 3; ubiquitin carrier protein [Homo sapiens]
 MALKRINKELSDLARDPPAQC SAGPVGDDMFHWQATIMGPNDSPYQGGVFLTIHFPTDYPFKPPKVAFT
 TRIYHPNINSNGSICLDILRSQWPALT ISKVLLSIC SLLCDPNPDDPLVPEIARIYKTDRDKYNRLARE
 WTEKYAML

>gi|37539365|ref|XP_353789.1| similar to dopamine beta-hydroxylase-like [Homo sapiens]
 MAHDLLFRFLPPLLALGVPLQSNRLGPTSRRLYSRFLDPNSVIFLRWDFDLEAEIIISFELQVR TAGWVGFG
 VTNRYTNVGS DLLVGGVL PNGN VYF SDQHLVEEDTLKEDGSQDAELLGLTEDAVYTTMHFSRPF RSCDPH
 DLDITSNTVRVLAAYGLDDTLKLYRERTFVKSI FLLQVVPDDLDVPEDTI IH DLEITNFLI PEDDTTYA
 CTFLPLPIVSEKHHIYKFEPKLVYHN ETTVHHILVYACGNASVLPTGISDCYGADPAFSLCSQVIVGSA
 GGTLCKYDTDVLQLGFTFP IHFIPPGAESFMSYGLCRTEKFEEMNGAPMPDIQVYGYLLHTLAGRALQ
 AVQYRNGTQLRKICKDDSYDFNLQETRDLPSRVEIKPGDELLVECHYQTLDRDSMTFGGPSTINEMCLIF
 LFYYQPQNNI SMC GYPDII YVAHELGEASE

>gi|37183305|gb|AAQ89452.1| dopamine-oxygenase [Homo sapiens]
 MCCWPLLLLWGLLPGTAAGGSGRTYPHRTLLDSEGKYWLGSQRGSQIAFRLQVRTAGYVGFGFSPTGAM
 ASADIVVGGVAHGRPYLQDYFTNANRELKKDAQQDYHLEYAMENSTHTIIIEFTRELHTCDINDKSITDST
 VRVIWAYHHEDAGEAGPKYHDSNRGTSRLLNPEKTSVLSTALPYFDLVNQDVPIPNKD TTYWCQMFKI
 PVFQEKKHHVIKVEPVIQRGHESLVHHILLYQCSNNFND SVLES GH ECYHPNMPDAFLT CETVIFAWAIGG
 EGFSYPHVGLSLGTPLDPHYVLLEVHYDNPTYE EGLIDNSGLRLFYTM DIR KYDAGVIEAGLWVSLFHT
 IPPGMPEFQSEGHC TLECLEA EAEKPSGIHVFAVLLHAHLAGRGIRLRFRKKGEMKLLAYDDDFDN
 FQE FQYLKEEQTILPGDNLITECRYNTKDR AEMTWGGLSTRSEMCLSYLLYYPRINTRCASIPDIMEQL
 QFIGVKEIYRPVTTWPFI IKSPKQYK NLSFMDAMNKFKWTKKEGLSFNKLVLSPVNVRCSKTDNAEWSI
 QGMTALPPDIERPYKAEPPLVCGTSSSSSLHRDFSINLLVCL LLSCTLSTKSL